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Summary 
I SUMMARY 
 
Cellular transformation and cancer progression is accompanied by changes in the 
metabolic landscape. Master co-regulators of metabolism orchestrate the modulation of multiple 
metabolic pathways through transcriptional programs, and hence constitute a probabilistically 
parsimonious mechanism for general metabolic rewiring. In this thesis work we have shown that 
the transcriptional co-activator peroxisome proliferator-activated receptor gamma co-activator 1α 
(PGC1α) suppresses prostate cancer progression and metastasis. We performed a data mining 
analysis of major metabolic co-regulators, which unveiled that PGC1α is downregulated in prostate 
cancer and is associated with disease progression. Using genetically engineered mouse models 
and xenografts, we demonstrated that PGC1α opposes prostate cancer progression and 
metastasis. Mechanistically, the use of integrative metabolomics and transcriptomics revealed that 
PGC1α activates an oestrogen-related receptor alpha (ERRα)-dependent transcriptional program 
to elicit a catabolic state and metastasis suppression. Moreover, we have observed that PGC1α 
expression leads to altered cytoskeleton remodelling.  Importantly, a signature based on the 
PGC1α-ERRα pathway exhibited prognostic potential in prostate cancer, thus uncovering the 
relevance of monitoring and manipulating this pathway for prostate cancer stratification and 
treatment. 
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I Cancer 
 
Cancer refers to a class of diseases characterized by out-of-control cell proliferation that leads 
to the formation of an abnormal cellular mass, denominated tumour. This term refers to more than 100 
forms of the disease, as every tissue can spawn this kind of malignancy, and some even yield several 
types2. Here emerges the difficulty of approaching the study of this disease, as although a share feature 
of tumours involves their ability to sustain chronic proliferation, each of them requires unique treatment 
and diagnosis3. 
According to the World Health Organization (WHO, with data collected by the International 
Agency for Research in Cancer-IARC on the last Globocan 2012 report), cancer is one of the leading 
causes of morbidity and mortality worldwide. Indeed, 14 million new cases were diagnosed in 2012, 
and this number is expected to rise by about 70% over the next two decades 
(http://www.who.int/cancer/en). Estimations from the Spanish Network of Cancer Registries 
(REDECAN) revealed that in 2015, nearly a quarter of a million new invasive cancer cases were 
diagnosed in Spain. The five most common cancers were breast (28%), prostate (22%), colorectal 
(17%), lung (15%), and urinary bladder (12%) 4. All these facts underscore the need and relevance for 
cancer research. 
 
I.1 Tumour progression and the hallmarks of cancer 
 
Tumour development begins when cells within a normal population sustain genetic alterations 
or are expose to environmental factors that increase their propensity to proliferate. First, the 
accumulation of mutations leads to the presence of pre-malignant lesions, such as hyperplasia and 
dysplasia, which occur prior to the appearance of fully invasive tumours. Then, the accumulation of 
genetic alterations occurs in one (or more) cells, which still become more abnormal in growth and 
appearance. If this tumour does not break boundaries between tissues, it is called in situ cancer. 
Eventually, when these tumour cells acquire additional genetic changes, they will be able to invade 
underlying tissue and reach the blood or lymph. Those cells are then able to establish new tumours 
(metastases) throughout the body, becoming lethal by disrupting a vital organ2,5,6.  
Tumour progression towards metastasis is often depicted as a multistage process in which 
malignant cells spread from the tumour of origin to colonize distant organs. The stepwise progression 
of human cancer has been clinically well characterized (Fig I1)7.  
Introduction  
42 
 
IN
T
R
O
D
U
C
T
IO
N
 
 
Figure I 1. Representation of the tumour progression cascade.  
 
This tumour progression model remarks the notion that cancer is a genetic disease8. During 
decades of molecular biological studies on human cancer, a great number of genes have been 
identified to be genetically and/or epigenetically altered, especially in advance or highly metastatic 
cancer cells 5. Of note, no single gene defect “causes” cancer, but rather contributes to the cause. 
Because of this, and together with the identification of multiple genetic alterations in cancer cells, it is 
widely accepted that these alterations accumulate in the cells in a stepwise manner during tumour 
progression5. Alterations in three types of genes are responsible for tumorigenesis: oncogenes, tumour-
suppressor genes and stability genes. Mutations in oncogenes often result in enhanced levels or 
activity, whereas in tumour suppressors they tend to downregulate or inhibit the protein. Finally, stability 
genes or caretakers are responsible for repairing mistakes made during normal DNA replication8 and, 
therefore, mutations in these genes alter DNA repairing. 
As cancer development represents a highly complex process and several cancer types and 
subtypes have been established, more than a decade ago Hanahan and Weinberg unified and identify 
common features of cancer cells, the hallmarks of cancer6. They suggested that the vast catalogue of 
cancer cell phenotypes led to six essential alterations in cell physiology: i) self-sufficiency in growth 
signals, ii) insensitivity to anti-growth signals, iii) evasion of programmed cell death (apoptosis), iv) 
limitless replicative potential, v) sustained angiogenesis and vi) tissue invasion and metastasis. In the 
course of remarkable and extensive progress in cancer research during the last years, new 
observations have emerged to clarify and modify the original hallmarks (Fig I2). Thus, the same authors 
proposed that in order to acquire these capabilities, cancer cells must gain enabling characteristics, 
such as genome instability and tumour promoting inflammation. On the one hand, the genome instability 
or the malfunction of genomic integrity control mechanisms in cancer cellsincreases the mutation rate, 
leading to selective advantages6. On the other hand, immune cells can promote tumorigenesis and 
tumour progression sustaining proliferative signalling through growth factors. This leads to cell death 
Genetically
altered cell
Hyperplasia Dysplasia
In situ Cancer
Invasive Cancer
Genetic alterations
Environmental factors
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limitation, providing extracellular matrix-modifying enzymes that facilitate angiogenesis, invasion and 
metastasis, and inducing signals leading to EMT activation and reactive oxygen species (ROS) 
production in the tumour microenvironment9,10. Moreover, two other hallmarks of cancer were included 
due to their relevance in the development of the disease: evading immune destruction (avoiding the 
detection by the immune system of formation and progression of neoplasias, late-stage tumours and 
micrometastases) and reprogramming of energy metabolism. Remarkably, increasing evidence 
support the notion that tumorigenesis is dependent on the reprogramming of cellular metabolism as 
both direct and indirect consequence of oncogenic mutations3,11. 
 
Figure I 2. Revised hallmarks of cancer. (Adapted from Hanahan D. and Weinberg R.A. Cell.2011) 
 
I.2 Progression to metastasis: cell migration and invasion 
 
The invasion-metastasis cascade is composed by a complex succession of cell-biological 
events by which epithelial cells from a primary tumour: i) invade locally (surrounding extracellular 
matrix-ECM and stromal cell layers), ii) intravasate into the blood vessels, iii) survive through the 
vasculature, iv) arrest at distant organ sites, v) extravasate into the parenchyma of distant tissues, vi) 
survive and form micrometastases in the distant site, and vii) reinitiate proliferative programs at the 
metastatic site to generate macroscopic neoplastic growths (Fig I3)12. Over the last decade, the 
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metastatic capacity of cancer cells has been extensively studied, several regulatory nodes have been 
ascertained and new research tools and experimental models have become available. Importantly, 
during these years we have learnt that the main feature of these cells is the capacity to alter their shape, 
their attachment to other cells and to the extracellular matrix (ECM), and to adapt to foreign tissue 
microenvironments3.  
 
 
Figure I 3. The Invasion-Metastasis cascade. (Adapted from Valastyan S. and Weinberg R.A. Cell.2011) 
 
The epithelial to mesenchymal transition (EMT), has become widely accepted to play a major 
role in the invasion, resistance to apoptosis, and dissemination of transformed epithelial cells13,14 It 
encompasses the expression of several transcription factors (Snail, Slug, Twist and Zeb 1/2) and the 
loss of E-cadherin expression, which evoke the loss of adherent junctions, the shift from an epithelial 
to a fibroblastic morphology, and heighten the resistance to apoptosis15 3. Nonetheless, during the 
invasion-metastasis cascade, cells that have undergone EMT in the initial steps may pass through a 
reverse process, termed mesenchymal-epithelial transition (MET), in order to form new tumour colonies 
in distant organs14.  
The acquisition of the invasive behaviour also involves the activation of signalling pathways 
controlling cytoskeletal dynamics, as well as turnover of cell-matrix and cell-cell adhesions16 . By means 
of cytoskeleton organisation, there are five steps that cancer cells follow in order to migrate16 (Fig I4):  
1) Polarization of the cytoskeleton by actin polymerization forming a protrusion at the leading 
site. The growing actin filaments connect to adaptor proteins and push the cell membrane 
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in an outward direction. In this step, guanine-nucleotide exchange factors (GEFs) 
regulate the activity of small GTPases RAC, CDC42 and RHO, which regulate 
intracellular actin dynamics.  
2) Cell-matrix interaction and formation of focal contacts. Recruitment of integrins that 
establish contact with the ECM and recruit adaptor proteins, such as the focal adhesion 
kinase (FAK) and consequently, the phosphorylation and activation of actin binding 
proteins (paxillin) and the presence of regulatory molecules (PI3K and RHO-family 
GTPases). Importantly, paxillin is an adaptor/scaffolding protein that participates in a wide 
number of cell signalling pathways. It is one of the first protein present in nascent 
adhesions and recruis many structural and regulatory protein to the cell adhesion. Its 
relevance has make it an attractive target for anti-metastatic drugs, since its inhibition 
prevents the formation of focal adhesions, which are crucial for cell contractility17. 
3) Cell surface proteases execute locally controlled proteolysis to allow onward cell 
movement and give space for the advancing cell body. 
4) Cell contraction by actomyosin. Actin myosin II binds to actin filaments and generates 
actomyosin contraction. This is mediated through phosphorylation of the myosin light 
chain II (MLC2). RHO regulates this contraction through its effector, ROCK. 
5) Detachment of the trailing edge. The contraction leads to the gradual turnover of adhesion 
bonds at the trailing edge, which slides forward while the leading edge protrudes further. 
At this step, actin filament strands break thanks to actin binding and severing proteins 
(gelsolin and cofilin). 
 
Figure I 4.Five-step model of cell migration. 
According to these steps, the actin polymerization and organization into different cytoskeletal 
structures in crucial for cell migration and invasion. These reorganizations are controlled by the Rho 
family of GTPases, which switch between their active (GTP bound) and inactive state (GDP bound), 
and are controlled by guanine exchange factors (GEFs). Three members of this family have been 
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extensively related with cell migration regulation (Rac, Rho and Cdc42). Rho activates the Rho-
associated coiled-coil-containing protein kinase (ROCK), which drives contraction of actin filaments in 
an ATP-dependent manner through myosin II phosphorylation. In addition, ROCK can also 
phosphorylate other protein important for migration, such as LIM kinases (LIMK1 and LIMK2). The 
activation of LIMKs allows the specific inactivating phosphorylation at Ser-3 of the actin-severing protein 
cofilin. Cofilin is an actin-binding protein that plays a role in actin filament dynamics and reorganization 
by stimulating severance and depolymerisation of actin filaments. Moreover, it contributes to actin 
filament assembly by increasing actin monomer concentration for polymerization, increasing the 
turnover rate of actin filaments in cells. Importantly, protein kinases such as LIMK play a pivotal and 
essential role in regulating actin cytoskeletal reorganization and diverse cell activities related to actin 
dynamics18-20.  
II Prostate cancer 
 
II.1 Human and murine prostate physiology 
 
The prostate is part of the male reproductive system, and is the largest accessory gland in 
the body21. The glandular tissue of the prostate secretes a slightly acidic fluid that contains an 
antimicrobial chemical and citric acid for energy production (in the mitochondria of sperm cells). The 
smooth muscle of the prostate gland contracts during ejaculation to contribute to the expulsion of semen 
from the urethra22. In order to further comprehend the nature of this thesis work, we will describe in 
depth the anatomic and physiological characteristics of human and murine prostate. 
The human prostate gland is about 3 cm high by 4 cm wide by 2 cm deep (about the size of 
a walnut), and it surrounds the first centimetre of the urethra as it emerges from the bladder22 (Fig I5A). 
The human prostate conforms a pseudo-capsule that consist on glandular and stromal elements. While 
the inner layer of this capsule is composed of smooth muscle, the outer layer is covered with collagen. 
The prostate gland in humans is divided into four regions: the central zone (CZ), transition zone (TZ), 
peripheral zone (PZ), and anterior fibromuscular stroma (Fig I5B). The central zone is located at the 
base of the prostate surrounding the urethra, and accounts for 25% of the glandular tissue. The 
peripheral zone is the larger one (70% of glandular tissue) and it extends from the base to the posterior 
surface and surrounds the distal urethra. Carcinoma, chronic prostatitis and post-inflammatory atrophy 
are more common in this zone than in others. Finally, the transition zone forms only 5% of the anterior 
glandular tissue. It is formed by two small lobules that enlarge when benign prostatic hyperplasia 
occurs21. The prostate (human and murine) contains glands (acini) and ducts with epithelial cells that 
include columnar luminal secretory cells, basal cells and neuroendocrine cells (Fig I5C)23. 
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In mice, the prostate is not a single anatomical structure, but rather an organ comprised of 
three lobes located around the urethra. The mouse prostate can be separated into the anterior or 
coagulating gland (AP), ventral (VP), and dorsal and lateral lobes, often grouped together as the dorso-
lateral gland (DLP) (Fig I5D). All are generally surrounded by a thin mesothelial-lined capsule that 
separates the various lobes from each other. The glandular prostate is separated from this capsule by 
fibro-adipose connective tissue containing major vascular channels, nerves, and ganglia. Moreover, 
the individual murine prostate lobes are composed of a series of branching ducts, formed by few layers 
of bland spindle cells interspersed in eosinophilic collagen24. The individual murine prostate glands are 
histologically different. The ventral prostate is located anterior to the urethra and caudal to the bladder. 
The VP presents cuboidal epithelium with flat luminal edges, with spare in-folding, abundant luminal 
pale serous secretions and small nucleoli. It is flanked by two lobes that lay on both sides of the urethra 
to shape the DLP. The DLP is located at the base of the seminal vesicles and is lined by cuboidal and 
columnar epithelium, moderate infolding, granular cytoplasm with eosinophilic secretions and basally 
located uniform nuclei. The anterior prostate lobes are translucent and bilaterally attached to the lesser 
curvature of the seminal vesicles23,24 (Fig I5D).  
 
Figure I 5. Anatomy and histology of male human and murine reproductive system. A-B, Picture of human 
anatomy showing the localization and structure of the different regions of the prostate gland respectively. C, 
Scheme depicting the different cellular types in a histological section of the human prostate duct. D, Anatomy of 
the prostate glands in mice tissue (left) and representation of the different lobes of murine prostate. SV: Seminal 
vesicles, ED: Ejaculatory conducts, AFS: Anterior fibromuscular stroma, AP: Anterior Prostate, LP-DP: Dorso-
Lareral Prostate, VP: Ventral Prostate, U: Urethra. Images adapted from (in panel order): (Scanlon, V. C. & 
Sanders, F. 2015, A. Davis; Bhavsar, A. & Verma, S Biomed Res Int 2014; Nardella C et al. Curr Top Microbiol 
Immunol.2010 and Oliveira D.S. et al J Basic Med Sci. 2016). 
The glands of each of the mouse prostate lobes appear to have normal cells populations 
homologous to the human prostate. Indeed, interspecies comparisons of mRNA expression signatures 
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have shown homologies between the PZ in humans and the murine DLP (where 75-85% of prostate 
adenocarcinomas occur). Nonetheless, they present different embryologic origins, and can be 
distinguished not only anatomically, but also according to their biological functions21,23. Furthermore, 
the most conspicuous histological difference between the two species lies on the stromal component, 
which is very developed in humans as an anterior fibromuscular region, whereas in mice is conformed 
of minimal smooth muscle cell layer23. Hence, there is no definitive evidence for a direct relationship 
between the specific mouse prostate lobes and the ones in the human prostate. These fundamental 
anatomic differences between human and murine prostates should be taken into account when 
studying the neoplastic development of this organ. 
 
II.2 Prostate cancer progression model 
 
Despite the dissimilar anatomy, morphology and histology of the rodent and human prostate, 
several studies strongly support the validity of mouse models for prostate cancer (PCa) research, as 
disease progression in both species is strikingly similar25,26.  
PCa arises from the accumulation of genetic alterations in the epithelium of the prostate gland 
(both in humans and rodents), leading from an initial epithelial hyperplasia to a low grade prostatic 
intraepithelial neoplasia (PIN). From this state, the lesion can progress to a high grade prostatic 
intraepithelial neoplasia (HGPIN). The accumulation of further mutations leads to a more aggressive 
lesion, in which the prostate epithelium invades the basement membrane and arrives to the surrounding 
stroma, establishing a localized invasive adenocarcinoma25. This adenocarcinoma can stay confined 
in the prostate, or can become more aggressive and invade other organs, causing metastasis, that 
ultimately may result in lethality27 (Fig I6). 
The benign prostate hyperplasia (BPH), which arises in the TZ, is not a precursor for PCa, 
and it is represented as diffuse or local small areas of nuclear atypia. PIN is characterized by cellular 
proliferations within existing ducts and acini with cytosolic changes such as nuclear and nucleolar 
enlargements. In this type of premalignant neoplasia, inversion of the normal epithelial proliferation 
orientation occurs, going from the basal cell compartment to the luminal surface28. However, the 
basement membrane remains intact contrary to invasive carcinoma conditions. Of note, PIN lesions 
can be distinguished architecturally and cytologically from other histological abnormalities of the 
prostatic epithelium, such as BPH or atypical adenomatous hyperplasia (AAH), which are not believed 
to be precursor states for PCa26.  
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Figure I 6. Schematic representation of PCa progression. In the upper panel a draft of progression steps is 
represented. In the lower one the histological images represent the PCa progression cascade. (Adapted from 
Trotman LC et al PLoS Biol 2003 and Nardella C et al. Curr Top Microbiol Immunol.2010). 
 
PIN progresses to HGPIN, which represents an early stromal invasion and the earliest 
evidence of carcinoma (microinvasion). It is multicentric and most commonly found in the PZ of the 
prostate28. Invasive carcinoma can be then recognized by an infiltrative and destructive growth pattern 
of atypical cells with at least focal glandular differentiation29.Cancer cells that acquire the capacity to 
detach from the ECM will be eventually able to metastasize. In this step, tumour cells must acquire the 
capacity to survive upon loss of contact with the prostate basement membrane, and avoid anoikis 
signals. Anoikis is a programmed cell death induced upon cell detachment from ECM, and is believed 
to be a critical mechanism to avoid the colonization of distant organs during tumorigenesis30.  
Lymph nodes, bone, lung and liver are the most frequent sites of distant PCa metastases31. 
Remarkably, metastasis to the bone with skeletal involvements account for approximately 90% of 
patients with advance PCa31. The process requires the vascular spread of tumour cells to the bone 
marrow (through the lymph or blood circulatory system). Then, cancer cells adhere to the bone 
microvasculature and matrix components, invading and surviving into the bone marrow. Finally, a new 
tumour is established in the bone microenvironment and there is a recruitment of reactive stroma from 
cells in the marrow. Tumour dissemination to the bone can cause bone marrow replacement, spinal 
cord compression, severe bone pain, cachexia and death32.  
 
 
Normal PIN HGPIN Invasive PCa
Introduction  
50 
 
IN
T
R
O
D
U
C
T
IO
N
 
II.3 Prostate cancer diagnosis, pathology and treatment 
 
According to the last IARC report in 2012, PCa is the second most common cancer in men 
and the fifth cause of death from cancer in men worldwide. In 2012, approximately 1.1 million men 
worldwide were diagnosed with PCa (http://www.who.int/cancer/en). In Spain, PCa is the first most 
common cancer in men, with a number of 33,370 new cases in 20154. PCa is intimately associated 
with aging, indeed, aging is the single most significant risk factor for this type of cancer. Although PIN 
can be found in 20-30 year old men, clinically detectable PCa is not generally manifest until the age of 
60 or 70. In addition to the age, the etiological factors related to PCa are various and encompass 
environmental factors, race, diet, familial inheritance, lifestyle and hormonal influences (steroid 
hormones)26. 
 
II.3.1 Prostate cancer diagnosis and pathology 
 
The preliminary clinical diagnosis of PCa is suspected on the basis of digital rectal 
examination (DRE) and prostate specific antigen (PSA) levels. As most of the prostate carcinomas are 
located in the PZ, they are detected through DRE when the volume is higher than 0.2 mL 
(http://uroweb.org/guideline/prostate-cancer). In addition, the levels of the PSA are used for further 
diagnosis. PSA is a kallikrein-related serine protease produced in normal prostatic tissue with the 
physiological role of liquefying seminal fluid. Nonetheless, this peptidase is also produced in BPH and 
PCa, and its presence in blood is thought to be caused by normal prostate architecture disruption, 
especially in invasive cancer when the basal layer of cells is lost33. Of note, PIN does not increase PSA 
levels, and the selectivity and specificity of PSA has been further studied as it can give many false 
positives28,34. In addition, further diagnostic tests have been developed35: 
1- Progensa, a kit that detects the prostate cancer gene 3 (PCA3), a non-coding mRNA 
biomarker detectable in urine after DRE. 
2- The Prostate Health Index test (PHI), which combines the detection of free, total PSA and 
the (-2) pro-PSA isoform (p2PSA) in blood (http://uroweb.org/guideline/prostate-cancer). 
3- The 4Kscore test, which combines the detection in blood of 3 kallikreins panel (free, total 
and intact PSA and hexokinase 2-hK2). 
4- MiPS test, in which plasma PSA and urine TMPRSS2: ERG (Transmembrane protease, 
serine 2: erythroblast transformation-specific related gene) and PCA3 are detected. 
 
Introduction 
 
51 
 
IN
T
R
O
D
U
C
T
IO
N
 
Definitive diagnosis depends on histopathological verification of adenocarcinoma in prostate 
biopsy cores or specimens from transurethral resection of the prostate (TURP) or prostatectomy 
(http://uroweb.org/guideline/prostate-cancer). These biopsies are histopathologically evaluated and 
classified according to two different methods, the Gleason Score, and the tumour, node, metastasis 
system (TNM)36,37. The Gleason grading system is based on the histologic pattern of arrangement of 
carcinoma cells in haematoxylin-eosin stained prostatic tissue sections, analysing glandular 
differentiation extent and the pattern of tumour growth in the prostatic stroma. Nine different patterns 
were established initially in five grades (Fig I7A). Increasing Gleason grade is directly related to 
histological end points, including risk of extra-prostatic extension and metastasis38. The TNM system 
encompasses evaluation of the primary tumour status, from prostate confined to invasive (T1-4), 
absence or presence of lymph node involvement (N0 or 1) and absence or presence and degree of 
metastasis (M1-1a-c)36 (Fig. I7B).  
 
Figure I 7. Grading systems employed for histopathological evaluation of PCa. A, Scheme depicting the 
histological patterns and the corresponding PCa grade according to Gleason Score system (Adapted from 
Humphrey PA, Modern Pathology.2004). B, Table describing the extent of primary tumour (T), lymph node 
involvement (N) and metastasis detection according to the TNM evaluation system (taken from 
http://uroweb.org/guideline/prostate-cancer). 
 
Emerging molecular data is enabling to establish new prognostic biomarkers and tests, which 
could help to establish PCa patient stratification criteria for better treatment strategies. For instance, 
the tissue EPCA IHC test for PCa risk prediction, commercially offered by Onconome, is based on the 
A B
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detection of EPCA nuclear structural protein in the epithelium of prostatic glands, which has been 
associated with carcinogenesis 39. The Prolaris test is based on a 46 gene signature (31 cancer –
specific and 15 reference genes) which expression establishes a cell cycle progression (CCP) score 
(https://prolaris.com). In line with this test, other gene signature-based technologies and kits have been 
developed, such as the Oncotype DX GPS (Genomic Prostate Score) (17 genes signature), and the 
Decipher test (22 gene signature), which also predict clinical recurrence. Interestingly, an exosome-
based diagnostic test has been released, which also provides information about disease 
aggressiveness. This test analyses the expression of three genetic biomarkers of PCa aggressiveness 
in cell-derived small vesicles present in the urine (http://www.exosomedx.com/prostate-cancer) 35,40. 
Still, the applicability of some of these kits into the clinic is an undergoing process. 
 
II.3.2 Prostate cancer treatment 
 
Based on the DRE, PSA levels and the histological characterization of the biopsies through 
Gleason score and TNM classifications, different therapeutic options based on tumour stage are carried 
out following the Guidelines on Prostate Cancer, assessed by Urology Associations. Generally, the 
treatment options for PCa comprise radical prostatectomy (RP, surgical excision of the prostate), 
radiotherapy (irradiation through external beam therapy or implantation of radioactive “seeds”- 
brachytherapy), pelvic lymphadenectomy (excision of lymph nodes), hormonal therapy (androgen 
deprivation therapy or chemical castration) and chemotherapy41. In figure I8 the different therapeutic 
strategies follow according to tumour classification are represented.  
Of note, for those patients with low risk localised PCa, active surveillance is emerging as the 
main recommendation, with the aim of minimizing over-treatment and treatment related side effects. 
Under this close patient follow-up, a decision about the therapeutic strategy to apply if cancer 
progresses is made (http://uroweb.org/guideline/prostate-cancer). Importantly, there is a high necessity 
for personalized medicine in PCa, as although there are prognostic factors to guide management and 
several studies are being developed, there are no established predictive biomarkers to choose one 
particular treatment over another41. 
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Figure I 8. Stage-matched therapeutic strategies. Therapeutic strategies followed according to the European 
Society for Medical Oncology. 
III Prostate cancer mouse model 
 
Mouse models of cancer have enabled a better understanding of tumour biology in 
complicated and dynamic physiological systems. The development of gene targeting in mice has been 
useful for validating gene function, identifying novel cancer genes and tumour biomarkers. This has 
given insight in the molecular requirements of tumour cells for cancer initiation and dissemination, and 
allowed the generation of clinical models to test novel and more personalized therapeutic strategies42. 
Several specific genetically engineered mouse models (GEMMs) have been generated for PCa 
research. Overall, these mouse models have been based on the modulation of PTEN/AKT43, 
PTEN/TP5344, MYC oncogene45, ERG46, Retinoblastoma47, fibroblast growth factor48, androgen 
receptor49, WNT/β-catenin/APC and TGF-β pathways50, and SV40 T-antigen expression29,51. In this 
thesis work, a genetic engineered mouse model based on conditional PTEN loss has been used. 
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III.1 PI3K deregulation in PCa 
 
The phosphoinositide 3-kinase (PI3K)/AKT pathway is the major signalling pathway that is 
activated in many human malignancies. In fact, the activation of this pathway by a variety of 
mechanisms has been found in almost all of the late-stage prostate cancers1. PI3K signalling is initiated 
by the activation of receptor tyrosine kinases that phosphorylate PI3K at the cell membrane. This 
phosphorylation is transmitted to phosphatidylinositol-4,5-diphosphate (PIP2), leading to accumulation 
of phosphatidylinositol-4,5-triphosphate (PIP3). This accumulation leads to Akt (or protein kinase B) 
and phosphoinositide dependent protein kinase 1 (PDK1) recruitment to the cell membrane, where Akt 
is phosphorylated by PDK1 and mTOR complex 2 (mTORC2). Phosphorylated Akt activity extends 
over a wide range of substrates, but most importantly activates the serine/threonine kinase mammalian 
target of rapamycin (mTOR), which plays a significant role in tumorigenesis, regulating cell growth, 
survival, and division52. Also the interaction of Akt with the androgen receptor (AR) can lead to AR 
activation in a ligand-independent manner, ultimately up-regulating genes involved in castration 
resistant prostate cancer (CRPC)53. Remarkably, both AR and PI3K kinase pathways have been shown 
to regulate each other by reciprocal negative feedback. Thus, tumour cells can adapt and survive when 
one of them is inhibited pharmacologically, leading to CRPC development 54. Of note, the most common 
mechanism triggering hyperactivation of PI3K pathway is the somatic loss of PTEN due to genetic or 
epigenetic alterations, which has made this lipid phosphatase to become a key tumour suppressor43,55. 
Sequencing of PTEN revealed that it is one of the most commonly mutated and deleted tumour 
suppressors among human cancers56. According to the catalogue of somatic mutations in cancer 
(COSMIC), somatic mutations of PTEN have been observed in 8% of PCa cases57, and approximately 
25% of prostate HGPINs and 70% of PCa at early stage show heterozygous deletions in PTEN58. Of 
note, heterozygous inactivation of PTEN occurs as an early event in PCa initiation, and loss of the other 
allele appears as the disease progresses59.  
 
III.2 Genetic model of prostate-specific Pten deletion 
 
As mentioned before, genetic engineered mouse models (GEMMs) have been extensively 
used to study gene function in vivo. Nonetheless, gene expression loss in the whole body can lead in 
some cases to exhibit intrinsic limitations to model postnatal pathologies, mostly due to their whole 
body range of action60. In order to circumvent the consequence of losing Pten in all the cells of the 
body, and to study the role of Pten loss in the prostate, a transgenic mouse line with prostate-specific 
expression of Cre recombinase was used. This technique combines the use of the bacteriophage P1 
site specific DNA recombinase (Cre), which excises DNA sequences located between two 
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unidirectional loxP recognition sequences (“flox”), and the creation of conditional target alleles 
expressing Cre under the control of cell-type specific or inducible promoters60. 
To achieve specific deletion of Pten in the prostate, PtenloxP/loxP mice were crossed with 
Probasin-Cre (PB-Cre) transgenic mice. In PB-Cre transgenic mice Cre recombinase is expressed 
specifically in the prostate epithelium post-puberty due to its regulation by the rat Probasin (PB) gene 
promoter, which is an androgen responsive promoter25. In this thesis work PB-Cre4 version of the PB 
promoter has been used, in which Cre expression is driven by a composite promoter, ARR1PB, a more 
potent derivative of the original rat PB. Cre expression under ARR2PB promoter led to widespread Pten 
deletion in the prostate epithelium, prostate enlargement and invasive PCa with multifocal origin61. 
Homozygous prostate-specific Pten deletion leads to HGPIN development at 9 weeks of age. 
Moreover, after bypassing Pten loss induced senescence at 11 weeks of age, these HGPIN lesions 
further progress into full penetrance invasive PCa by 6 months. Although disease aggressiveness 
increased with time, these mice do not show metastatic lesions62(Fig. I9). 
 
 
Figure I 9. Prostate-specific Pten knockout mouse model. Representation of the genotype (pc: 
prostate specific, +/+: wild-type, +/-: one copy loss, and -/-: two copy loss). 
IV Regulation of cell metabolism 
 
Metabolism is defined as the sum of biochemical processes that occur within living organisms 
that either produce, or consume energy. As annotated in the Kyoto Encyclopedia of Genes and 
Genomes (http://www.genome.jp/kegg/pathway.html), it encompasses more than 8,700 reactions and 
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16,000 metabolites. All these pathways can be integrated into a “core” metabolism, based on the 
different use of nutrients allowing the homeostasis and macromolecular synthesis in organisms. This 
core can conveniently be separated in three classes: (i) routes that synthesize simple molecules or 
polymerize them into more complex macromolecules (anabolism); (ii) routes that degrade molecules to 
release energy (catabolism) and (iii) routes that help the elimination of toxic waste produced by the 
other two processes (waste disposal). The integration of all these pathways is crucial, as are the source 
of energy that allows life63. As metabolism plays a crucial role in cellular functions and biology, the 
understanding of its regulation has been the focus of research during decades. 
Organisms and cells have evolved systems for short and long term modulation of metabolic 
fluxes. For instance, hormones and other extracellular factors can communicate signals to regulate 
metabolic functions. At a cellular level, genes encoding enzyme isoforms and regulatory factors allow 
tissue- and context-specific responses, and the abundance of these proteins is controlled by mRNA 
transcription, splicing, stability, and translation64.  Once translated, the regulation of the enzymatic 
activity can be achieved through post translational modifications (PTM), providing also a feedback 
mechanisms for metabolites acting as substrates for PTM reactions. Finally, allosteric effects on 
enzymes can alter the metabolic flux. For a better comprehension of this thesis work, I will describe in 
depth the transcriptional control of cell metabolism65.  
 
IV.1 Transcriptional control of metabolism 
 
A major discovery for the study of metabolism occurred when deciphering the galactose 
operon in bacteria. It revealed how organisms can adapt their metabolic activity to environmental 
changes modifying the expression levels of metabolic enzymes. Furthermore, it showed for the first 
time a link between enzymatic activity modulation and transcriptional control of gene expression 66. 
Transcriptional control of metabolism requires specific signals to be transduced to the cell nucleus 
where defined sets of genes are targeted. Although virtually all transcription factors (TFs) are involved 
in metabolic regulation, few of them have been shown to play a predominant role in it. Particularly, 
nuclear receptors act as metabolic sensors that when activated, bind to specific response elements 
located in the vicinity of the promoter of their target genes, being responsible for the metabolic 
adaptation66. Among them is it worth to mention the following ones: the Peroxisome Proliferator 
Activated Receptors (PPARs)67, which are nuclear, lipid-sensing molecules that control genes involved 
in lipid metabolism; the Hepatic Nuclear Factor 4α (HNF4α)68; the retinoid X receptor (RXRs)69, which 
act as active heterodimers with metabolic sensor nuclear receptors (except for HNF4α); Sterol 
Regulatory Element Binding Proteins (SREBP)70, Liver X Receptor (LXR)71, Farnesol X Receptors 
(FXR)72, which are closely involved in cholesterol metabolism; and finally, CCAAT/enhancer-binding 
proteins (C/EBPs)73, which play a major role in energy metabolism66. Recently, cholesterol has also 
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been identified as a physiological and functional endogenous agonist of the estrogen-related receptor 
α (ERRα), therefore, this TF could also be included in the aforementioned list74. 
Importantly, in the last years the interest has also been focused on transcriptional co-factors 
that regulate the transcriptional activity of TFs. Therefore, they have emerged as crucial regulators to 
fine-tune many homeostatic processes75. Among many metabolic co-regulators (Fig I10), an extensive 
body of literature has highlighted the relevance of the peroxisome proliferator-activate receptor 
coactivator 1α (PGC1α) and Sirtuin 1(SIRT1) in mitochondrial function and metabolism regulation. 
Because of this, recent research has focused the attention in this additional layer of physiological 
control and has augmented the awareness to define the regulatory roles of these co-regulators in 
homeostasis and physiology75. 
 
 
Figure I 10.Metabolic co-regulator protein families Representation of the 23 major co-regulators involved in 
metabolic regulation ((PGC1A, HDAC1, HDAC9, HDAC3, KAT2A, NCOR2, NRIP1, CRTC3, PGC1B, NCOA2, 
CRTC2, MED1, NCOA3, NCOA1, KAT2B, HDAC7, NCOR1, HDAC4, RB1, SIRT1, HDAC5, CRTC1 and HDAC2). 
(Adapted from Mouchiroud L. et al Cell Metabolism. 2014). 
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IV.1.1 PGC1 co-regulator family 
 
The PGC1 co-regulator family comprises three different members PGC1α, PGC1β and PGC-
related coactivator (PRC). Of these members, PGC1α was the first described and is the most highly 
regulated among them. Initially, PGC1α was discovered as an interacting partner of PPARγ in brown 
adipose tissue, driving mitochondrial biogenesis and thermogenesis under cold exposure76. PGC1α is 
a 798-amino acid protein that is encoded by the PPARGC1A gene located on human chromosome 4. 
Up to ten different isoforms have been found for PGC1α, which shared a high level of similarity, but 
differ in the modulation of functions across tissue types77. PGC1β and PRC were identified by sequence 
homology with PGC1α and share functional similarities regulating mitochondrial biogenesis and 
metabolism78,79. 
Collectively, all the three PGC1 co-regulator family members act like docking platforms for 
assembly of the transcription machinery, orchestrating the functions of transcription factors, chromatin-
modifying complexes, and transcription initiators that act in concert to drive target gene expression80. 
All the members present an activation domain at the N terminus containing the nuclear receptor 
coactivator motif LXXLL, which recruits protein complexes that facilitate transcription, such as histone 
acetyltransferases (CBP/p300 and SRC1). Furthermore, a proline-rich domain divides two distinct 
regions for nuclear respiratory factor 1 (NRF1) binding. Preceding the C terminus there is an interaction 
domain for the Mediator complex (thyroid receptor-associated protein/vitamin D receptor-interacting 
protein complex TRAP/DRIP) that mediates transcription initiation. This region is also thought to recruit 
the SWI/SNF chromatin remodelling complex, thus providing another level of transcriptional activation. 
Finally, the C-terminal region presents an Arginine/Serine-rich domain and a RNA recognition motif, 
which can couple pre-mRNA splicing with transcription80,81.  
The presence of leucine-rich motifs in the protein surface allow this members to interact with 
different nuclear receptors or transcription factors, including NRF1/2, GABP, PPARs, ERRs and YY1. 
Among their actions, which are tissue and transcription factor-specific, they control mitochondrial 
biogenesis and remodelling, expression of muscle contractile proteins, hepatic gluconeogenesis, 
lipoprotein metabolism, circadian metabolic rhythm, reactive oxygen species (ROS) detoxification and 
angiogenesis81,82. Due to their capacity to promote mitochondrial biogenesis, improve oxidative 
metabolism and antioxidant responses, they are highly expressed in energy-demanding tissues, such 
as heart, skeletal muscle, brown fat, brain and kidney82,83.  Importantly, the nuclear receptor 
corepressor receptor-interacting protein 140 (RIP140) acts as a brake on mitochondrial biogenesis, 
being the antithesis of PGC1 co-regulators. It can bind to different nuclear receptor (including ERRs 
and PPARs) via LXXLL motifs, similar to PGC1 co-regulators81 (Fig I11). According to the results 
obtained in this thesis work, we have focused our attention in PGC1α co-regulator and its binding to 
ERRα, and the function they exert regulating mitochondrial biogenesis and metabolism. 
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V Metabolic deregulation and cancer 
 
The first evidence reporting a reprogramming of cell metabolism was provided by Otto 
Warburg almost a century ago84. This German pioneer physiologist demonstrated that tumour cells 
consume massive amounts of glucose to produce lactate through aerobic glycolysis, even being 
exposed to ambient oxygen85. Nonetheless, this discovery was left aside for many years in cancer 
research until recently, when cancer metabolism become a topic of renewed interest. Aided by new 
biochemical and molecular tools, studies in cell metabolism have expanded our understanding of 
mechanisms and functional consequences of tumour-associated metabolic alterations. The 
consolidation of this field has led to the determination of metabolic rewiring in cancer as a hallmark of 
the disease3. 
 
 
Figure I 11. PGC1 family functions according to TFs binding. PGC1α is represented in the figure as it is the 
better characterised among the members of the family, although PGC1β has been shown to play a similar role. 
 
V.1 Hallmarks of cancer metabolism 
 
The metabolic rewiring that tumour cells undergo has the aim to support anabolic growth 
during nutrient replete conditions (generation of biomass), to sustain catabolism to support cell survival 
during nutrient limitation (adaptation to microenvironment), and to fortify the redox homeostatic systems 
to counteract the metabolic effects of oncogene activation, tumour suppressor loss and other 
stresses86. In figure I12 a summary of the processes explain below can be seen. 
Mitochondrial Biogenesis
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V.1.1 Bioenergetics and biosynthesis 
 
The two principal nutrients that support survival and biosynthesis in cells are glucose and 
glutamine. The initial observations of increased glucose uptake by cancer cells made by Warburg have 
been confirmed in a variety of tumour contexts, through positron emission tomography (PET)-based 
imaging of the uptake of a radioactive fluorine-labelled glucose analogue, 18F-fluorodeoxyglucose (18F-
FDG). Interestingly, this technique has been used for tumour diagnosis and staging and for monitoring 
responsiveness to treatment87. Nevertheless, it has also been observed that the majority of tumours 
have the capacity to produce energy through glucose oxidation, this is glucose-derived carbons 
entering into the TCA cycle and being oxidized to CO2. This has been confirmed by pyruvate kinase 
inhibition, which did not lead to tumorigenesis prevention, suggesting that the major role of glycolysis 
is not to supply ATP, and is not caused by a respiration defect, but rather an adaptation to increase 
biosynthetic demand88. In order to sustain ATP production, pyruvate cannot only be derived from 
glycolysis, but also from fatty acids (FAS) and amino acids. Through β-oxidation (breakdown of FAs) 
cells obtain acetyl-CoA, which can enter into the TCA, and NADH and FADH2, which are used in the 
electron transport chain (ECT) to produce mitochondrial ATP. Furthermore, when converted to 
glutamate and subsequently α-ketoglutarate (α-KG) glutamine can fuel the TCA cycle through series 
of reactions termed glutaminolysis89. Nonetheless, the role of glutamine in tumorigenesis is 
controversial. This is, to some extent, due to the discrepancies observed in vitro and in vivo 90,91. 
Through inputs to the TCA cycle, cancer cells can adapt to obtain energy through metabolic 
flexibility in the changing microenvironment during tumour evolution. For instance, in nutrient and 
oxygen poor environments, KRas-driven pancreatic cancer cells can use proteins scavenged form the 
extracellular space to produce glutamine and fuel the TCA cycle92. Interestingly, in genetically 
engineered lung and pancreatic cancer tumours in fasted mice, circulating lactate can also fuel the TCA 
cycle, in a higher extent than glucose93. Moreover, pancreatic ductal adenocarcinoma cells can obtain 
proline from collagen present in the extracellular matrix to survive under nutrient limited conditions94. 
Moreover, proline metabolism can favour metastasis through mitochondrial ATP production95, and 
serine supports the methionine cycle through de novo ATP synthesis in cancer96 cells. Finally, cells 
sometimes adapt decreasing their demand for ATP under certain conditions and obtain it from adjacent 
cells. For example, ovarian cancer cells use FAs from neighbouring adipocytes to fuel mitochondrial 
ATP production97.  
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Figure I 12. Metabolic requirements of resting cells versus proliferating cell ones.  
 
In order to build a tumour, cancer cells proliferate from one aberrant or mutated cell, to more 
than 109 cells 98. To achieve and sustain that proliferative capacity, cells must activate biosynthetic or 
anabolic pathways to produce macromolecules required for cell division and tumour growth98. Proteins, 
lipids and nucleic acids, which comprise 60, 15 and 5% of cells respectively, are the most studied 
macromolecules in cancer metabolism. Conditions in which glutamine and other amino acids are 
available, mTORC1 can mediate the activation of protein synthesis via its effect on translation and 
ribosome biogenesis99. Also, ammonia accumulation has been shown to be able to generate amino 
acids through glutamate dehydrogenase activity100. Nevertheless, when nutrients are scarce, cells take 
advantage of intracellular proteins and other macromolecules, which can be recycled through 
autophagy. Autophagy is a survival pathway normally activated under nutrient or growth factor 
deprivation, and genetic studies have demonstrated that it contributes to tumorigenesis101. Regarding 
FAs synthesis for cell membrane biosynthesis, lipidation reactions and cellular signalling, cells must 
obtain acetyl-CoA and reducing power in form of cytosolic nicotinamide adenine dinucleotide phosphate 
(NADPH). On the one hand, acetyl-CoA can be obtained primarily from glucose or glutamine and 
acetate under hypoxic or mitochondrial dysfunction conditions86. On the other hand, NADPH pools used 
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for FA synthesis arise mainly from the pentose phosphate pathway (PPP) 102. Also, both FAs and lipids 
can be obtained from the extracellular space to supply membrane biosynthesis86. Moreover, CD36+ 
metastasis initiating cells rely on dietary lipids to promote metastasis103. PI3K signalling can activate 
their uptake and suppress fatty acid oxidation, maximizing lipogenesis in proliferating cells under the 
control of growth factors104. Finally, purine and pyrimidine nucleotides are required for DNA and RNA 
synthesis, which novo biosynthesis is complex and requires the input from several pathways, such as 
PPP, to obtain the ribose-5-phosphate backbone, and the presence of non-essential amino acids and 
methyl groups donated from one-carbon and folate metabolisms to build the purine and pyrimidine 
bases105. 
 
V.1.2 Redox balance 
 
Mitochondrial oxygen metabolism is linked to the generation of reactive oxygen species 
(ROS), which, at high levels, can damage nucleotides, proteins and lipids, then impairing cell viability106. 
In fact, during tumorigenesis and metastasis, redox homeostasis is required. When tumour initiates, 
the metabolic activity of cancer cells changes, boosting ROS levels and resulting in the activation of 
signalling pathways that support cancer cell proliferation and survival. Accordingly, tumour cells 
increase their antioxidant capacity to prevent toxic levels of ROS and to allow cancer progression107. In 
this case, cell increase NADPH levels activating AMPK by stimulating PPP, inactivating anabolic 
pathways and from serine through one carbon metabolism108. When generated, NADPH can feed into 
the glutathione (GSH) oxidation-reduction pathway, which is crucial for ROS detoxification98. However, 
the role of ROS in cancer is controversial, as in some cases it can either promote or suppress 
tumorigenesis109. 
 
V.2 PGC1α and cancer  
 
PGC1 co-regulators have a great capacity to integrate environmental signalling cues and 
cellular energetic demands. Therefore, it is not surprising that changes in their expression and activity 
could affect the metabolic status of tumours and play a role in shaping responses to metabolic stress 
during tumorigenesis80. To have a better comprehension of this thesis work, we will define the role of 
PGC1α in cancer initiation, progression and metastasis. The literature and the role of PGC1α in 
tumorigenesis in cancer exponentially growth in the course of this thesis work. In order to aid the correct 
understanding of the complexity of this field, a summary table is shown at the end of the section (Table 
I1). 
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V.2.1 PGC1α, cancer initiation and therapeutic response 
 
PGC1α is differentially expressed among different cancer tumours, presenting a great 
capacity to shape cellular metabolism. It has been tightly associated with both enhancement and 
suppression of tumour initiation and progression. On the one hand, clinical correlative analysis have 
indicated that PGC1α expression is reduced in colon and ovarian tumours compared with their 
respective adjacent normal tissues110,111. On the other hand, its genetic ablation protects mice from 
colon carcinogenesis112, and its loss within tumour-prone mouse background enhances intestinal 
cancer tumorigenesis 113. In melanoma, the melanogenesis associated transcription factor (MITF) 
upregulates PGC1α expression controlling cell growth and survival114,115. Furthermore, the androgen 
receptor-AMP activated protein kinase (AMPK) signalling axis controls the expression of PGC1α in 
prostate tumours, driving growth advantages116. In the context of tumour TP53 (p53) status, it has been 
observed that lung adenocarcinomas with wild-type p53 present higher expression of PGC1α than p53 
mutated ones117. 
Tumour cells require a well-tuned mitochondria to sustain anabolic pathways. Therefore, the 
oxidative and lipogenic functions of PGC1α have been widely studied in tumorigenesis. For instance, 
in liver and colon cancer cells, PGC1α drives the expression of lipogenic enzymes and of the 
mitochondrial citrate exporter, enabling TCA cycle carbon flux towards anabolic processes that fuel 
tumour growth112. Furthermore, PGC1α over-expression (through ERRα activation) in ERBB2-positive 
breast cancer cells confers growth advantage through glutamine use, which enters the TCA cycle and 
leads to de novo fatty acid biosynthesis. In this case, high expression of PGC1α and its downstream 
glutamine pathway genes are associated with poor patient prognosis118. In contrast, PGC1α re-
expression in clear renal cell carcinomas (cRCC) restores mitochondrial function, and the oxidative 
stress induced inhibits tumour cell growth and enhances the sensitivity to cytotoxic therapies119. In line 
with this data, a higher mitochondrial mass has been associated with reduced tumour aggressiveness 
in ccRCC, and lower PGC1αlevels associate with worst patient outcome 120. Similarly, in colorectal 
cancer cells PGC1α over-expression suppresses tumour growth by boosting intrinsic oxidative 
stress113. Furthermore, pancreatic cancer stem cells (CSC) exhibit great dependency on oxidative 
phosphorylation, unlike the differentiated progeny that relies on glycolysis. The increased expression 
of PGC1α in CSC restricts their metabolic plasticity, increasing their susceptibility to metabolic drugs121. 
In line with this work, breast cancer with elevated PGC1α activity are more reliant on folate cycle and 
thereby more vulnerable to antifolate drugs122. 
Interestingly, high PGC1α expression in melanoma cells drives dependence on mitochondrial 
respiration and resistance to oxidative stress. Indeed, melanomas with low levels of this co-regulator 
are more dependent on glycolysis and more sensitive to oxidative stress.  When glycolysis is inhibited 
in these cells, a shift towards glutamine sustains tumour growth123. Furthermore, while in liver it has 
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been reported that PGC1α genetic suppression leads to increased oxidative stress and p53-induced 
apoptosis, increased levels of PGC1α prevent p53-induced cell death by maintaining a balance 
between oxidative phosphorylation and glycolysis in lung124,125. These findings suggest the high 
metabolic and bioenergetics flexibility in cancer and imply the necessity of combinatorial approaches 
to target metabolic components during tumorigenesis. 
 
V.2.2 PGC1α and metastasis 
 
Metastasis represents a multi-step process that among many other requirements, involves 
switching from a fast-proliferating state to a slow growing, but highly invasive state. Apart from 
regulating tumour growth, the expression of PGC1α has been implicated in shaping the tumour 
microenvironment, a crucial step to metastasize. For instance, PGC1α can regulate angiogenic 
processes in multiple myeloma and some breast cancers, promoting vascularization126,127.  
Some recent studies suggest the implication of PGC1α-induced metabolic state in metastasis. 
For example, circulating mammary epithelia cancer cells exhibit elevated PGC1α expression and 
enhanced mitochondrial biogenesis, which associates with distant metastasis and poor patient 
outcome128. In this case, PGC1α knockdown abolishes cytoskeleton remodelling, anchorage-
independent survival, and intra- and/or extravasation128. Moreover, highly metastatic melanoma cells 
contain fewer mitochondria and express low levels of PGC1α129,130. Therefore, PGC1α expression is 
heterogeneous among different cell subpopulations with proliferative or invasive properties in 
melanoma, which allow phenotype switching and adaptation to local environment. Finally, a recent 
study has highlighted the role of PGC1α promoting breast cancer migration and invasion in vitro and 
inducing lung metastasis in vivo. This metastatic potential is mediated by the bioenergetics potential of 
PGC1α, which facilitates adaptation to metabolic drugs131. 
Table I 1. Summary of PGC1α expression and function in cancer. (Adapted from Luo C et al. Trends in 
Cancer 2016) 
Tissue/ 
Tumour 
Expression level Cellular process Ref 
Breast 
Heterogeneous PGC1α 
levels: high expression 
correlation with reduced 
survival and metastasesα 
Promotes glutamine metabolism to 
enhance growth an chemoresistance, 
induces mitochondrial respiration and 
ATP production to drive metastasis, 
promotes metastasis to lung and bone 
conferring bioenergetics potential,  
promotes vascularization and sensitivity 
to antifolate drugs 
118,126,128, 
122,131 
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Colon 
Decreased PGC1α in tumour 
compared to normal mucosa 
Not determined 110 
Not specified Promotes chemoresistance 132 
Not specified 
Promotes tumour growth by controlling 
mitochondrial and FA metabolism 
112 
Intestinal PGC1α highly expressed Protects against tumorigenesis 113 
Kidney 
Decreased expression 
correlated with poor outcome 
Induces mitochondrial function, oxidative 
stress and sensitivity to cytotoxic 
therapies 
119 
Liver Not specified 
Promotes tumour growth by regulating 
mitochondrial and FA metabolism, and 
enhances cell survival with p53. 
112,125 
Lung 
Heterogeneous PGC1α 
levels 
Correlation with oxidative metabolism, 
enhance survival with wild-type p53 
117,124 
Melanoma 
Increased in 20% 
melanomas, highly 
heterogeneous, its levels are 
associated with reduced 
primary melanoma invasion 
and improved outcome, but 
with increased 
aggressiveness of metastatic 
disease 
Promotes mitochondrial biogenesis and 
protects against oxidative stress to 
influence drug sensitivity and survival, 
and suppresses migration and/or 
invasion gene sets to inhibit metastasis 
114,115,130 
Multiple 
myeloma 
Not specified 
Promotes vascularization and 
chemoresistance 
127,133 
Ovarian 
Decreased in tumours 
compared to normal ovaries 
Induces apoptosis 111 
Pancreatic Not specified 
Promotes oxidative metabolism to 
maintain cancer stem cell function 
121 
Prostate 
Increased in 5% of patients 
 
Promotes mitochondrial biogenesis, ATP 
production, and cell growth downstream 
of androgen receptor-AMPK axis 
116 
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 Despite Prostate Cancer (PCa) has been investigated during decades, it is the third most 
common cancer and the third leading cause of cancer death in men in Europe. These facts remark the 
high necessity to develop more selective and efficient therapies, as well as prognostic tools in order to 
eradicate the disease. The deregulation of metabolism has been established as one of the main 
hallmarks of cancer. On the one hand, this rewiring is possible due to multiple and complex alterations 
in metabolic pathways. On the other hand, transcriptional programs modulate metabolic programs in 
the cell. This thesis work stems from the interest in deciphering how metabolic pathways are modulated 
during prostate cancer progression, dissemination and invasion, and is based in the following 
hypothesis: Transcriptional control of metabolism contributes to PCa aggressiveness. 
  
We based our work in the premise that transcriptional co-factors control a wide range of 
metabolic pathways, which makes them ideal targets to modulate tumorigenic events. Interestingly, this 
metabolic reprogramming may lead to therapeutic vulnerabilities, being of great interest to develop new 
treatments.  
In order to test this hypothesis, we establish the following specific aims: 
 
Aim1: To identify central regulators of tumour metabolism through the gene expression 
analysis of known metabolic transcriptional co-regulators in prostate cancer (PCa) patient data 
sets. 
1. Bioinformatics analysis to define the expression of transcriptional co-regulators in a preliminary 
data set. 
2. Differential expression in additional PCa patient data sets. 
3. Association of the expression of the co-regulators with the progression and aggressiveness of 
the disease. 
 
Aim 2: To elucidate the causal contribution of the selected co-regulator in vivo  
1. Analysis of a mouse model driven by loss of PTEN in the prostate epithelium and altered 
expression of the selected candidate. 
2. Histopathological analysis of mutant mice. 
 
Aim 3: To evaluate the activity of the candidate in PCa cell biology. 
1. Generation of a cellular system to study the candidate´s effect in PCa cell lines. 
2. Validation of the candidate activity in PCa cell lines. 
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 Aim 4: To decipher the mechanism of action of the co-regulator in PCa. 
In order to characterize the metabolic, transcriptional and cellular effect elicited by the 
candidate, we will undertake the following integrative approach: 
1. Metabolic changes elicited by the candidate in PCa: Liquid Chromatography-Mass 
Spectometry (LC/MS) and targeted metabolomics/Metabolic Flux Analysis (MFA) and biochemical 
assays to study the most altered and relevant pathways. 
2. Transcriptional modulation by the co-regulator in PCa: transcriptomic analysis. 
3. Cellular characterization and cytoskeletal modulation by the candidate in PCa cells. 
 
Aim 5: To ascertain the therapeutic and prognostic potential of the candidate for personalized 
medicine. 
Based on the need of new efficient and reliable prognostic tools, we will approach this aim in 
two ways: 
1. Evaluation of the transcription/metabolic signatures as therapeutic tools. 
2. Evaluation of the transcription/metabolic signatures as prognostic tools. 
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I Materials 
I.1 Cell lines and culture conditions 
 
Human prostate carcinoma cell lines (PC3, LNCaP, DU145) were purchased from Leibniz-
Institut DSMZ (Deutsche SammLung von Mikroorganismen und Zellkulturen GmbH), who provided 
authentication certificate, or American Type Culture Collection (ATCC) in the case of 22RV1 and VCaP 
cell-line. Virus packaging cell lines (HEK293FT) and C4-2 were generously provided by the laboratory 
of Dr. Rosa Barrio and Pier Paolo Pandolfi, respectively. Melanoma cell lines (HT114, HT294T, A375 
and MeWo) were kindly provided by Maria Dolores Boyano and Aitziber Buqué.  PC3, DU145 and 
293FT were cultured in Dulbecco's Modified Eagle Medium without pyruvate (DMEM; Gibco 41965-
039), HT294T and A375 were cultured in DMEM with pyruvate (Gibco 41966-029) and LNCaP, C4-2 
and 22RV1 were cultured in RPMI 1640 Medium (Gibco 61870-010; with GlutaMAX supplement). 
MeWo cell line was cultured in Eagle's Minimum Essential Medium (Gibco 11095080) and HT114 cells 
in McCoy´s 5a Medium Modified (Gibco 1660082).  
All culture media were supplemented with 10% inactivated Fetal Bovine Serum (FBS) (Gibco), 
from same lot and previously analysed to ensure experimental reproducibility, and 1% 
Penicillin/Streptomycin (Gibco) (named complete media). All the experiments were performed with 
complete media unless otherwise specified. LnCaP and HEK293FT were seeded on poly-lysine coated 
plates (Sigma P8920). See table M1 for cell line specifications. All cell lines were grown at 37ºC in a 
humidified atmosphere of 5 % CO2. Cells were regularly cultured in 100mm dishes and split every 3-4 
days, maintaining them below 80-90 % density, up to 30 passages maximum. In order to split the cells, 
they were incubated with trypsin-EDTA solution (Gibco) at 0.05 % for 5 minutes at 37ºC, and re-
suspended in fresh complete media. All cell-lines were routinely monitored by PCR for mycoplasma 
presence and replaced or treated in case of positive result. For cell counting after trypsinization, cells 
were diluted 1:2 in Trypan Blue Dye 0.4% (Amresco) and 10 μL were loaded in a Neubauer chamber 
to count viable cells by optical microscopy (Olympus CKX31). The Trypan Blue dye allows to determine 
cell viability based in the fact that dead cells show disrupted plasma membrane and allow the 
internalization of the dye staining their cytoplasm in blue, while alive ones remain with intact cell 
membrane and non-stained.  
I.2  Drugs 
 
All drugs used in this thesis study have undergone a titration in order to find the appropriate 
concentration for its activity. The information regarding the different inhibitors and drugs is shown in 
table M2. 
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Table M1. Detailed list of the characteristics of the different PCa cell lines employed in the work. 
Cell-line Cell type Morphology Derivation 
Pten 
status 
PC3 
(ACC 465) 
Prostate 
adenocarcinoma 
Epithelial-like 
Bone marrow metastasis of grade IV 
prostate cancer after androgen 
suppression therapy 
Negative 
DU145 
(ACC 261) 
Prostate 
Carcinoma 
Epithelial-like 
From metastatic central nervous 
system lesion 
Positive 
LnCaP 
(ACC 256) 
Prostate 
Carcinoma 
Fibroblastoid 
From supraclavicular lymph node 
metastasis 
Negative 
VCaP 
(CRL-
2876) 
Prostate 
Carcinoma 
Epithelial 
From vertebral bone metastasis 
from a patient with hormone 
refractory prostate cancer 
Positive 
C4-2 
Prostate 
Carcinoma 
Fibroblastoid LNCaP derived androgen-resistant Negative 
22rV1 
(CRL-
2505TM) 
Prostate 
Carcinoma 
Epithelial 
From CWR22 xenograft propagation 
after castration-induced regression 
and relapse 
Positive 
HT114 
Malignant 
Melanoma 
Fibroblastoid 
Derived from metastatic site, 
subcutaneous tissue 
- 
HS294T Melanoma 
Mixed stellate and 
polygonal 
Skin, derived from metastatic site 
(lymph node) 
- 
A375 Melanoma Epithelial 
Skin, derived from metastatis 
melanoma 
- 
MeWo 
Malignant 
Melanoma 
Epithelial 
Skin, derived from metastatic site 
(lymph node) 
- 
HEK293FT 
Human 
embryonic kidney 
cells 
Fibroblastoid 
From human primary embryonal 
kidney transformed by adenovirus 
type 5 
Negative 
  
II Cellular analysis 
 
The experiments carried out based on cellular assay were performed mainly with PC3, DU145 
and LnCaP cell lines. All of them were counted as previously described (I.1). For either WT or L2L3M 
Pgc1a expression (alone or in combination with ESRRA silencing) a chronic induction with doxycycline 
(0.5 g/mL) was performed as explained in figure M1. The concentration of doxycycline used was 
determined according to a previous titration.  
 
II.1 Proliferation assay by crystal violet staining 
 
Cells were seeded in 12-well plates (5,000 cells/well) and kept for 0, 2, 4 and 6 days. Each 
plate (one per day) was washed with 10% PBS, fixed with 10% formalin and stored at 4ºC. All plates 
were processed at the same time once the experiment was finished. Once fixed (the day 6-plate for at 
least 15 minutes with formalin at room temperature (RT)), plates were washed again with 10% PBS 
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and stained with crystal violet 0.1% crystal violet (SIGMA C3886) and 20% methanol for 1 hour. After 
washing with distilled water (dH2O) (until the water comes out clean) and air dry the plates, precipitates 
were dissolved in 10% acetic acid for 30 minutes and absorbance was measure in 96-well plates in the 
spectrophotometer at 595nm. 
Table M2. Commercial information and experimental specifications for the different drugs used during 
the thesis work. 
Drug Supplier Dose Function 
Hygromycin 
Invitrogen 
(10687010) 
1.5 
g/mL 
Cell selection after infection 
Puromycin Sigma (P8833) 2 g/mL Cell selection after infection 
Doxycycline Sigma (D9891) 0.5 g/l Gene-inducible system 
XCT 790 Sigma (X4753) 2-8 M Potent and specific inverse agonist of ERRα 
Etomoxir Sigma (E1905) 25 M Inhibition of fatty acid oxidation 
NAC Sigma (A7250) 1 mM Anti-oxidant 
MnTBAP Millipore (475870) 100 M Anti-oxidant 
UK5099 Sigma (PZ0160) 25 M Inhibitor of mitochondrial pyruvate carrier 
Oligomycin Sigma (75351) 1 M 
Oligomycin blocks oxidative phosphorylation by 
inhibiting membrane bound mitochondrial ATP 
synthase (ATPase) and proton channel (pump, FO 
subunit) blocker. 
FCCP Sigma (C2920) 1 M 
FCCP is a protonophore (H+ ionophore) and 
uncoupler of oxidative phosphorylation in 
mitochondria. It is capable of depolarizing plasma and 
mitochondrial membranes 
Rotenone Sigma (R8875) 1 M 
Inhibitor of mitochondrial electron transport at NADH: 
ubiquinone oxidoreductase. 
Antimycin A Sigma (A8674) 1 M 
Inhibitor of electron transfer at complex III. Induces 
apoptosis 
Ampicillin 
sodium salt 
Sigma (A0166-59) 50 g/mL Bacterial selection 
BPTES Sigma (SML0601) 8 M Glutaminase 1 inhibitor 
 
 
Figure M1. Scheme of doxycycline (0.5 g/mL) cell induction (p1; 1st pass and p2; 2nd pass). 
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II.2 Anchorage-independent growth (Soft Agar) 
 
As an aggressiveness parameter, cells were maintained in anchorage independent growth. 
For cell plating in anchorage independent conditions, 6 well-plates were previously coated with a lower 
layer of 0,6% agar (SeaKem LE agarose, Lonza) medium mixture (3 mL/well) and stored at 4ºC for at 
least 30 minutes to let the agar solidify. Previous to the upper layer seeding, cells (5,000 cells/well) 
were suspended in a 0.3% low melting agar (Agarose LM. Pronadisa. Conda) medium mixture and 1 
mL/well were plated. Low melting agar allows to maintain the agar/cell mixture liquid at lower 
temperature, to avoid harming cells. Plates were stored at 4ºC (around 30 mins) to allow the 
solidification of the upper layer and then incubated at 37ºC in a humidified atmosphere of 5% CO2 for 
3-4 weeks (depending on cell line), until colony detection. Colonies were then quantified using Fiji 
software. 
 
II.3 DNA synthesis rate analysis by bromo deoxyurdine (BrdU) 
 
In order to analyze cell proliferation, the incorporation of the thymidine pyrimidine analogue 
BrdU (5-bromodeoxyurdine) into newly replicated DNA was used. This technique is based on the direct 
correlation between DNA replication and cell division. 
BrdU Incorporation 
BrdU is a thymidine analogue. During DNA replication process134. BrdU gets incorporated into 
the DNA. Since monoclonal antibodies were developed to detect and bind to incorporated BrdU into 
DNA 135, BrdU has been extensively used to estimate cell proliferation by immunofluorescence. In this 
thesis work, the BrdU incorporation was performed in asynchronic cell cultures. Cells were seeded on 
coverslips (10,000 cells/well) and after 3 days, BrdU (Sigma B5002) was added to culture media to a 
final concentration of 0.2 µg/mL and incubated for 3-4h at 37ºC in the incubator. After incubation, cells 
were washed with PBS and fixed with 4% paraformaldehide (PFA) solution in 10% PBS for 15 minutes. 
Cells were washed twice to eliminate remaining PFA and coverslips were stored in 10% PBS at 4ºC 
until processing. 
 
DNA exposure and detection by immunofluorescence (IF) 
DNA, and therefore the BrdU, needs to be exposed and detected with monoclonal antibodies. 
To this end, coverslips were incubated with HCl 2 M for 5 minutes and quickly washed twice with PBS 
to further neutralize the acid with Borax (Sodium tetraborate 0.1 M, pH8.5) for 5 minutes. Cells were 
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then permeabilized with Triton X100 0.1%/Glycine 0.1 M for 5 minutes and 10% goat serum (diluted in 
10% PBS) was employed as blocking reagent for 30 minutes at RT.  
Primary antibody against BrdU (BD Pharmingen™, Cat# 555627) was incubated at 1:100 
dilution in 10% goat serum overnight at 4ºC. The next day, secondary anti-mouse antibody (Alexa 
Fluor® 594 dye) was incubated at 1:1000 dilution in 10% goat serum for 1 hour in the dark. Finally, 
cells were stained with DAPI (Ref. D1306 Thermo Fisher) (1:10,000 dilution in 10% PBS) for nuclear 
staining and coverslips were mounted onto slides with home-made Mowiol (Ref 324590 Sigma). The 
slides were stored at 4ºC in the dark until analysis with the upright fluorescent microscope AxioImager 
D1 (Carl Zeiss). Cells positive for BrdU staining were counted, as well as total number of cells (DAPI 
staining) and cell division ratio was calculated. 
 
II.4 Cell cycle analysis 
 
Propidium Iodide (PI) is an intercalating fluorescent agent extensively used for cell cycle 
analysis136. Cells (75,000 cells/well) were plated and after 3 days, harvested and washed twice with 
10% PBS. Harvested cells were suspended in 1 mL of 10% PBS and fixed drop by drop with 2.5 mL of 
absolute ethanol (70% final ethanol concentration). Next, cells were centrifuged (6 minutes at 400 rcf) 
and re-suspended in 200-500 µl of PI staining solution [RNase 25 g/mL (stock 1 mg/mL), Triton X-100 
0.05%, PI (Invitrogen P3566): 1 µg/mL (stock 1 mg/mL)]. Samples were incubated for 20-40 minutes 
at 37ºC and analysed by flow cytometry (FACS Canto). 
 
II.5 Invasion in transwell system 
 
Invasion was carried out using chambers with matrigel (BD CioCoatTM 354480). Cells (50,000 
cells/well) were re-suspended in 0.1% FBS DMEM and seeded in the upper part of the chamber. In the 
well (bottom part) 1.4 mL of complete DMEM were added. Plates were maintained at 37ºC and 5% CO2 
for 48 hours. Invasion was stopped washing the well twice with 10% PBS and using a cotton bud to 
clean the upper part of the membrane, being careful not to compromise the matrigel. The membrane 
was fixed with 10% formalin (15 minutes at 4 ºC) and stained with DAPI (1:10,000 10 minutes) or crystal 
violet (as previously described). Cells that were stained, were the ones that had invaded into the 
matrigel membrane in the chamber and were counted at the microscope (see figure M2). 
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II.6 Migration in transwell system 
 
Migration was done in chambers with transmembranes of 8 m pores (BD Falcon 351185). 
Cell plating, washing and fixation conditions were the same as in the invasion assay. The only 
difference was in the incubation time, which in this case was 24 hours (see figure M2). 
 
 
 
 
 
II.7 Invasive growth (spheroids) 
 
 To study invasive growth, cells (700 cells/drop) were maintained in drops (25 L/drop) with 
DMEM and 6 % methylcellulose (Sigma M0387) on the cover of a 100 mm culture plate and 10 % PBS 
was added on the bottom of the plate. This allowed the formation of a suspension system that brought 
the cells together in order to form spheroids, and the PBS avoided them to dry. Drops were incubated 
at 37ºC and 5% CO2 for 48 hours (Fig M3). After that time, spheroids could be observed and drops 
were collected with 5 mL of complete DMEM and centrifuged at 500 rpm during 15 seconds. The pellet 
containing the spheroids was re-suspended in 300 L of bovine collagen I (Advanced BioMatrix 
PureCol®) mix and added to 12–well plates. After 4 hours, 500 l of complete DMEM were added to 
each well. Pictures of the spheroids in collagen were taken at day 0 and after 48 hours to calculate the 
invasive growth ratio. 
Bovine Collagen I mix preparation: The components and the mix were kept on ice during all 
the process and added in the following order per mL: 555.6 l bovine collagen I, 200 L of DMEM 5X 
(Gibco powder DMEM 12800-017 five times concentrated), 213.5 L of filtered milliQ water (mqH2O) 
and 30 L of NaOH 0.1 N. All components were mixed by pipetting up and down and bubbles were 
taken out applying vacuum in the closed tube with a needle in the top. 
 
Figure M 2. Scheme of the invasion and migration transwell system.  
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Figure M 3. Picture of a spheroids formed in a DMEM-methylcellulose drop for 48 hours. 
II.8 3D Invasion 
 
Before starting the experiment, a coating of BSA 0.2% (Ref. 0332 VWR AMRESCO) diluted 
in DMEM 5X was done in a 96-well plate for 30 minutes at 4ºC. Empty wells were filled with 10% PBS. 
After this, cells suspended in bovine collagen I (15,000 cells/well) were plated. The preparation per mL 
of collagen mix was: 720 L of collagen I, 260 L of DMEM 5X and 39 L of NaOH 0.1N, and it was 
mixed and prepared as previously described (II.7). After being re-suspended in collagen (100L/well) 
and added to the wells, cells were centrifuged at 1,800 rpm during 8 minutes at 4 ºC.  The plate was 
then incubated at 37ºC and 10% CO2 for 4 hours. Then, 100L of fresh complete media were added to 
each well and the plate was incubated 24 hours at 37ºC and 10% CO2. The following day, cells were 
fixed overnight with 50L of formaldehyde 20% (Sigma F8775) with 1:200 Hoechst (Invitrogen H3569). 
Invasion was analysed in a confocal microscope (Leica TCS SP5), doing stacks at the well base, and 
50 and 100 m from it. Cells that were able to invade the collagen matrix will reach higher distance 
from the base (Fig M4). 
 
Figure M 4. 3D invasion scheme. Cells are initially platted in the bottom of the well and the capacity to invade 
into collagen is measure taking pictures at 50 and 100 m from the well base. 
 
II.9  Phalloidin immunostaining (Cell Morphology) 
 
Cells (10,000 cells/well) were seeded during two days in a 12-well plate with coverslips on 
the bottom. Cells were then fixed with 4 % formaldehyde, washed with 10% PBS and permeabilized for 
20 minutes with a solution of 10% PBS, 4% BSA and 0.3% Triton X-100 (Ref. T8787 Sigma). After 3 
Cells
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washes with 10% PBS, a blocking solution (10% PBS- 4%BSA) was added and incubated for 30 
minutes. Then, fluorescent phalloidin (ThemoFisher F432; 1:400 dilution) was incubated during 1 hour 
at RT. After the incubation, a wash with DAPI (Ref. D1306 Thermo Fisher) was performed at 1: 10,000 
dilution. Coverslips were then mounted with Mowiol and pictures were taken with AxioImager D1 
microscope (Carl Zeiss). Cell area was measured using Fiji Software. 
 
II.10 Cell adhesion assay 
 
Cells were plated (40,000 cells/well) on a 12-well plate which was previously coated during 1 
hour with rat tail collagen I (Corning 354236) at 50 μg/mL and diluted in 0.02 N of acetic acid. After 30 
minutes, plates were washed twice with 10% PBS and stained with crystal violet as previously 
described (II.1). The cells with a higher capacity to adhere, were attached to the plate and stained.  
 
II.11 Mitochondrial ATP assay 
 
The mitochondrial ATP assay was performed in collaboration with Paolo Pinton´s laboratory. 
Cells (50,000 cells/well) were plated onto 13-mm coverslips and transfected with a mitochondrial 
targeted luciferase chimera (mtLuc). Cells were perfused in the luminometer at 37°C with Krebs Ringer 
Bicarbonate (KRB) solution containing 25 µM luciferin and 1 mM CaCl2 and supplemented with 5.5 mM 
glucose. Under these conditions, the light output of a coverslip of transfected cells was in the range of 
5,000–20,000 counts per second (cps) for the luciferase construct versus a background lower than 100 
cps. Luminescence was entirely dependent on the presence of luciferin and was proportional to the 
perfused luciferin concentration between 20 and 200 µM. 
 
II.12 Mitochondrial morphology  
 
The mitochondrial morphology was also performed in collaboration with Paolo Pinton´s 
laboratory. It was assessed by using a cDNA encoding mitochondrial matrix-targeted DsRed 
(mtDsRed). Cells were seeded onto 24-mm diameter coverslip (thickness between 0.16–0.19 mm) 
(Thermo Scientific) and 24 hours later they were transfected with 2 μg mtDSred (Lipofectamine LTX 
reagent; Invitrogen). mtDsRed expression was assessed 36 hours after transfection. All the acquisitions 
were performed with a confocal Nikon Eclipse Ti system and fluorescent images were captured by 
using NisElements 3.2.  
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Mitochondrial images in live cells (PC3 cell line) shown in this thesis work were performed 
using NuncTM Lab-TekTM (ThermoFisher 155411) chambers in which 10,000 cells/well were plated. 
The following day, live cells were incubated with MitoTracker® Red CM-H2Xros at 1: 5,000 dilution and 
Hoechst (Invitrogen H3569) at 1:5,000 dilution in complete media during 30 minutes. All the image 
acquisitions were performed with a confocal microscope and maximal resolution was performed (Leica 
TCS SP5). 
 
II.13 Seahorse assay 
 
Oxygen consumption rate (OCR) and the extracellular acidification rate (ECAR) were 
measured with a Sea Horse XFe24 analyser (Agilent Technologies). Cells (20,000 cells/well in a final 
volume of 100 μL/well) were plated in a XFe24 plate, with the corresponding background wells without 
cells, and incubated 24 hours at 37C in a humidified atmosphere of 5% CO2. The following day, one 
hour before running the experiment in the Seahorse analyser, 675 μL of Sigma D5030 media 
supplemented with 1%FBS, 25 mM glucose (Ref. G8270 Sigma) and 4 mM glutamine (Ref.25030081 
Gibco) were added to each well. In the meantime, the dilutions of the drugs to be charged in each 
injector were prepared with the same media (see table M2 for drug information and final 
concentrations). In the injector A (Oligomycin) 75 μL are loaded, in B (FCCP) 83 μL, in C 92 μL and in 
case of using additional drugs, in port D102 μL are loaded (Fig M8A). The concentration of the drugs 
in the injector was 10 times higher than the one expected to be in the wells. In this assay, ATP 
production and basal and maximal respirations were analysed (Fig M8B). After the assay, the protein 
of each well was extracted and quantified as explained in section III.4.1 for normalization. In the basal 
respiration analysed for XCT790 treatment and Pgc1a mutant (L2L3M), the normalization was 
performed by cell density using crystal violet as explained in II.1. 
 
Figure M 5. Seahorse experiment set up. A, Injectors-scheme from the Seahorse drug-plate. B, Graph showing 
the data that can be analyzed and studied according to the drugs used. Adapted from www.agilent.com. 
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II.14 Survival and nutrient deprivation assays 
 
When metabolic drugs were tested cells (200,000 cells/well) were plated on a 6-well plate, 
and the following day media was changed and the drug under study was used (Table M2). The same 
number of cells was seeded when incubations with nutrient depleted media were performed. In both 
cases, after 48 hours, cells were fixed and stained with crystal violet as previously described (II.1). 
 
II.15 ROS production measurement 
 
MitoSOX and DCF staining were used to measure ROS production measurements as 
previously described137. This assay was carried out in collaboration with Paolo Pinto´s lab. MitoSOX 
Red is a dye commonly used to measure superoxide production in the mitochondrial matrix. Due to its 
cationic behaviour, it rapidly reacts with superoxide anions and is oxidized to form 2-
hydroxymitoethidium, which excites and emits at 510 and 580 nm respectively. Fluoresecent DCF, 
which is excited at 495nm and emits at 520nm, results from the oxidation of the DCFH carboxylate 
anion. This anion results from the hydroxylation of CM-H2DCFDA, the hydrogen peroxide-detecting 
probe for the measurement of hydrogen peroxide (H2O2) in intact cells. In both cases, cells were plated 
in multiwall plates and fluorescence was monitored with a microplate reader set to the corresponding 
wavelength. 
 
II.16 Fatty acid oxidation assay 
 
Day1 
In the morning, cells were plated (200,000 cells/well) in a 6-well plate and kept at 37ºC and 
10% CO2. In parallel, control wells were plated for every condition to extract the protein for 
normalization. Ion exchange columns were prepared. In order to do that, long pasteur pipets were 
sealed by burning and the loaded with 0.5-1 cm of glass wool (Supelco 2-3084). Then, 2 mL of DOWEX 
(Sigma 217395) 36.7 % diluted in distilled water were added to each column and let settle overnight. 
An overnight incubation with DMEM with 10 % FBS, 1% penicillin/streptomycin, 100M palmitic acid 
(Sigma P0500) and 1mM carnitine (Sigma C0158) is performed in order to activate lipid metabolic 
machinery. 
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Day2 
The following day, DMEM with 10%FBS, 1% penicillin/streptomycin, 100M palmitic acid and 
1mM carnitine was prepared, to which a final concentration of 1.6Ci of 3H-Palmitate (TRK909) was 
added. Etomoxir, an inhibitor of the fatty acid oxidation, is used as a blank for the assay (see table M8). 
It is used at a final concentration of 25 M. Cells were incubated during 2 hours at 37ºC and 10 % CO2. 
The aim of this incubation with3H-Palmitate was to detect the 3H2O formed during cellular oxidation. 
During the incubation time, the bottom part of the columns was broken so that the water from 
the DOWEX flows out of them. Moreover, tubes containing 500 L 10 %TCA (Sigma T6399) and 100 
l of 6M NaOH per sample were prepared. After the 2 hours’ incubation time, 500 L of the media from 
the wells are added to the TCA tubes. The mix is centrifuged at 4,000rpm during 10 minutes. The 
supernatant was collected and mixed with the NaOH and directly injected into the corresponding 
column already placed in a scintillation vial (Sigma V8255-500EA) with 5 mL of scintillation fluid 
(Fischer Scintisafe plus 50%). The liquid was let to enter into the column and the radioactive product 
was eluted adding 850L of milliQ (mQ) water were added twice. Then, the vials were closed and 
shaken vigorously. Radioactivity was measured in a Beckman scintillator counter. Radioactive media 
prepared for the assay is used to control the specific activity. All the radioactivity data was analysed 
after protein normalization and extraction of radioactivity data from Etomoxir control wells. 
II.17 Lactate measurement 
 
Cells were plated (200,000 cells/well) in a 6-well plate and let grow during 48 hours. Then, 4 
L of the cell supernatant were mixed with 100 L of Lactate reagent (Trinity Biotech 735-10) in a 96-
well plate. The plate was incubated during 10 minutes at room temperature and then read at 540 nm in 
a spectrophotometer. A standard curve was performed with the lactate standard solution (Trinity 
Biotech 826-10) in which 0, 1, 2, 4 and 8 l of the standard stock were used. Protein content was 
determined for normalization (III.4.1). 
 
II.18 Stable cell line generation 
II.18.1 Virus production and cell infection 
 
The virus production was performed in a BSL-2 laboratory, using a packaging cell line 
(HEK293FT) and a target cell line in which the desired transgene was introduced. In this thesis work, 
all the cell lines were generated through lentivirus production (Fig M7). The general protocol was: 
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Day 1 
o Morning: HEK293FT cells were seeded at high density (4x106 cells/100mm plate). 
o Afternoon: HEK293FT cells were transfected with the desired transgene-carrying lentiviral 
vector and packaging plasmids. 
Day2 
o The media from the transfected HEK293FT cells was changed with fresh one and the target 
cell line was seeded (depending on the target cell line from 300,000 to 400,000 cells/100mm 
plate). 
Day3 
o First infection: The supernatant (SN)-containing the lentivirus- from HEK293FT cells was 
collected, filtered with 0.45 m filters and toped up to 13 mL with fresh complete media. To 
increase the infection efficiency, the virus-contained-SN was supplemented with 8 µg/mL 
protamine sulfate and added to the target cells. Fresh complete media was added to the 
HEK293FT cells for further virus production. 
Day 4 
o Second infection of target cells was performed with SN as in Day 3. Packaging cells were 
discarded. 
Day 5 
o Selection of infected cells: The media of target cells was changed and replaced with fresh 
media supplemented with the corresponding antibiotic (the selection with puromycin took 3 
days, and the hygromycin up to 5 days). In this last step, it was important to have a negative 
control (non-infected cell line) to verify the activity of the antibiotic. 
 
Figure M6. Scheme showing the experimental protocol for virus production in HEK293FT cells. 
Materials and Methods 
85 
 
M
A
T
E
R
IA
L
S
 A
N
D
 
M
E
T
H
O
D
S
 
II.18.1.1 Lentivirus production and target cell line infection 
 
Lentivirus production was performed in HEK294FT cells (packaging cells) that were 
transfected with packaging vector and the vector carrying the transgene (Fig M8). Lentiviral infections 
were used to re-express WT and mutant PGC1A, and to silence both PGC1A and ESRRA in prostate 
cancer cell lines. Depending on the back-bone vector containing our gene or shRNA of interest, a 
second-generation variant or third generation packaging vectors were employed. 
II.18.1.1.1 Second Generation Variant Lentivirus production 
 
HA-Pgc1a and HA-Pgc1aL2L3M were cloned in the doxycycline inducible TRIPZ vector (see 
section III.1). For this vector, a second-generation strategy was followed to produce the lentivirus, 
consisting of three plasmids: the transfer vector, containing all the cis-acting sequences required and 
the transgene to be delivered, and two packaging vectors psPAX2 and pVSV-G, which provide the 
trans-acting factors (Gag/Pol/Rev/Tat). 
 
Figure M7. Representative image showing the packaging system and lentivirus production in HEK293FT 
cells. 
 
The separation of cis-acting and trans-acting sequences reduces the probability of 
recombination producing replication-competent viral particles. In this particular case, due to the TRIPZ 
backbone of the Pgc1a and Pgc1aL2L3M bearing vector, a pTAT vector was needed to help in 
transcription (and hence we define it as second generation “variant”, see table M3). Second generation 
lentiviruses were produced as previously described (II.18.1) and target cell lines were PC3, DU145 and 
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LnCaP. TRIPZ vector had puromycin resistance, so to select the infected cells, they were submitted to 
puromycin (2 g/mL) during 2-3 days. 
 
II.18.1.1.2 Third Generation Lentivirus production 
 
Third generation virus were generated for constitutive silencing of PGC1A and ESRRA. In the 
case of PGC1A silencing, the target cells were PC3. ESRRA silencing was performed in cells re-
expressing PGC1A (PC3 TRIPZ-HA-Pgc1a). In both cases, the short-hairpin RNA (shRNA) sequences 
were purchased from SIGMA in a puromycin-resistance pLKO backbone (MISSION® shRNA Bacterial 
Glycerol Stock) (Table M4). 
The set of shRNAs was validated and two efficient shRNAs were selected for further 
experiments (in the silencing of Pgc1a only one was selected due to the low efficiency and lack of 
Pgc1a expression). pLKO vectors are compatible with third generation lentivirus production. Third 
generation lentivirus require three packaging vectors (pRRE, pREV, pVSV-G; which decreases 
recombination probability and makes them more secure to handle than second generation) and a 
transfer vector (Table M4). 
 
Table M 3. Specific vector used for second generation lentivirus production. 
Vector 
name 
Role 
Encoding 
Sequences 
Function Origin 
Amount 
transfected 
psPAX2 
Packaging 
vector 
Gag-Pol 
Integrase, reverse 
transcriptase, and 
structural proteins 
Dr. James D. 
Sutherland 
1.66g RRE 
Rev-responsive 
element 
Rev 
Enhancer of unspliced 
viral genomic RNA 
nuclear export 
pVSVG 
Packaging 
vector 
VSV-G Envelope protein 
Dr. James D. 
Sutherland 
1.66g 
pTAT 
Helper 
vector 
TAT 
Enhances trancription 
efficiency 
Dr. James D. 
Sutherland 
1.66g 
TRIPZ-HA- 
Pgc1a 
Transfer 
vector 
PGC1A Gene to re-express 
Verónica 
Torrano 
5g 
TRIPZ-HA- 
Pgc1aWT 
Transfer 
vector 
PGC1AWT Gene to re-express 
Verónica 
Torrano 
5g 
TRIPZ-HA- 
Pgc1aL2L3M 
Transfer 
vector 
PGC1AL2L3M Mutant to express 
Verónica 
Torrano 
5g 
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Table M 4. Information regarding the specific vectors used for third generation lentivirus production. 
Vector 
name 
Role 
Encoding 
sequences 
Function 
Sequence 
Origin 
Amount 
transfected 
pRRE 
Packaging 
vector 
Gag-Pol 
Integrase, reverse 
transcriptase, and 
structural proteins 
Dr. James D. 
Sutherland 
1.66g 
RRE Rev-responsive element 
pREV 
Packaging 
vector 
Rev 
Enhancer of unspliced 
viral genomic RNA 
nuclear export 
Dr. James D. 
Sutherland 
1.66g 
pVSVG 
Packaging 
vector 
VSV-G Envelope protein 
Dr. James D. 
Sutherland 
1.66g 
shPGC1A-
pLKO 
Transfer 
vector 
shRNA 
against 
PGC1A 
CCGGCCGTTATACCT 
GTGATGCTTTCTCGA 
GAAAGCATCACAGGT 
ATAACGGTTTTT 
SIGMA 
TRCN000000116 
5g 
sh79ERRA-
pLKO 
Transfer 
vector 
shRNA 
against 
ERRA 
CCGGGACCTCTTTGA 
CCGAGAGATTCTCGA 
GAATCTCTCGGTCAAA 
GAGGTCTTTTT 
SIGMA 
TRCN0000022179 
5g 
sh80ERRA-
pLKO 
Transfer 
vector 
shRNA 
against 
ERRA 
CCGGGCTACCACTATG 
GTGTGGCATCTCGAGA 
TGCCACACCATAGTGG 
TAGCTTTTT 
SIGMA 
TRCN0000022180 
5g 
Scramble-
pLKO 
Transfer 
control 
vector 
Control 
shRNA  
CCGGCAACAAGATGA 
AGAGCACCAACTCGA 
GTTGGTGCTCTTCATC 
TTGTTG 
- 5g 
 
 
II.18.1.1.3  Lentivirus Concentration  
 
For some experiments, virus was submitted to concentration procedures. Concentrated virus 
aliquots were generated following the time-schedule mentioned in II.18.1. Filtered SN from HEK293FT 
cells was combined with Lenti-XTM Concentrator (Clontech 631232) (3 volumes of clarified SN by 1 
volume of concentrator). After mixing it by inversion, the mix was incubated at 4ºC. Same procedure 
was performed the following day, but the incubation at 4ºC was at least for 30 minutes. Both SN were 
mixed and centrifuged at 1,500 rcf for 45 minutes at 4ºC. After centrifugation, the SN was discarded 
and the pellet was resuspended in 400 µL of PBS and aliquoted in 20 µL aliquots, based on the setup 
performed in the Carracedo lab. Once the virus was concentrated, target cells were seeded on day 1 
in the morning, infected with an aliquot in the afternoon, infected for the second time on day 2 and 
treated with puromycin (2 µg/mL) or hygromycin (1.5 mg/mL) on day 3, during three days for puromycin 
and five days for hygromycin selection.  
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III Molecular analysis 
 
III.1 Cloning 
 
Cloning strategies where designed and performed for the following purposes: PGC1 re-
expression, PGC1 silencing, and ERR silencing upon PGC1 re-expression. The different strategies 
are explained below. 
 
TRIPZ-HA-Pgc1a/WT/L2L3M 
The TRIPZTM lentiviral inducible vector (Dharmacon) used to re-express Pgc1a WT/L2L3M is 
engineered to be Tet-On (Fig M8). The Tet-On technology, equips the TRIPZ vector to provide for 
induced expression of a desired construct in the presence of doxycycline. This induction is carried out 
by the tetracyclicne response element (TRE) and the transactivator (rtTA3). In the presence of 
doxycycline, the TRIPZ transactivator binds to and activates the expression from TRE promoters. 
Therefore, we aim to clone the construct we want to re-express between the TRE promoter and the 
transactivator. In order to do that, TRIPZ lentiviral doxycycline-inducible vector was digested using AgeI 
and MluI restriction enzymes and, as a consequence, RFP and miR30 regions where released. The 
linear vector was gel-purified. In parallel, cDNA-FLAG-Pgc1a (Addgene #14426) and cDNA-FLAG-
Pgc1aL2L3M 138 were amplified with primers PGC1A01 and PGC1A02 specified in table M5, which 
provided AgeI and MluI restriction sites, Kozak, ATG and stops sequences. The PCR protocol was as 
follows: 95C 2 minutes and 95C 30 seconds, 55C 30 seconds, 72C 90 seconds and 72C for 10 
minutes for 30 cycles. The resulting amplicon was subcloned with TOPO cloning technology. Then, 
TOPO was digested with AgeI-MluI and the resulting product was introduced in the linearized TRIPZ 
vector. The ligation performed was in a 1:18 ratio during 20 hours at 16C using T4 ligase (Ref. 
15224017 Invitrogen). As a result, RFP and miR30 regions where replaced by HA-Flag-Pgc1a or HA-
Flag-Pgc1AL2L3M.The band resulting from the ligation was then gel purified and transformed in XL-10 
Gold ultra-competent cells (2 L of ligation per 30 L of competent cells) to obtain the DNA. The mix 
was kept 20 minutes in ice and then was heat shocked during 30 seconds at 42C and 2 minutes in 
ice. Then, 250 L of LB Browth (Conda-Pronadisa) were added and the tube was incubated during 30 
minutes at 37C in a shaker. Then, the transformation was spin down and the pellet was re-suspended 
and spread in an LB agar (Conda-Pronadisa) plate containing the corresponding antibiotic, in this case 
Ampicillin at 50 g/mL (Ref. A0166 Sigma). The plates were incubated overnight at 37C. The resulting 
colonies were the ones carrying the TRIPZ-HA-Pgc1a/WT/L2L3M plasmids. 
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Figure M 8. TRIPZTM inducible vector (modified from Dharmacon website). The construct inserted replaces tRFP 
and mir30 regions. 
Table M5. Information about the specific primers used for the cloning strategy. 
 
sh79/80 ESRRA pLKO HYGRO 
The short-hairpin RNAs for ESRRA (called sh79 and sh80) were purchased in the pLKO 
plasmid with puromycin resistance. The aim of this cloning was to change puromycin resistance 
cassette to hygromycin. 5 g of sh79/80 pLKO-puro plasmids (Table M4) and pLKO–hygro plasmid 
(Addgene #24150) were digested with 1 L of each restriction enzyme, BamHI and Acc65I using Tango 
buffer at 2X. The hygro and the shERRA-pLKO fragments were gel-purified and ligated using the T4 
ligase (Ref. 15224017 Invitrogen). The resulting construct from the ligation was purified and 
transformed in XL-10 Gold ultra-competent cells using ampicillin agar plates as explained before. The 
resulting colonies for the ligation were carrying sh79/80 ERRA-pLKO hygro plasmids. 
 
III.2 Genotyping of mice colonies 
 
Breeding, tag and tailing was carried out by the animal facility personnel from CICbioGUNE. 
Genotyping was performed by technicians in Carracedo lab, Sonia Fernández, Pilar Sanchez-
Mosquera and Ianire Astobiza. 
 
 
 
Name Primers Purpose Sequence 
PGC1A01 
Age1 HA-PGC1a F 
 
To produce a PCR 
product with AgeI site 
in the 5´end 
ACCGGTACCATGGCTTATCCTTACGA 
CGTGCCTGACTACGCCATGGACTACA 
AAGACGATGACGATAAAGC 
PGC1A01 
HA-PGC1A MLuI R 
 
To produce a PCR 
product with MLuI site 
in the 3´end 
ACGCGTGAGTTACCTGCGCAAGCTT 
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III.2.1 Genomic DNA purification from mouse tail 
 
Mouse tail samples were lysed in 195 µL of lysis buffer [100 mM NaCl, 50 mM Tris-HCl (pH 
8.0), 25mM EDTA, 0.5% SDS or 100mM NaCl, 50mM Tris-HCl (pH 8.0), 5mM EDTA, 1% SDS]. Then, 
0.25 mg/mL of Proteinase K (Sigma, PCR grade) were added and mixed briefly. The mix was kept for 
3-6 hours at 55ºC. 
Once soft tissue was solubilized, 200µL of phenol/chloroform/isoamyl (25:24:1) were added 
to separate DNA (in upper aqueous phase) from denaturalized proteins (in interphase) and RNA and 
lipids (in lower organic phase) by mixing well by inversion and centrifugation for 15 minutes at 14,000 
rpm at room temperature. DNA containing aqueous phase (150 µL) was transferred to new tubes and 
precipitated/washed by adding 15 µL sodium acetate (3 M) and 400 µL of 100% ethanol. The mix was 
incubated at -20ºC overnight to enhance precipitation. Samples were centrifuged 10 minutes at 14,000 
rpm at 4ºC and supernatant was discarded to dry DNA pellets. Finally, the dry pellets were re-
suspended in 50-100 µL H2O (up to 500 µL for tail fragments of 1 cm). 
III.2.2 Polymerase Chain Reaction (PCR) 
 
For genotyping, extracted mouse tail DNAs (1 μL) were subjected to Polymerase Chain 
Reactions (PCR), optimized with specific primers (1 μM) (specified in table M6) and PCR programs 
(see table M7) for each gene of interest. All PCR assays were performed with DreamTaq Green PCR 
Master Mix (1X) (K1082, Thermo Scientific) in a final reaction volume of 10 μL. Following to PCR, DNA 
fragments were run in a 1.5-3% agarose gel.  
 
Table M6. Specific primers used for genotyping mouse colonies. 
Gene Primers Band size 
Cre 
 
5´-GGTGCAAGTTGAATAACCGGA-3´ 
3´- CGGTATTGAAACTCCAGCGC-5´ 
850pb 
Pgc1a 
 
5´-TCCAGTAGGCAGAGATTTATGAC-3´ 
3´-TGTCTGGTTTGACAATCTGCTAGGTC-5´ 
Pten pc+: 350pb 
Pten pc lox: 480pb 
Pten 
 
5´-TGTTTTTGACCAATTAAAGTAGGCTGTG-3´ 
3´-AAAAGTTCCCCTGCTGATGATTTGT-5´ 
Pgc1a pc+: 350pb 
Pgc1a pc lox: 480pb 
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Table M7. PCR protocols followed for genotyping mouse colonies. 
PCR steps Cre Pten Pgc1a 
Denaturalization (1st cycle) 94C 3 min 94C 3 min 94C 3 min 
Denaturalization 94C 30 sec 94C 30 sec 94C 30 sec 
Alineation 59C 1 min 59C 1 min 58C 30 sec 
Elongation 72C 1 min 72C 1 min 72C 30 sec 
Elongation (last cycle) 72C 10 min 72C 10 min 72C 5 min 
Final temperature 4C  4C  4C  
Number of cycles 35 35 35 
 
III.3 Gene expression analysis 
 
III.3.1 RNA extraction 
 
For gene expression analysis in vitro, cells were seeded for a final density of around 70-80 % 
in 6-well plates (with the corresponding doxycycline induction as explained in figure M1). Plates were 
washed with PBS and processed or snap-frozen in liquid-nitrogen for later RNA extraction, unless 
otherwise specified. RNA was extracted using NucleoSpin RNA isolation kit from Macherey-Nagel 
(740955.240C) according to manufacturer´s protocol. 
For RNA extraction from human and murine prostatic tissue and xenografts, samples were 
incubated overnight at -20C with 200L of RNAlater ICE (LifeTechnologies), which was previously 
kept at -80C. The following day, tissues were transferred to a tube with 800L of TRIzol reagent with 
2.8 mm ceramic beads (Ref. 13114-50 MO BIO Laboratories). Precellys machine was used to 
homogenize the tissue at 6,000 rpm during 30 seconds (step repeated twice). Then, 160 L of 
chloroform (SIGMA 34854) were added and, after vortexing, the mix was centrifuged at 12,000 rcf 
during 15 minutes at 4C. The aqueous phase was collected and mixed with the corresponding volume 
of ethanol and the protocol use to follow the RNA extraction was the one from Macherey Nagel RNA 
extraction kits (NucleoSpin miRNA 740971.50 for humans and 740955.250 for mice). The RNA 
concentration was determined by using the Nanodrip ND-1000 Spectrophotometer. The same protocol 
was used for cell lines, human and murine prostatic tissue, and xenograft to perform retrotranscription 
and gene expression analysis by Real Time-Quantitative-Polymerase Chain Reaction (RT-QPCR). 
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III.3.2 RNA retrotranscription 
 
For RNA retrotranscription 1 g of the obtained RNA was used for complementary DNA 
(cDNA) synthesis using qScript cDNA Supermix from Quanta (95048) of iScript TM Reverse from 
BioRad (1708841). Resulting cDNA was diluted 1:3 in fresh mQwater and 1 L was used for RT-QPCR 
reaction. 
 
III.3.3 Real Time quantitative PCR (RT-Q-PCR) 
 
RT-QPCR was performed using either Viia7 or QS6 systems from Life Technologies. The RT-
QPCRs were performed using the following program: 2 minutes at 50 ºC and 10 minutes at 95ºC (hold 
stage) followed by 40 cycles of 15 seconds at 95ºC (denaturalization) and 1 minute at 60ºC (annealing 
and elongation). All gene expression studied was analysed with primers and probes from Universal 
Probe Library from Roche. The Universal Probe Library Assay Design Center is available online 
(https://lifescience.roche.com/en_es/brands/universal-probe-library.htmL). This tool allows the 
designing of primers and also assigns the corresponding probe needed for each reaction in order to 
perform a TaqMan assay.  For the reaction, 0.3 L of primers at 20 M, 3 L of TaqMan universal 
master mix II with UNG (Applied Biosystems) and 0.05 L of the corresponding probe were used. For 
the analysis of house-keeping genes (Gapdh, GAPDH, -Actin and -ACTIN) commercial TaqMan 
probes (Life technologies) were used. Comparative Ct method was selected for the quantification of 
gene expression changes. See table M8 for specific primer sequences and references. 
 
III.3.4 Transcriptomic analysis 
 
For transcriptomic analysis in PC3 TRIPZ-HA-Flag-Pgc1α cells, Illumina whole genome -
HumanHT-12_V4.0 (DirHyb, nt) method was used as reported139. Promoter enrichment analysis was 
assessed with the Transcription Factors (TFs) dataset from MSigDB (The Molecular Signature 
Database; http://www.broadinstitute.org/gsea/msigdb/collections.jsp). TFs dataset contain genes that 
share a transcription factor-binding site defined in the TRANSFAC (version 7.4, http://www.gene-
regulation.com/) database. Each of these gene set was annotated by a TRANSFAC record. A 
hypergeometric test was used to detect enriched dataset categories. The GSEA was performed using 
the GenePattern web tool from the Broad Institute (http://genepattern.broadinstitute.org). The list of 
PGC1α upregulated genes ranked by their fold change was uploaded and analysed against a list of 
ERRα target genes140. The number of permutations carried out were 1000 and the threshold was 0.05. 
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III.4 Protein expression analysis 
III.4.1 Protein extraction 
 
For protein expression analysis, cells were seeded for a final density of around 70-80 % in 6-
well plates (with the corresponding doxycycline induction as explained in figure M1). Plates were 
washed with PBS and processed or snap-frozen in liquid-nitrogen for later protein extraction, unless 
otherwise specified. Cells were lysed using RIPA buffer for protein extraction. Buffer components were 
the following ones: 50 mM TrisHCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.10% SDS, 1% Sodium 
Deoxycholate, 1%NP-40, 1 pill of complete protease inhibitors cocktail (11836170001 Roche) per 50 
mL of buffer, and 1 mM of sodium fluoride, sodium orthovanadate and -glycerol phosphate. Lysates 
were stored for 15-20 minutes on ice and vortexed every 5 minutes, centrifuged at 14,000 g during 10 
minutes, and the supernatant was collected. 
For protein extraction in murine prostate tissues and xenograft, tissues were transferred to a 
tube with 400L of RIPA lysis buffer (50mM TrisHCl pH7.5, 150mM NaCl, 1mM EDTA, 0.10%SDS, 
1%Sodium Deoxycholate, 1% NP-40) containing 1mM of phosphatase inhibitors (sodium fluoride, 
sodium orthovanadate and β-glycerophosphate) and two tablets of protease inhibitor cocktail (Roche). 
Precellys machine was used to homogenize the tissue as explained before (section III.3.1). The same 
protocol was used for cell lines, human and murine prostatic tissue, and xenograft to perform protein 
extraction and western blotting. 
 
Table M8. Information about primer sequences and probe numbers from Universal Probe Library (Roche). 
Gene Specie Forward 5´-3´ Reverse 5´-3´ Probe 
ACACB human cagacgctacaggtcccaac ctgtccactccactgtcagg 37 
Acacb mouse tgaatctcacgcgcctacta ttgtgttctcggcctctctt 107 
ACADM human aggagccattgatgtgtgc ctgctttggtctttataccagcta 1 
ACAT1 human gatccccaaaaagtgaatatcaa atcctggctccagacatcc 17 
Acat1 mouse agggaagtttgccagtgaga ttcaccaccacatctggtttac 9 
ACO2 human gtgtagactccatctcctgcact tgtggttgtaagggaacacg 49 
ACSL4 human tgtactgtactgaagcccacactt ttcatctcttggactttgctca 66 
Acsl4 mouse gaaattcacagcatgcaatcag tctacttggaggaacgctcaa 17 
ATP1B1 human cggtggcagttggtttaag agcatcacttggatggttcc 20 
ATP5C1 human tctggtgctgcagctctgt gaggaacagtttcttcggaca 74 
CDH1 human tggaggaattcttgctttgc cgctctcctccgaagaaac 84 
Cdh1 mouse gctctcatcatcgccacag gatgggagcgttgtcattg 2 
CLYBL human gcccagaacactgttacgc tgcagcttcaataccctttagc 10 
ETFDH human cccgggataaggacaagag catctgcttcttctgcaaacc 12 
FH human gcacagatcatcaagattggac ttgttgaacataaccactaaattcct 89 
Fh1 mouse gcaccccaatgatcatgtta attgctgtgggaaaggtgtc 106 
GAPDH human Hs02758991_g1   
Gapdh mouse Mm99999915_g1   
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III.4.2 Protein quantification and sample preparation 
 
Protein quantification was carried out using PierceTM BCA Protein Assay Kit (Thermo Fisher 
Scientific 23225). Samples were prepared in Laemmli 5X sample buffer (10 % SDS, 50Mm Tris pH 6.8, 
10% H2O, 50% Glycerol, 1% -mercaptoethanol, 0.01M DTT and 0.2 mg/mL of bromophenol blue). 
GOT1 human agctgtgcttctcgtcttgc agattgcacacctcctaccc 26 
GSTM4 human tgctacagccctgactttga tgatcttgtctccaacaaaccat 60 
HADHA human caccctcactgcgctagac ttcttcactttgtcattcaatcct 56 
IDH3A human tttttgatgctgccaaagc ttcctccaggtccttgaatg 52 
Idh3a mouse gaggttttgctggtggtgtt tgaaatttctgggccaattc 80 
ISCU human aacacagatatcgccaaggag attgcatcttcagccagcat 8 
KRT8 human cataattgcagtagacttgtgctga gggggtccccaggtagta 48 
Krt8 mouse agttcgcctccttcattgac gctgcaacaggctccact 67 
LAMB2 human ctggtggcagtcagagaatg cagcagggcgaaatgtct 42 
MMP1 human gctaacctttgatgctataactacga tttgtgcgcatgtagaatctg 7 
MPC1 human gcggcttatcaaacacgag agggaggctatttataatgaaatctg 56 
MPC2 human aaaattggagtctgtttgctgtt tgtgctttagcttttagttcttgg 18 
NNT human gacaatgtcaacggcttctg caatgcccaaacccagtatc 62 
Pgc1α  mouse gaaagggccaaacagagaga gtaaatcacacggcgctctt 29 
PGC1α  human tgagagggccaagcaaag ataaatcacacggcgctctt 13 
Pten mouse tccacaaacagaacaagatgct ccattttccactttttctgagg 93 
SDHA human tccactacatgacggagcag ccatcttcagttctgctaaacg 70 
Sdha mouse tgttcagttccaccccaca tctccacgacacccttctg 71 
SNAIL1 human gctgcaggactctaatccaga gctgcaggactctaatccaga 11 
Snail1 mouse cttgtgtctgcacgacctgt caggagaatggcttctcacc 71 
SNAI2 human tggttgcttcaaggacacat gcaaatgctctgttgcagtg 7 
Snai2 mouse cattgccttgtgtctgcaag agaaaggcttttccccagtg 71 
Snai3 mouse gtccccaactacgggaaact gggatcctgccaactcct 15 
SOD2 human aatcaggatccactgcaagg taagcgtgctcccacacat 3 
SUCLA2 human gttctacggcaggctagtgg acaatccagaacttcccagaac 66 
Sucla2 mouse tccgatgaagcttacgcaat tgtaaatgttccttttcctctgc 98 
TP53INP2 human ccttgaagtcctagagtccaataaa ctatggcagtgcaaaaacctc 16 
TWIST human agctacgccttctcggtct ccttctctggaaacaatgacatc 58 
Twist mouse agctacgccttctccgtct tccttctctggaaacaatgaca 58 
VIMENTIN human tggtctaacggtttccccta gacctcggagcgagagtg 56 
Vimentin mouse tgcgccagcagtatgaaa gcctcagagaggtcagcaaa 79 
ZEB1 human tttttcctgaggcacctgaa aaaatgcatctggtgttccat 34 
Zeb1 mouse tggagttcaaaggttgtcgtt ttgccacatcaacactggtc 109 
ZEB2 human cgatccagaccgcaattaac tgctgactgcatgaccatc 65 
Zeb2 mouse ccagaggaaacaaggatttcag aggcctgacatgtagtcttgtg 42 
-ACTIN human Hs99999903_m1   
-Actin mouse Mm00607939_s1   
Materials and Methods 
95 
 
M
A
T
E
R
IA
L
S
 A
N
D
 
M
E
T
H
O
D
S
 
III.4.3 Westerm blotting (WB) 
 
Protein lysates with Laemmli buffer 1X were boiled at 95ºC for 5 minutes for protein 
denaturalization, and resolved either in NuPAGE Novex 4-12% Bis-Tris Midi Protein gels (Invitrogen 
NG1403BX10) or mini protein gels (Invitrogen NP0322BOX) at 200 V for 1 hour and 15 minutes in MES 
SDS buffer (VWR K856) or MOPS SDS buffer (NuPAGE NP0001-02). Precision Plus ProteinTM Dual 
Color Standards marker (BioRad #1610374) and Pink pre-stained protein marker (Nippon MWP02) 
were used as protein weight markers. Then, proteins were transferred to nitrocellulose membranes at 
80 V during 2 hours and membranes were blocked with 5% non-fat milk prepared in Tris-buffered saline 
solution containing 0.01% Tween-20 (TBS-T).  
Primary antibodies were prepared in TBS-T with 0.2% sodium azide and incubated with the 
membranes overnight at 4ºC (except from PGC1a antibody which was prepared in 5% milk and used 
4 hours at room temperature). The following day, the membranes were washed 3 times (10 minutes 
each) with TBS-T and were 1 hour incubated with the secondary antibody in 5% milk. After that, 
membranes were again washed three times and developed with home-made ECL solution A: 10% Tris 
pH 8.5, 90% H2O, 0.2 mM coumaric acid (Sigma 9008) and 1.25 mM luminol (Sigma 09253) and 
solution B: 10% H202 (3 L of 10% solution B were used per 1 mL of solution A). See table M9 for 
references of antibodies used for Western Blotting. 
III.4.4 Proteomics 
 
The label-free proteomic analysis was carried out in collaboration with Felix Elorza and 
Mikel Azkargorta from the Proteomics platform in the CIC bioGUNE. The protocol was as follows: 
In solution digestion: Protein was extracted using 7M urea, 2M thiourea, 4% CHAPS. Samples were 
incubated for 30 min at RT under agitation and digested following the filter-aided FASP protocol 
described by Wisniewski et al141 with minor modifications. Trypsin was added to a trypsin: protein ratio 
of 1:10, and the mixture was incubated overnight at 37oC, dried out in a RVC2 25 speedvac 
concentrator (Christ), and re-suspended in 0.1% FA. 
 
Mass spectrometry analysis: The equivalent of approximately 500ng of each sample was submitted 
to LC-MS label-free analysis. Peptide separation was performed on a nanoACQUITY UPLC System 
(Waters) on-line connected to an LTQ Orbitrap XL mass spectrometer (Thermo Electron). An aliquot of 
each sample was loaded onto a Symmetry 300 C18 UPLC Trap column (180 µm x 20 mm, 5 µm 
(Waters)). The pre-column was connected to a BEH130 C18 column (75 μm x 200 mm, 1.7 μm 
(Waters), and equilibrated in 3% acetonitrile and 0.1% FA. Peptides were eluted directly into an LTQ 
Orbitrap XL mass spectrometer (Thermo Finnigan) through a nanoelectrospray capillary source 
Materials and Methods 
96 
 
M
A
T
E
R
IA
L
S
 A
N
D
 
M
E
T
H
O
D
S
 
(Proxeon Biosystems), at 300 nl/min and using a 120 min linear gradient of 3–50% acetonitrile.  The 
mass spectrometer automatically switched between MS and MS/MS acquisition in DDA mode. Full MS 
scan survey spectra (m/z 400–2000) were acquired in the orbitrap with mass resolution of 30000 at m/z 
400. After each survey scan, the six most intense ions above 1000 counts were sequentially subjected 
to collision-induced dissociation (CID) in the linear ion trap. Precursors with charge states of 2 and 3 
were specifically selected for CID. Peptides were excluded from further analysis during 60 s using the 
dynamic exclusion feature.  
 
Progenesis LC-MS software analysis: Progenesis LC-MS (version 2.0.5556.29015, Nonlinear 
Dynamics) was used for the label-free differential protein expression analysis. One of the runs was 
used as the reference to which the precursor masses in all other samples were aligned to. Only features 
comprising charges of 2+ and 3+ were selected. The raw abundances of each feature were 
automatically normalized and logarithmized against the reference run. Samples were grouped in 
accordance to the comparison being performed, and an ANOVA analysis was performed. A peak list 
containing the information of all the features was generated and exported to the Mascot search engine 
(Matrix Science Ltd.). This file was searched against a Uniprot/Swissprot database, and the list of 
identified peptides was imported back to Progenesis LC-MS. Protein quantitation was performed based 
on the three most intense non-conflicting peptides (peptides occurring in only one protein), except for 
proteins with only two non-conflicting peptides. The significance of expression changes was tested at 
protein level, and proteins with an ANOVA p-value ≤ 0.05 were selected for further analyses. 
 
Functional analysis: GO enrichment analysis was carried out using the DAVID online tool 
(http://david.abcc.ncifcrf.gov/summary.jsp)142. DAVID is a GO Term annotation and enrichment 
analysis tool used to highlight the most relevant GO terms associated with a given gene list. A Fisher 
Exact test is used in order to determine whether the proportion of genes considered into certain GO 
term or categories differ significantly between the dataset and the background. A FDR-corrected 
version of the Fisher’s test p-value can be obtained and used for more conservative result selection. 
Biological Process (BP), Molecular Function (MF) and Cellular Component (CC) categories were 
assessed, and only GO Terms enriched with a FDR<5% were considered for comparison and 
discussion. Additionally, KEGG Pathways, keywords, sequences, and Interpro and Smart databases 
were also analyzed, considering terms with an enrichment p-value<0.05. 
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Table M9. References and preparation of primary and secondary antibodies employed for Western 
Blotting. 
Antibody Reference Specie Diltuion 
PGC1 
Santa Cruz Biotechnology 
sc-13067 
Rabbit 1:1000 
Cleaved-PARP Cell Signaling Technology #5625 Rabbit 1:1000 
Phospho-paxillin Cell Signaling Technology #2541 Rabbit 1:1000 
Total paxillin Cell Signaling Technology #2542 Rabbit 1:1000 
Phospho-cofilin Cell Signaling Technology #3313 Rabbit 1:1000 
Total cofilin Cell Signaling Technology #5175 Rabbit 1:1000 
Phopho-LIMK 
Thermo Fisher Scientific 
 PA5-36663 
Rabbit 1:1000 
Total LIMK Cell Signaling Technology #3842 Rabbit 1:1000 
ERR (E1G1J) Cell Signaling Technology #13826 Rabbit 1:1000 
OXPHOS antibody cocktail Abcam (ab110411) Mouse 1:1000 
GAPDH Cell Signaling Technology #2118 Rabbit 1:1000 
HSP90 Cell Signaling Technology #4874 v Rabbit 1:1000 
-ACTIN SIGMA A5316 Mouse 1:1000 
Secondary Rabbit Ab Jackson ImmunoResearch Rabbit 1:1000 
Secondary Mouse Ab Jackson ImmunoResearch Mouse 1:1000 
 
III.5 Metabolomic analysis 
 
Two different approaches were carried out to perform metabolomic analysis in vitro (Fig M10). 
In the first strategy, glucose labelled and untargeted metabolomics (intracellular extraction) were 
performed, while in the second strategy, a glutamine labelled time course (intra and extra-cellular 
extraction) was carried out. The first approach was carried out in collaboration with Jason Locasale and 
Xiaojing Liu (Duke University)143-145, while the second one was performed in collaboration with Christian 
Frezza and Sofia Costa (MRC Cancer Unit-Cambridge). 
For the first strategy, cells (200,000 cells/well) were plated in a 6-well plate and after 24 hours, 
media with 4 mM L-Glutamine (Ref.25030081 Gibco) and 1mM 13C-labelled D-Glucose (CLM-1396 
Cambridge Isotope Laboratories) and without pyruvate was added. After 24 hours, an additional pulse 
of 2 hours with the same labelled media was performed before metabolite extraction. In parallel, a 6-
well plate with 4 mM L-Glutamine (Ref.25030081 Gibco) and 1 mM D-Glucose (Ref. G8270 Sigma) 
and without pyruvate was seeded to perform the untargeted metabolomics. 
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For the second strategy, cells (300,000 cells/well) were plated in a 6-well plate and once 
adhered, media with 25 mM D-Glucose (Ref. G8270 Sigma), 4 mM 13C-labelled L-glutamine (CLM-
1822 Cambridge Isotope Laboratories) and without pyruvate was added. In this case, a glutamine 
labelled time course was performed and metabolites were extracted at 30 minutes, 1, 2, 4 and 6 hours 
after labelled media addition. It is important to remark that, before labelled media addition, cells were 
washed at least twice with PBS in both strategies. 
In addition, dry pellets from the metabolic extraction of frozen prostate tissues and xenograft 
tumours for metabolomics analysis were sent in dry ice to Duke University and liquid-chromatography 
high-resolution mass spectrometry (LC-HRMS) was performed by Xiaojing Liu and Jason Locasale. 
 
Figure M 9. Metabolomic analysis strategies.  
 
III.5.1 Metabolite extraction from adherent cells (Intracellular) 
 
First strategy metabolite extraction: 1mL of 80%methanol/water (both HPLC grade) pre-
cooled was added to each well. The plate was then transferred to -80C during 15 minutes to further 
inactivate enzyme activities. Then, the plate was placed again on dry ice and cells were scraped into 
extraction solvent. The complete volume was centrifuged at 20,000 during 10 minutes at 4C. The 
samples were speed vacuum dried at room temperature. Finally, the pellets obtained were stored at -
80C for further LC/MS analysis. 
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Second strategy metabolite extraction: 1mL of extraction solution per 106 of cells was used. 
The extraction solution contained 50% methanol (LC-MS grade), 30% acetonitrile (LC-MS grade), 20% 
of ultrapure water and 100 ng/mL of HEPES. Therefore, before adding the extraction solution the cells 
from the normalization plate were counted with CASY counter and the volume was calculated. Also, 
protein and cell volume was analysed from this plate. The media was aspirated from the experimental 
plates and these where washed 3 times quickly with 10% PBS. The adequate amount of extraction 
buffer was added and incubated during 15 minutes on dry-ice. Cells were scraped and kept in agitation 
during 15 minutes at 4ºC at maximum speed. Samples were then incubated for 1 hour at -20ºC and 
centrifuge twice for 10 minutes at 4ºC. The supernatant was collected and kept at -80ºC until further 
LC/MS analysis.  
 
III.5.2 Metabolite extraction from cell culture media 
 
Half a milliliter was taken from cell culture media and centrifuge for 5 minutes at 4ºC at 
maximum speed to eliminate dead cells and debris. Then, 50 L of the supernatant were mixed with 
750 L of the extraction solution (same used for intracellular metabolites). Samples are vortexed for 5 
seconds and left in agitation for 15 minutes at 4ºC at maximum speed. Samples were then incubated 
for 1 hour at -20ºC and centrifuged twice for 10 minutes at 4ºC. The supernatant was collected and 
kept at -80ºC until further LC/MS analysis. 
 
III.5.3 Metabolite extraction from murine prostate tissues and xenograft tumours 
 
Three to ten milligrams of tissues were weight and kept in 200L of HPLC grade ice-cold 80% 
methanol. Precellys equipment was used to homogenize the tissue using the same beads and 
protocol as explained before (section III.3.1). After adding 300L more of 80% methanol, the mix was 
centrifuged at 20,000 rcf for 10 minutes at 4C. The supernatant was speed vacuumed at room 
temperature during 1 hour. The dry pellet was saved at -80C for further LC-HRMS analysis.  
 
III.5.4 LC/MS and data analysis 
 
First strategy: LC-MS and data analysis was performed by Xiaojing Liu from Jason Locasale 
laboratory (Duke University). For metabolite separation and detection, the HPLC (Ultimate 3000 
UHPLC) was coupled to QE-MS (Thermo Scientific). An Xbridge amide column (100 × 2.1 mm i.d., 3.5 
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μm; Waters) was employed for compound separation at room temperature. The mobile phase A was 
20 mM ammonium acetate and 15 mM ammonium hydroxide in water with 3% acetonitrile, pH 9.0, and 
mobile phase B was acetonitrile. The linear gradient used was as follows: 0 min, 85% B; 1.5 min, 85% 
B, 5.5 min, 35% B; 10 min, 35% B, 10.5 min, 35% B, 14.5 min, 35% B, 15 min, 85% B, and 20 min, 
85% B. The flow rate was 0.15 mL/min from 0 to 10 min and 15 to 20 min and 0.3 mL/min from 10.5 to 
14.5 min. Raw data collected from the LC-QE-MS were processed on Thermo Scientific, Sieve 2.0. 
Peak alignment and detection were performed according to manufacturer protocols. For a targeted 
metabolomics analysis, a frame seed including 194 metabolites was used for targeted metabolites 
analysis with data collected in positive mode, while a frame seed of 262 metabolites was used for 
negative mode, where m/z width is set at 10 ppm. For an untargeted metabolomics analysis, the 
following parameter values were used to extract untargeted components (pairs of m/z and R.T.): 
background signal-to-noise ratio, 3; minimum ion count, 1 × 105; minimum scans across the peak, 
5; m/z step, 10 ppm. 
Second strategy: LC-MS and data analysis was performed by Sofia Costa from Christian 
Frezza´s laboratory (MRC Cancer Unit, Cambridge). LC-MS analysis was performed using a QExactive 
Orbitrap mass spectrometer coupled to a Dionex U3000 UHPLC system (Thermo). The liquid 
chromatography system was fitted with a Sequant ZIC-pHILIC column (150 mm × 2.1 mm) and guard 
column (20 mm × 2.1 mm) from Merck Millipore (Germany) and temperature maintained at 45 °C. The 
mobile phase was composed of 20 mM ammonium carbonate and 0.1% ammonium hydroxide in water, 
and acetonitrile. The flow rate was set at 200 µL/min with the gradient previously described 146. The 
mass spectrometer was operated in full MS and polarity switching mode, and samples were randomised 
in order to avoid bias due to machine drift and processed blindly. The acquired spectra were analysed 
using XCalibur Qual Browser and XCalibur Quan Browser software (Thermo Scientific). The peak areas 
of all isotopologues of a given metabolite were summed to estimate the total metabolite pool, and each 
isotopologue was then represented as the percentage of the total.  
IV Murine and human samples 
 
IV.1 Analysis of murine samples 
 
All mouse experiments were carried out following the ethical guidelines established by the 
Biosafety and Animal Welfare Committee at CIC bioGUNE and The Institutional Animal Care and Use 
Committee of IRB Barcelona. The procedures employed were carried out following the 
recommendations from AAALAC. Mice were housed under controlled environmental conditions, such 
as time controlled lighting on standard 12:12 light:dark cycles, controlled temperature at 22 ± 2ºC and  
30-50% relative humidity. Mice were fed regular Chow diet ad libitum, unless otherwise specified based 
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on experimental designs. Mice were fasted for 6h prior to tissue harvest (9 am-3 pm) in order to prevent 
metabolic alterations due to immediate food intake. Before intra-tibial and intra-cardiac injections mice 
were anaesthetized with a mixture of ketamine (80 mg kg-1) and xylazine (8 mg kg-1). At experimental 
end-point, all mice were sacrificed by CO2 inhalation followed by cervical dislocation. After euthanasia, 
the prostate glands, lymph nodes, long bones from lower limbs, liver and lung of mice were extracted 
and kept in formalin or frozen at -80C for further analysis. 
 
IV.1.1 Genetically engineered mouse models (GEMMs) 
 
In this thesis work two genetic alterations in mice have been studied: Cre recombinase-
dependent Pten conditional deletion62 and Cre-recombinase-dependent Pgc1a conditional deletion. 
The conditional tissue specific Pten knockout (C57BL6/129sv; Pb-Cre4; Pten lox/lox) model was kindly 
provided by Dr. Pandolfi, and the conditional tissue specific Pgc1a null homogeneous background 
model by Dr. Spiegelman. The Cre recombinase expression, under the control of androgen-dependent 
ARR2B Probasin promoter (Pb-Cre4), allowed the deletion of both Pten and Pgc1a genes in the 
prostate epithelium at puberty.  
We generated a mouse line (termed PTP) by breeding Pten prostate-specific knockout mice 
(Pb-Cre4; Pten lox/lox) and Pgc1a conditional knockout mice (Pgc1a lox/lox). These two lines were 
intercrossed for at least three generations to obtain a founder colony with mixed homogeneous 
background. Probasin Cre was always retained in male mice, since in females Pb-Cre4 expression in 
utero can lead to recombination in embryos during pregnancy. Prostate Pten/Pgc1a-deleted male mice 
were termed pc-/+ (heterozygous) or pc-/ - (homozygous knockout) for each gene. The time of analysis 
was based on the experimental design, and it is indicated in the results section. Pgc1a pc-/+ and Pgc1a 
pc-/- in a Pten pc-/+ background were established in order to elucidate the role of Pgc1a in PCa initiation, 
and in a Pten pc-/- in order to ascertain the role of Pgc1a in disease progression.  
 
IV.1.2 Subcutaneous xenograft experiments in nude mice 
 
PC3 TRIPZ-HA-Pgc1a cells in suspension were injected subcutaneously into 
immunocompromised 8-10-week-old male nude mice (Harlan). Measurement of tumour size was 
performed every two-three days and tumour volume was estimated using the formula of spheroid 
volume: volume = length x width2 x 0.526. One million of PC3 TRIPZ-HA-Pgc1a cells were injected 
in two flanks per mouse. 24 hours post-injections mice were fed with chow or doxycycline diet 
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(Research diets, D12100402). After 6 weeks, final tumour weight was measured upon tissue harvest. 
This experiment was performed by Patricia Zuñiga (CICbioGUNE). 
 
IV.1.3 Metastasis xenograft experiments in nude mice 
 
The metastasis activity in nude mice was performed in collaboration with Roger Gomis´ 
laboratory in the IRB (Barcelona). For intra-tibial and intra-cardiac injections BALB/c nude male mice 
(Harlan) of 9-11 weeks of age were used. The protocol was followed as previously described 147. Before 
the injections, PC3 TRIPZ-HA-Pgc1a (WT, L2L3M, shScr, shERRa) cell lines were pre-treated for 48 
hours with PBS or doxycycline (0.5 μg/mL). Mice injected with cells treated with doxycycline were also 
pre-treated for 48 hours with 1 mg/mL of doxycycline in drinking water. 
 After the injections, this group of mice was left on continuous doxycycline treatment (1 mg/mL 
in drinking water).  For intra-tibial injections, 104 cells were re-suspended in a final volume of 5 μL of 
cold PBS and injected as described previously. For intra-cardiac injections 2.105 cells were re-
suspended in final volume of 100 μL of cold PBS and injected as described previously. Upon the 
injections, tumour development was followed on weekly basis by bioluminescence imaging (BLI) using 
the IVIS-200 imaging system from Xenogen. Quantification of bioluminescent images was done with 
Living Image 2.60.1 software. The development of metastasis was confirmed by doing in vivo or ex vivo 
(upon necropsy) bioluminescent analysis of organs of interest (metastasis positivity in lesion incidence 
analysis was defined as tibias or lungs with luciferase signals greater than 50,000 units). When 
comparing cell lines independently transduced with the luciferase-expressing vector, photon flux values 
per limb where presented as normalized signal (corrected by basal signal, obtained within 24 hours 
after injection): Normalized photon flux = [day 14 signal/day 0 signal] × 1,000. For metastasis-free 
survival curves metastatic event was scored when measured value of bioluminescence surpassed 1/10 
of the day 0 value. 
 
IV.2 Pathological analysis of prostate tissue and xenograft samples  
 
At the experimental end-point of all in vivo genetic mouse model experiments, a necropsy is 
performed in order to analyse the anatomic phenotype between control and experimental mice. 
According to the mouse prostate, one of the lobes (AP, DLP and VP) was fixed in 10% neutral buffered 
formalin (Ref. BAF 0010-25A CellPath) and stored at 4ºC for 24 hours to allow tissue fixation for 
pathological analysis, and the other one was directly frozen with liquid nitrogen and kept at -80C for 
further molecular analysis. Before fixing and freezing, all prostate lobes were weighted. In xenograft 
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experiments, when tumours were harvested, half of the tumour was fixed in 10% neutral buffered 
formalin and the other half was frozen and kept for molecular analysis. 
 
IV.2.1 Tissue processing, paraffin embedding and block sectioning 
 
The tissue processing and staining steps were performed by Sonia Fernández (CIC 
bioGUNE) and Mireia Castillo Martín (Fundação Champalimaud). After 24 hours of fixation with 10% 
buffered formalin at 4ºC, tissue samples were dehydrated and infiltrated with paraffin following the steps 
in table M10 (automatic tissue processor Leica TP1020). Then, infiltrated tissues were embedded in 
paraffin blocks (Leica EG1150C heated embedding module and cold block). If samples were not 
processed after 24 hours, they were washed with PBS, Ethanol 50% and 70% (10 minutes each wash). 
Before sectioning, paraffin blocks were maintained on ice. Then, 3 μm sections were done (Leica 
RM2245 microtome) and adhered to slides for tissues staining and analysis (in water bath at 60C). 
 
Table M10. Steps followed to process mice tissues in the automatic processor. 
Tray Time Reagent Function 
T1 1h 30 min 50 % Ethanol Dehydration 
T2 1h 30 min 70 % Ethanol Dehydration 
T3 1h 30 min 80 % Ethanol Dehydration 
T4 1h 30 min 96 % Ethanol Dehydration 
T5 1h 30 min 100 % Ethanol Dehydration 
T6 1h 30 min 100 % Ethanol Dehydration 
T7 1h 30 min 100 % Ethanol Dehydration 
T8 45 min Citrosol or Xylene substitute Rinse, replace the ethanol with citrosol 
T9 2h Paraffin Replace the citrosol with paraffin 
T10 2h Paraffin Replace the citrosol with paraffin 
 
IV.2.2 Slide processing for immunohistochemistry 
 
Tissue slides were de-paraffinated during 30 minutes in an oven at 65C.  Then, to allow 
immunohistochemical staining and analysis, the slides were further de-paraffinated and hydrated 
following steps in table M11. After hydration, the desired staining was performed in each case. 
Following to the staining, slides were dehydrated with 95% and 100% ethanol and cleared in xylene (3 
minutes each reagent). For final coverslip mounting, DPX (Dinbutyl Phthalate Xylene) was used. 
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Table M11. Steps followed to process tissue slides for immunohistochemistry. 
Time Reagent Function 
10-15 min (x2) Citrosol or Xylene substitute De-paraffine 
3 min (x2) 100 % Ethanol Hydration 
3 min (x2) 95 % Ethanol Hydration 
3 min (x2) dH2O Hydration 
 
IV.2.3 Haematoxylin and Eosin (H&E) staining 
 
Slides were incubated with haematoxylin during 5 minutes and rinsed in water during 1 
minute. Next, slides were maintained in acid alcohol (70% ethanol and 3% HCl) during 2 seconds for 
controlled leaching of non-specific background coloration, and rinsed again during 30 seconds with 
water. Finally, slides were incubated during 2 minutes with eosin and washed during 2 seconds with 
water. Slides were mounted as previously described (section IV.2.2). 
 
IV.2.4 Specific antibody staining 
 
The specific antibody staining was performed in each case as explained in table M12. The 
preparation of buffers and reactive catalogue numbers were as follows: citrate buffer pH=6 (17.8% citric 
acid 0.1 M and 81,2% sodium citrate 0.1 M), avidin-biotin blocking kit (vector SP-2001), goat serum 
(Gibco 16210-064), secondary antibody goat anti-rabbit (vector BA-1000), secondary antibody goat 
anti-mouse (vector BA-9200), DAB (Sigma D8001) diluted in PBS- 0.5%Triton and H2O2, and FAB (115-
007-003 Jackson Immuno Research). Schematic procedures for immunohistochemistry are shown in 
figure M10. 
 
IV.2.5 Pathological evaluation and analysis 
 
After euthanasia, histological evaluation of a Haematoxylin and eosin (H&E) stained section 
from formalin-fixed paraffin embedded tissues of prostate glands, lymph nodes (LN), long bones from 
lower limbs and liver was performed by the pathologist, Dr. Mireia Castillo Martin. 
Following the consensus reported by Ittmann et al. 29, prostate gland alterations were 
classified into 4 categories: gland within normal limits; high grade prostatic intraepithelial neoplasia 
(HGPIN); HGPIN with focal micro-invasion; and invasive carcinoma. Lymphovascular invasion was 
assessed in all cases where micro-invasion foci or invasive carcinoma were observed. LN metastasis 
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and the presence of groups of prostate cancer cells in bone marrow (BM), were determined after 
haematoxylin-eosin (H&E) staining (LN) and immunohistochemical identification of cytokeratin (CK) 
and androgen receptor (AR) -expressing cells (LN and BM). In the case of BM, cases were classified 
as “dissemination negative” when none or few scattered (less than 5) CK-expressing cells were 
identified and “dissemination positive" when more than 5 or small groups of these cells were observed. 
Proliferation was assessed in paraffin embedded xenografts samples by using Ki67 antibody and 
counting the positive cells with Fiji software.  
 .  
Figure M10. Scheme of the immunohistochemistry procedure: Avidin/Biotin Complex (ABC) method 
(adapted from https://www.novusbio.com/ihc-detection).  
 
Table M12. Protocols and antibodies used for each immuno-staining. 
Step /Reagent Ki67 AR (N-20) Pan Cytokeratin* 
Antigen retrieval 
Citrate Buffer (pH=6) 
30 min in steamer 
Citrate Buffer (pH=6) 
30 min in steamer 
 
Citrate Buffer (pH=6) 
20 min in steamer 
H2O2 (3%) 15 min RT 15 min RT 10 min RT 
A/B 15 min/15 min RT 15 min/15 min RT 15 min/15 min RT 
Blocking serum 
(10%) 
GOAT. 30 min RT GOAT. 30 min RT 
*FAB 1/10 in PBS with 2%BSA 
and 0.01% azide. 
GOAT. 30 min RT 
1st Antibody 1:200 O/N 4C 1:100 O/N 4C 1:100 O/N 4C 
2nd Antibody 
1:1000 30 min RT 
(Rabbit) 
1:500 30 min RT 
(Rabbit) 
1:1000 30 min RT 
(Mouse) 
ABC Kit 1:25 30 min RT 1:25 30 min RT 1:25 30 min RT 
DAB Depending on tissue Depending on tissue Depending on tissue 
Haematoxylin 40 seconds 40 seconds 40 seconds 
Reference 
Thermo Scientific 
RM-9106 
Santa Cruz 
SC-816 
Citokeratin clones AE1/AE3 
Dako M3515 
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IV.3 Analysis of human samples 
 
All prostate specimens were obtained from the Basque Biobank for research (BIOEF, Basurto 
University Hospital) on informed consent and with evaluation and approval from the corresponding 
ethics committee (CEIC code OHEUN11-12 and OHEUN 14-14) (Table M13). All the samples were 
collected and processed as previously described148. 
 
Table M13. Detailed data of patient specimens from the BIOEF biobank describing sample type, specific 
characteristics of the sample and aggressiveness parameters of prostate cancer samples (Gleason Score 
and Tumor Node Metastasis (TNM) Classification). 
Patient Sample type Characteristics Gleason TNM 
Patient 1 BPH Adenomiomatous hiperplasia    
Patient 2 BPH Adenomiomatous hiperplasia   
Patient 3 BPH Adenomiomatous hiperplasia   
Patient 4 BPH Adenomiomatous hiperplasia   
Patient 5 BPH Adenomiomatous hiperplasia   
Patient 6 BPH Adenomiomatous hiperplasia   
Patient 7 BPH Adenomiomatous hiperplasia   
Patient 8 BPH Adenomiomatous hiperplasia   
Patient 9 BPH Adenomiomatous hiperplasia   
Patient 10 BPH Adenomiomatous hiperplasia   
Patient 11 BPH Adenomiomatous hiperplasia   
Patient 12 BPH Adenomiomatous hiperplasia   
Patient 13 BPH Adenomiomatous hiperplasia   
Patient 14 BPH Adenomiomatous hiperplasia   
Patient 15 Cancer Prostate Adenocarcinoma   4+3 pT3a  
Patient 16 Cancer Prostate Adenocarcinoma (Acinar) 3+4  pT3b  
Patient 17 Cancer Prostate Adenocarcinoma (Acinar) 3+4  pT2c  
Patient 18 Cancer Prostate Adenocarcinoma (Acinar) 4+5   pT3b 
Patient 19 Cancer Prostate Adenocarcinoma (Acinar)  4+3   pT2c 
Patient 20 Cancer Prostate Adenocarcinoma (Acinar) 3+4 pT2c 
Patient 21 Cancer Prostate Adenocarcinoma (Acinar) 3+4  pT2c  
Patient 22 Cancer Prostate Adenocarcinoma (Acinar)   4+3   pT3b 
Patient 23 Cancer Prostate Adenocarcinoma (Acinar) 4+4 pT2c 
Patient 24 Cancer Prostate Adenocarcinoma (Acinar) 4+4 pT2c 
Patient 25 Cancer Prostate Adenocarcinoma (Acinar) 3+4 pT3a 
Patient 26 Cancer Prostate Adenocarcinoma (Acinar) 3+4 pT2c 
Patient 27 Cancer Prostate Adenocarcinoma (Acinar) 3+4 pT2c 
Patient 28 Cancer Prostate Adenocarcinoma (Acinar) 3+4 pT2c 
Patient 29 Cancer Prostate Adenocarcinoma 3+4 pT2c 
Patient 30 Cancer Prostate Adenocarcinoma 4+4 pT3a 
 
 
Materials and Methods 
107 
 
M
A
T
E
R
IA
L
S
 A
N
D
 
M
E
T
H
O
D
S
 
V Bioinformatic analysis 
 
The bioinformatics analysis was carried out by Ana Rosa Cortazar from CICbioGUNE. All the 
datasets used for the data mining analysis were downloaded from GEO or TCGA, and subjected to 
background correction, log2 transformation and quartile normalization. In the case of using a pre-
processed dataset, this normalization was reviewed and corrected if required. A summary of the 
datasets used is shown in table M14. 
Frequency of alteration of metabolic co-regulators: expression levels of the selected co-
regulators were obtained from the pilot dataset reported by Taylor et al1, which contained normal, 
primary tumour (PT) and metastasis data and disease free survival (DFS), Gleason Score and 
recurrence information. A matrix containing signal values and clinical information was prepared in order 
to ascertain the up- or down-regulation. We computed the relative expression of an individual gene and 
sample to the expression distribution in a reference population (patients without prostate tumour or 
metastasis). The returned value indicates the number of standard deviations away from the mean of 
expression in the reference population (Z-score). Using a fold change of +2 and -2 as a threshold, we 
determined the number of samples from the cancer dataset in which the expression of a given co-
regulator was up- or down-regulated. p- values were calculated by comparing the means of normal and 
cancerous biopsies. 
Quartile analysis in DFS: Patients specimens from primary tumours were organized into 
four quartiles according to the expression of the gene of interest in two datasets (Taylor et al1 and 
TCGA provisional dataset149,150). The recurrence of the disease was selected as the event of interest. 
Kaplan-Meier estimator was used to perform the test as it takes into account right-censoring, which 
occurs if a patient withdraws from a study. On the plot, small vertical tick-marks indicate losses, where 
a patient's survival time has been right-censored. With this estimator we obtained a survival curve, a 
graphical representation of the occurrence of the event in the different groups, and a p-value that 
estimate the statistical power of the differences observed. 
Genomic analysis: For PGC1A genomic analysis, data from prostate cancer patients with 
copy number alteration information in Taylor1, Grasso151 and Robinson152 et al. datasets was extracted 
from cbioportal.org. Percentage of shallow deletions of primary tumours and metastatic patients was 
calculated separately. 
Correlation analysis: Pearson correlation test was applied to analyse the relationship 
between paired genes. From this analysis, Pearson's coefficient (R) indicates the existing linear 
correlation (dependence) between two variables X and Y, giving a value between +1 and −1 (both 
included), where 1 is total positive correlation, 0 is no correlation, and −1 is total negative correlation. 
The p-value indicates the significance of this R coefficient. 
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VI Statistical analysis 
 
All experiments were performed a minimum of three times (biological replicates) to ensure 
adequate statistical power, except for the exploratory experiments such as metabolomics (LC/MS) or 
xenograft experiments that were done once, but with independent biological replicates. For each 
independent in vitro experiment, at least three technical replicates were used.  
 Unless otherwise stated, data analysed by parametric tests is represented by the mean ± s.e.m. 
of pooled experiments and median ± interquartile range for experiments analysed by non-parametric 
tests. n values represent the number of independent experiments performed, the number of individual 
mice or patient specimens.  
For data mining analysis, ANOVA test was used for multi-component comparisons and 
Student T test for two component comparisons. In the in vitro experiments, normal distribution was 
confirmed or assumed (for n<5) and Student T test was applied for two component comparisons. When 
fold change is represented, one sample t-test with the corresponding hypothetical value (1 or 100) was 
used for statistical analysis. For in vivo experiments, as well as for experimental analysis of human 
biopsies (from Basurto University Hospital) a non-parametric Mann-Whitney exact test was used, 
without using approximate algorithms to avoid different outcomes of statistics packages. For 
contingency analysis, Fisher exact test was used for 2-group comparison (metastasis incidence) and 
Chi Square when analysing more than 2 groups (analysis of PGC1α-ERRα signature frequency in 
prostate cancer human specimens). The confidence level used for all the statistical analyses was of 
95% (alpha value = 0.05). Two-tail statistical analysis was applied for experimental design without 
predicted result, and one-tail for validation or hypothesis-driven experiments.  
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Table M 14. Information summary of datasets used in this thesis work. 
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I Bioinformatic screening of metabolic transcriptional co-regulators in 
prostate cancer (pca) patient data sets. 
 
The first aim of this thesis work was to identify central regulators of tumour metabolism through 
the expression analysis of known metabolic transcriptional co-regulators75 in prostate cancer (PCa) 
patient data sets. 
 
The metabolic rewiring is a hallmark of cancer3. This metabolic switch that cancer cells undergo 
is encompassed by alternative enzymatic activities that are coordinated in order to ensure biomass 
generation, modulation or redox programs and remodelling of the tumour microenvironment153-157. 
Though it has been observed that mutations in metabolic enzymes can trigger tumorigenesis158, cancer-
related genes that remodel the signalling landscape are accepted to be the main drivers for metabolic 
reprogramming155. Different signalling pathways involved in cancer can regulate enzymatic activities 
within a certain metabolic route. Therefore, the metabolic rewiring is not the consequence of a single 
mutation, but rather of different alterations in signalling pathways. However, it is not well understood 
how the complex metabolic network regulation occurs.  
Master transcriptional co-regulators of metabolism control a variety of genes that are in charge 
of remodelling the metabolic landscape, and their impact in cellular and systemic physiology has been 
studied for decades. It is worth noting that these co-regulators, owing to their capacity to interact and 
regulate diverse transcription factors, exhibit a unique capacity to control complex and extensive 
transcriptional networks, making them ideal candidates to promote or oppose oncogenic metabolic 
programs. According to this, we hypothesized that, by studying the implication of metabolic 
transcriptional co-regulators in PCa, we would be able to identify candidate genes that play an essential 
role in the disease. 
 
 
We approached the study of metabolic transcriptional co-regulators in PCa applying specific 
selection criteria to ensure the identification of relevant master co-regulators that contribute to the 
metabolic switch. Although transcriptional factors act as regulators of metabolic programs, 
transcriptional co-regulators have emerged as key mediators of metabolic processes. This is due to the 
balance they exert between the inhibitory actions of corepressors and the stimulatory effects of 
coactivators on transcription. According to this, we first analysed the expression of 23 master 
transcriptional co-factors of metabolism already described in the bibliography75 in a well annotated data 
HYPOTHESIS 
A major metabolic rewiring in prostate cancer is induced by alterations in master transcriptional 
co-regulators of metabolism 
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set1. Second, we extend the differential expression analysis in additional data sets, and finally, we 
associated the expression of the candidate co-regulators with disease progression and aggressiveness 
parameters (Fig R1). 
 
 
 
I.1 Expression analysis in Taylor data set 
 
The first selection step was the analysis of the expression of the co-regulators in one PCa data 
set. Taylor data set presented normal, primary tumours (PT) and metastasis data, and disease free 
survival (DFS), Gleason Score and recurrence information. We performed a general study analysing 
the expression of 23 transcriptional co-regulators of metabolism previously described in the 
bibliography (PGC1A, HDAC1, HDAC9, HDAC3, KAT2A, NCOR2, NRIP1, CRTC3, PGC1B, NCOA2, 
CRTC2, MED1, NCOA3, NCOA1, KAT2B, HDAC7, NCOR1, HDAC4, RB1, SIRT1, HDAC5, CRTC1 
and HDAC2 75 in our ”Discovery” PCa patient data set comprising 150 PCa specimens and 29 non-
pathological prostate tissues (or controls)1. This initial analysis revealed 10 co-regulators in the set of 
study with significant differential expression in PCa compared with non-neoplastic prostate tissue (Fig 
R2). In figure R2A differences in expression in normal and PCa conditions are shown, while in R2B the 
percentage of patients with up or down-regulation in the specified gene is represented. PGC1A, 
HDAC1, HDAC9, NRIP1, CRTC3, PGC1B, HDAC7, NCOR1, HDAC5 and HDAC2 were significantly 
altered in PCa and chosen to continue with the candidate selection. 
 
I.2 Differential expression in different PCa patient data sets 
 
After the selection of the 10 preliminary candidates, we extended the analysis of the co-
regulators expression in up to four additional data sets (Lapointe, Varambally, Tomlins and Grasso), 
where data for non-tumoral and PCa tissues was available151,159-161 (Fig R3). PPARGC1A (PGC1A), 
PPARGC1B (PGC1B) and HDAC1 (circled with dotted line in Fig R3) were further confirmed to be 
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Figure R 1. Selection criteria of candidate metabolic co-regulators. 23 metabolic transcriptional co-regulators 
were initially analysed in a well-annotated data set (Taylor1). Differentially expressed candidates were further 
validated in up to four additional PCa data sets, and, finally, the expression of the positive hits was associated with 
disease progression and aggressiveness. Candidates complying with all criteria were selected for further studies. 
 
 
Results I 
 
 115 
R
E
S
U
L
T
S
 I
 
 
significantly altered in PCa patient data sets. PGC1A and PGC1B expression was consistently 
downregulated while HDAC1 was upregulated in cancer tissues.  
 
 
Figure R 2. Expression analysis of 23 co-regulators in Taylor data set. A, Statistically different expression of 
the indicated gene in PCa (n=131) versus normal (n=29) patient specimens in in Taylor data set. B, Frequency of 
alterations (differences greater than two-fold versus mean expression of non-tumour biopsies) in the expression 
of the 23 co-regulators of metabolism (*p<0.05). (N, normal; PCa, prostate cancer). Error bars represent minimum 
and maximum values. Points outlined by circles indicate statistical outliers (b). Statistical test: two-tailed Student 
T-test. p= p value *p˂0.05. 
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Figure R 3. Gene expression levels of the 10 pre-selected genes in up to four patient data sets. Sample 
size: Tomlins S.A. et al. (N, 23; PCa, 52); Grasso C.S. et al. (N, 12; PCa, 76); Lapointe J. et al. (N, 9; PCa, 17); 
and Varambally S. et al. (N, 6; PCa, 13). In Varambally data set gene expression levels are presented in Log2. In 
Tomlins, Grasso and Lapointe data sets gene expression levels are presented in median centred Log2. Error bars 
represent minimum and maximum values. Points outlined by circles indicate statistical outliers. Statistical test: two-
tailed Student T-test. p= p-value. *p˂0.05. (N, Normal; PCa, Prostate Cancer). 
 
I.3 Association with disease progression and aggressiveness 
 
To narrow down the candidate list, and to finish with the selection criteria, we associated the 
expression of the candidates with disease progression and aggressiveness parameters. First, we 
analysed and compare the expression of the three candidates in different stages of the disease 
(Primary tumour and metastasis) versus normal tissue (Fig R4). The expression of the three candidates 
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was analysed in Taylor, Lapointe and Grasso data sets. From them, only PGC1A and PGC1B 
downregulation showed a significant association with disease progression in the data sets analysed. 
 
 
Figure R 4. Association of the candidate gene expression with disease progression. Expression in normal 
prostate (N), primary tumour (PT) and metastatic (Met) specimens in Taylor, Lapointe and Grasso data sets. 
Sample size: Taylor (N:29; PT:131; Met:19), Lapointe (N:9; PT:13; Met:4) and Grasso (N:12; PT:49; Met:27). Error 
bars represent minimum and maximum values. Statistical test: ANOVA. (N, normal; PCa, Prostate Cancer; Met, 
Metastasis). p=p-value. 
 
Next, we analysed the association of the candidate gene expression with recurrence and 
disease-free survival (DFS). DFS refers to the period of time after a successful treatment during which 
there are no signs and symptoms of the treated disease. In order to analyse the association of these 
two parameters with the expression of the three candidates, we took advantage of the clinical data from 
Taylor data set and The Cancer Genome Atlas (TCGA) (https://cancergenome.nih.gov/) provisional 
data set. We analysed the expression of the three candidates in patients who recur and who did not 
(Fig R5A) and its association with DFS (Fig R5B). In both cases, only PGC1A downregulation was 
associated with recurrence and with reduced DFS. The data analysed in Taylor and TCGA data sets, 
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supports the notion that, patients with lower expression of PGC1A would be more prone to recur in the 
disease.  
 
 
 
 
Figure R 5. Association of candidate-gene expression with recurrence and disease-free survival (DFS). A, 
Recurrence analysis according to indicated gene expression. Sample sizes: TCGA provisional data, primary 
tumours n= 499; Taylor et al., primary tumours n=131. B, Association of the indicated genes in PCa with disease 
free survival (DFS) in two PCa data sets (low: first quartile distribution in target gene expression; high: fourth 
quartile distribution). Error bars represent minimum and maximum values (b). Statistical test: two-tailed Student´s 
test (a) and Log-rank Mantel Cox test (b). p=p-value. 
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Finally, to further characterize the role of PGC1A in prostate cancer aggressiveness, we 
investigated the association of its expression with the Gleason Score of the patients in Taylor and 
TCGA provisional data sets. Although many revisions have been done over it, the current PCa grading 
system (Gleason Score) was developed by Donal F Gleason and members of the Veterans 
Administration Cooperative Urological Research group in the 1970s37. This grading system is based on 
the histologic pattern of arrangement of carcinoma cells in H&E-stained prostatic tissue sections. 
Specifically, it categorizes the histologic patterns by the extent of glandular differentiation and the 
pattern of growth of the tumour in the prostatic stroma. Nine growth patterns were consolidated into five 
grades. Increasing Gleason grade is directly related to a number of histopathological end points, 
including lymph-vascular space invasion by the carcinoma, tumour size, positive surgical margins, and 
pathological stage, including risk of extra-prostatic extension and metastasis38. Although no significant 
changes were observed in Taylor data set, in TCGA provisional data set, PGC1A downregulation was 
associated with a higher Gleason score. As mentioned before, increasing Gleason score increases the 
risk to present metastatic lesions. Therefore, this data remarks the potential role of PGC1A 
downregulation in the aggressiveness of the disease. 
 
 
 
Figure R 6. Association of PGC1A expression with Gleason Score in Taylor data set and TCGA provisional 
data set. Error bars represent minimum and maximum values. Statistical test: ANOVA.GS=Gleason Score. p=p-
value. 
 
We have previously observed that PGC1A is downregulated in PCa patient data sets, and that 
this downregulation is associated with disease progression and aggressiveness. However, to obtain a 
more robust selection of the master co-regulator, we further investigated the role of PGC1A using PCa 
patient samples from Basurto University Hospital (see methods section for the list of patients and 
information). This samples were collected and processed as previously described148. In this case, we 
wanted to interrogate whether PGC1A downregulation could be a consequence or the cause of the 
disease. In order to ascertain so, we studied if cellular proliferation could contribute to the alteration of 
the metabolic co-regulator. We analysed the expression of PGC1A in PCa versus benign hyper-
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proliferative condition (benign prostate hyperplasia or BPH) (Fig R7). It is important to remark the 
relevance of using benign prostate hyperplasia as a control instead of normal samples. The results 
corroborated the data previously seen in the bioinformatics screening, and further showed that PGC1A 
expression is decreased and associated with a cancerous state rather than with a proliferative 
condition.  
 
Figure R 7. Analysis of PGC1A expression in patients. Analysis of PGC1A expression in patients in benign 
prostatic hyperplasia (BPH) and PCa specimens from Basurto University Hospital cohort (RT-qPCR, BPH n=14 
patient specimens and Cancer n=15 patient specimens). Statistical test (b): one-tailed Mann Whitney U test.  a.u, 
arbitrary units. 
 
As we have previously seen that PGC1A mRNA expression is downregulated progressively 
during the development of the disease, we wanted to ascertain if genetic alterations could contribute to 
the reduction in the expression of this co-regulator. In order to do so, we evaluated copy number 
alterations in three different data sets, Robinson, Taylor and Grasso. Strikingly, this analysis revealed 
shallow deletions of PGC1A in metastatic PCa specimens, with almost no detection of genetic deletions 
in primary tumours. These results are in full agreement with the notion that there is a selective pressure 
to reduce the expression of this transcriptional co-regulator as the disease progresses (Fig R8).   
 
 
Figure R 8. Incidence of PGC1A shallow deletions in three independent data sets (Robinson D. et al., Taylor 
B.S. et al., and Grasso C.S. et al.). PT=Primary Tumours, Met=Metastasis. 
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SUMMARY AND CONCLUSIONS 
 
o Bioinformatics screening and analysis of publicly available patient data sets emerge as 
an invaluable tool to interrogate the implication of genes (in the case of the present 
work, genes involved in metabolic transcriptional regulation) in cancer pathogenesis, 
aggressiveness and progression. 
 
o PGC1 expression decreases in prostate cancer patients in comparison to normal and 
BPH patients specimens. Therefore, its expression is not associated to a proliferative 
state but rather to cancer conditions. 
 
o The presence of genetic alterations (shallow deletions, potentially owing to loss of one 
allele) in metastatic patients could be one of the causes of the decrease in PGC1 
mRNA expression. 
 
o PGC1 is the only metabolic transcriptional co-regulator that is significantly altered in 
different PCa patient data sets and associated with disease progression and 
aggressiveness. 
 
o After selection criteria application, PGC1 emerges as the main master metabolic 
transcriptional co-regulator altered in PCa, with an expression pattern reminiscent of a 
tumour suppressor (Fig R9).  
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Figure R 9. Metabolic transcriptional co-regulators expression analysis summary. First, 23 metabolic 
transcriptional co-regulators 75 were analysed in a pilot data set (Taylor) in which 10 were significantly altered, but 
only 3 out of these 10 were consistently altered in different data sets (PGC1A, HDAC1, PGC1B). From these three, 
only the downregulation of PGC1A was associated with disease progression, disease free survival and 
aggressiveness. 
 
 
 
 
 
23 metabolic transcriptional co-regulators
(Mouchiroud L. et al.Cell Met. 2014)
10 altered in one data set
PGC1A, HDAC1, HDAC9, NRIP1, CRTC3, PGC1B, HDAC7, NCOR1, 
HDAC5 and HDAC2
(Taylor, B.S. et al.)
1 Associated to disease free 
survival, progression 
and agressiveness
PGC1α
3 altered in up to four additional data sets
PGC1A, PGC1B, HDAC1
(Lapointe J. et al; Varambally S. et al; Tomlins S.A. et al; 
Grasso C.S. et al.). 
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II Causal contribution of PGC1 to prostate cancer progression in 
vivo. 
 
The bioinformatics screening previously performed revealed PGC1 as the major metabolic 
transcriptional co-regulator altered in prostate cancer (PCa), which expression is associated with 
disease progression and aggressiveness. In order to ascertain the causal contribution of its loss to 
the disease, we took advantage of the Pten-KO PCa mouse model (Pten pc-/-) 62. This PCa mouse 
model is based on the conditional deletion of the tumour suppressor Pten in the prostate epithelium. 
In this genetic engineered mouse model (GEMM), one copy loss of Pten leads to prostate 
intraepithelial neoplasia (PIN) in mice at 6-12 months of age. Deletion of both Pten alleles results in 
cancer lesions at 6 months of age. Nevertheless, it is important to remark that this PCa mouse model 
does not derive into metastasis.  
 
 
Figure R 10. Scheme of PTEN KO PCa mouse model. pc, prostate-specific allelic changes; +, Wildtype allele; 
-, deleted allele. WT=wild-type. 
The second aim of this thesis work was to elucidate the contribution of PGC1 to the disease 
using a PCa mouse model. Since the bioinformatics analysis revealed that PGC1A downregulation 
is associated with poor prognosis, we will study the impact of its loss on cancer initiation and 
progression.  
 
Pten pc+/-
One copy lost
Pten pc-/-
Two copy lost
Pten pc+/+
WT
Cystic lesions
✓ (6 months)
✓ (3 months)
No signs of 
metastasis
Focused 
invasion
PINNormal 
epithelium
✓ (6 months)
✗
✗ ✗
HYPOTHESIS 
Pgc1a deletion in the prostate epithelia impacts on prostate cancer pathogenesis and 
progression  
Results II 
  124 
R
E
S
U
L
T
S
 I
I 
 
II.1 Study of generated mice colonies 
 
The mice colonies under study were the following ones (Fig R11A):  
1) Pgc1a deletion in order to study its sole contribution to the disease. Mice colony: 
Pgc1apc+/+vs. Pgc1a pc+/- vs. Pgc1a pc-/-.  
2) Pgc1a deletion together with heterozygous deletion of Pten to analyse the effect in PCa 
initiation. Mice colony: Pten pc+/-, Pgc1apc+/+ vs Pten pc+/-, Pgc1a pc+/- vs Pten pc+/-, Pgc1a 
pc-/-. 
3) Pgc1a deletion together with homozygous deletion of Pten to analyse the effect in PCa 
progression. Mice colony: Pten pc-/+, Pgc1apc+/+- vs Pten pc-/-, Pgc1a pc+/- vs Pten pc-/-, 
Pgc1a pc-/-. 
Tissue sample collection was carried out in mice older than 10 months in all cases. A table 
representing the average age of mice and the number of each group for each colony is shown in the 
table from Fig R11B. The deletion of Pgc1a and Pten was confirmed by RT-qPCR in the 
corresponding phenotypes (Fig R12). 
 
Figure R 11. Mice colony analysis information. A, Schematic representation of the genetic cross and the time 
of analysis. B, Age and number of mice per cohort. pc, prostate-specific allelic changes; +, Wildtype allele; -, 
deleted allele; wt. any given genotype resulting in the lack of deletion of Pgc1a and Pten alleles.  
A
B
PtenLoxP/LoxP; Pb-Cre
Pgc1aLoxP/LoxP
x
PCa initiation
PCa progression
> 10 months
Pgc1a contribution Pgc1a pc+/+ vs Pgc1a pc+/- or Pgc1a pc-/-
Ptenpc+/- vs Pgc1a pc+/- or Pgc1a pc-/-
Ptenpc -/- vs Pgc1a pc+/- or Pgc1a pc-/-
Genotype Age	(months;	ave ± stdv) n	
Ptenwt Pgc1awt 11.1	± 2.03 20
Ptenwt Pgc1apc+/- 11.5± 1 4
Ptenwt Pgc1apc-/- 13.4± 3.2 18
Ptenpc+/- Pgc1awt 14.2± 2.75 22
Ptenpc+/- Pgc1apc+/- 12.4± 2.82 17
Ptenpc+/- Pgc1apc-/- 12.08± 1.14 24
Ptenpc-/- Pgc1awt 12.68± 2.21 20
Ptenpc-/- Pgc1apc+/- 13.66± 3.01 7
Ptenpc-/- Pgc1apc-/- 11.31± 1.30 17
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Figure R 12. Pten and Pgc1a expression in Pten KO and DKO mice. Analysis of Pten and Pgc1a gene 
expression in GEMMs of the indicated phenotype (Pten pc+/+Pgc1a pc+/+ n=3 mice; Ptenpc-/-Pgc1apc+/+ n=7 mice; 
Pten+/+Pgc1apc-/- n=6 mice; Pten-/-Pgc1apc-/- n=12 mice; data is normalized to Gapdh expression. Error bars 
represent median with interquartile range. Statistics test: one-tailed Mann-Whitney U test. *p<0. 05; ***p<0.001. 
 
II.2 Analysis of prostate lobes 
 
The representation of all prostate lobes weights is shown for all the mice colonies under 
study in figure R13. In the upper panel (A), the contribution of one or both copy loss in Pgc1a is 
shown (in green). No differences were observed in any of the lobes compared to wild type conditions. 
In panel B, the loss of Pgc1a under Pten heterozygous deletion is shown (in blue) Finally, Pten 
homozygous loss in mice increased the weight of all lobes (in purple) (C). Despite the fact that Pgc1a 
deletion in both alleles exhibited a tendency to increase AP weight, there were no significant changes 
in any of the lobes. In the initial study performed with a lower number of mice162, a significant increase 
in the anterior lobe of DKO mice was observed. The loss of significance after adding more mice to 
the study, could be due to the ascetic nature of the tumours. Moreover, the AP lobes of two mice 
presenting metastatic phenotype could not be analysed due to their fusion to other organs. This data 
could have balanced the results presented, as the mass did not represent the whole prostate. 
Moreover, although most of the mice were analysed at 10-15 months of age, due to ethical and mouse 
well-being parameters, some mice were sacrificed in advance. According to these facts, the variability 
in the prostate lobes weight analysis was potentially increased.  
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Figure R 13. Prostate lobes tissue mass analysis. A, B and C, Comparison of ventral, dorso-lateral and 
anterior prostate lobe weights between genotypes. Error bars indicate interquartile range. A, contribution of 
Pgc1a deletion in mice, B, contribution of Pgc1a deletion in Pten pc+/- mice (initiation) and C, contribution of 
Pgc1a deletion in Pten pc-/- mice (progression). pc, prostate-specific allelic changes; +, Wildtype allele; -, deleted 
allele; wt. any given genotype resulting in the lack of deletion of Pgc1a and Pten alleles. Statistical test: two-
tailed Mann-Whitney U-test. 
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II.3 Histopathological characterization 
 
We further characterized the prostate lobes through histological analysis. Pgc1a deletion 
alone or in the context of Pten heterozygosity did not result in any differential histological alteration. 
These data, together with the tissue mass represented before, led us to conclude that Pgc1a loss 
does not promote PCa initiation. However, compound loss of both Pten and Pgc1a resulted in a 
remarkable increase in the rate of invasive cancer (Fig R14).  
 
 
 
Figure R 14. Histopathological characterization. A, Histopathological characterization of the prostate (HGPIN, 
high-grade prostatic intraepithelial neoplasia) in the indicated genotypes. pc, prostate-specific allelic changes; +, 
Wildtype allele; -, deleted allele; wt. any given genotype resulting in the lack of deletion of Pgc1a and Pten alleles. 
 
Strikingly, the histopathological analysis provided evidence of metastatic signs in lymph 
nodes (LN) and liver (Fig R15A) of Pten KO mice with one or both copy loss of Pgc1a. These 
metastatic signs were estimated to be 33.3% in the LN and liver of Pten KO Pgc1a het mice, and 
44% in the LN and 20%in the liver of DKO mice. Interestingly, although PTEN KO mice presented 
disseminated cells in the lymph nodes (Fig. R15B), they did not present clinical metastasis. This fact 
remarks the proliferative capacity of the DKO cells that arrive to the LN and are capable of tumour re-
growing. In Fig R15C and D, representative histological images of the LN and liver for DKO and Pten 
KO are shown. Pan-cytokeratin (panCK) and androgen receptor-positive PCa cells were observed in 
the LN of DKO mice, which confirms the prostatic epithelium origin of the metastatic cells. Of note, 
although Pten-KO mice presented small groups of panCK-positive cells in the LN, no clinical 
metastasis was observed. This indicates that these cells lack the capacity to grow in a secondary 
tissue to form a full-blown metastasis. 
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Figure R 15. Analysis of metastatic lesions. A, Quantification of the frequency of metastatic lesions in lymph 
nodes and liver of Pten-KO (n=5), Pten-KO/Pgc1a-het (n=3), and DKO (n=9) mice. B, Quantification of 
percentage of mice with disseminated cells in the lymph node of Pten-KO mice. C, Representative histological 
images (H&E) (x200 magnification) of lymph nodes with (up left) and without metastasis (up right) and 
representative immune-histochemical detection (x200 magnification) of Pan-cytokeratin (panCK) (down left) and 
androgen receptor (AR)-positive cells (down right) in metastatic lymph nodes of DKO mice. D, Representative 
Haematoxylin and eosin staining depicting liver metastasis in DKO mice. Pten KO= Pten pc-/- Pgc1a pc+/+ and 
DKO= Pten pc-/- Pgc1a pc-/-. 
 
According to the metastatic signs observed in the DKO, and as the main site of metastasis 
in patients is the bone, we performed the histopathological analysis of the lower limbs of the mice 
(Fig R16). Surprisingly, we could detect disseminated groups of cells in the bones of 75% DKO mice 
(Fig R16A). The epithelial and prostatic origin of these cell groups was confirmed through Pan-CK 
and androgen receptor staining (Fig R16B).  Although PCa GEMMs faithfully recapitulate many of 
the features of the human disease25, a reduced number of them with clinically relevant mutations 
show metastatic potential, being the bone metastasis especially rare163-166. This fact is of great 
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relevance since it is the prime site of metastasis in PCa patients. Here we have shown that the 
conditional deletion in the prostate epithelium of both Pten and Pgc1a leads to clinical metastasis in 
LN and liver, and leads to cancer cell dissemination in the bone.   
 
 
Figure R 16. Histopathological analysis of Pten KO vs DKO mice. A, Quantification of BM dissemination 
frequency (Pten KO n=6 mice, DKO n= 8 mice). B, Representative immune-histochemical detection (200x) pf 
PanCK positive cells in the bone marrow (BM) (down left) and androgen receptor (AR) in the bone marrow of 
DKO mice. Pink arrows indicate immunoreactive cells. Pten KO= Pten pc-/- Pgc1a pc+/+ and DKO= Pten pc-/- Pgc1a 
pc-/-. 
 
In order to extend the histopathological analysis and further decipher the role of Pgc1a in 
the clinical metastasis outcome, we investigated the presence of invasive signs. We compared the 
vascular invasion signs in Pten KO mice (Pten pc-/-; Pgc1a pc+/+), in which no metastasis was detected, 
and DKO mice (Pten pc-/-; Pgc1a pc+/+), that presented metastatic signs in lymph nodes and liver, and 
disseminated cells in the bone. The loss of both Pten and Pgc1a in the prostate epithelia (anterior 
prostate) led to an increase in the percentage of mice with vascular invasion (Fig R17). 
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Figure R 17. Invasive signs in Pten-KO and DKO mice. A, Haematoxylin-eosin representative micrographs 
(20X) of prostate tissue with vascular invasion signs (right panel, box indicates magnified area for the detail of 
the referred observation) and without them (left panel); quantification of the frequency of alteration in prostate 
specimens with invasive signs is provided in the histogram. Pten KO= Pten pc-/-; Pgc1a pc+/+ and DKO=Pten pc-/-; 
Pgc1a pc-/-. 
 
Owing to the cooperativity between Pten and Pgc1a loss in the PCa mouse model, we found 
interesting to study the correlation of the expression of both genes in the preliminary TCGA patient 
data set (Fig R18A). A direct correlation between both transcripts in PCa patients was observed. We 
could also confirm an association between PGC1A downregulation with PTEN genomic loss (Fig 
R18B).   
 
 
 
Figure R 18. PTEN and PGC1A status in TCGA provisional patient data set. Correlation between PGC1A 
and PTEN gene expression in prostate cancer specimens (A) and association of PTEN genomic loss to PGC1A 
gene expression in TCGA provisional data set. Statistic test: Pearson´s coefficient (a) and ANOVA (b). p=p-
value. 
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SUMMARY AND CONCLUSIONS 
 
o Pgc1a deletion alone or in combination with Pten heterozygous loss in the prostate 
epithelium does not contribute to PCa initiation.  
 
o Deletion of Pgc1a and Pten in the prostate epithelium derives in invasive cancer signs 
and clinical metastasis in liver and lymph nodes. 
 
o Disseminated prostate cancer cells are found in the bones of DKO mice. This is a 
remarkable fact, since this is the site of metastasis in PCa patients. This important feature 
highlights the DKO mouse model as a metastasis model for the disease. However, only 
disseminated cells and not metastatic signs were observed in the bone, which reflects a 
limitation in the model. 
 
o Deletion of Pgc1a and Pten leads to the presence of invasive signs in prostatic tissue. 
 
o PGC1A expression correlates directly with PTEN and with PTEN genomic loss in the 
TCGA patient data set. 
 
o Our results in GEMMs, together with the results reported in section 1, clearly 
demonstrate that the downregulation of PGC1 in PCa is a causal event for the 
progression of the disease and its metastatic dissemination. We can therefore confirm 
the tumour suppressor capacity of PGC1. 
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III Evaluation of PGC1α tumour suppressor activity in PCa 
III.1 Generation of the cellular system 
The analyses performed in section II of this thesis uncover the role of PGC1 as a tumour 
and metastasis suppressor in PCa, as its deletion in the prostate epithelium of mice leads to 
metastatic lesions. In order to characterize in vitro the tumour suppressor activity of PGC1, we took 
advantage of a panel of PCa cell lines available in the laboratory.  
 
 
 
III.1.1 PGC1 expression screening in PCa cell lines 
 
We first evaluated the protein expression of PGC1 in a panel of well-established metastatic 
PCa cell lines167, using as controls different melanoma cell lines that were previously reported to be 
positive (MeWo) and negative (HT114, HS294T and A375) for the expression of the transcriptional 
co-regulator 114 (Fig. R19A). We were not able to detect PGC1 protein expression in any of the PCa 
cell lines when comparingto the expression levels in MeWo. Furthermore, the expression of PGC1A 
mRNA was analysed by q-RT PCR, including benign prostate hyperplasia cell lines (RWPE1 and 
PWR1E) (Fig. R19B). Although for some PCa cell lines we did detect amplification, when comparing 
PGC1α expression between PCa cell lines and melanoma cell lines, we can determine that PCa ones 
are negative for the expression of it. Importantly, through the use of Taylor data set1, we could confirm 
that the reduced transcript levels in PGC1A in metastatic cell lines are comparable to those observed 
in human PCa specimens (Fig R19C). In order to further confirm the absence of functional PGC1 
in PCa, we silenced it using a short-hairpin RNA in PC3 cells. The minimal expression of PGC1a 
detected in PCa cells was reduced through its silencing. Also, and in agreement with the low PGC1A 
mRNA expression, its silencing failed to impact on the expression of well-established targets genes168 
(Fig. R19D). According to the cell line characterization analysis, and in line with what was previously 
observed in patient datasets (Fig. R4), we can conclude that PGC1 expression is decreased in PCa. 
Owing to the lack of PGC1 detection PCa cellular systems, we next aimed at reconstituting the 
expression of the transcriptional co-regulator to levels achievable in melanoma cell lines114. 
   
HYPOTHESIS 
Modulation of PGC1α in prostate cancer cells will impact cell proliferation and invasion 
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Figure R 19. PGC1α expression in PCa cell lines. Analysis of PGC1α expression by western blot (A) and by 
q-RT PCR (B) in a panel of PCa cell lines (technical duplicates shown).  Melanoma cell lines were used as 
negative (HT114, HS294T and A375) and positive (MeWo) controls for PGC1α expression (n=3, independent 
experiments). C, mRNA expression of PGC1A, ACO2 and HADHA by q-RT PCR in PC3 cells transduced with 
shRNA targeting PGC1A (shPGC1A) (n=3). Statistics test: one sample t-test (C). p, p-value. *p<0.05. Error bars 
indicate s.e.m. a.u.=arbitrary units. 
 
III.1.2 PGC1 reconstitution in PCa cell lines 
 
We aimed at reconstituting PGC1 expression in PCa cell lines using a doxycycline-inducible 
lentiviral vector (TRIPZ-HA-Pgc1a). After a doxycycline titration, 0.5 g/mL was the concentration 
chosen to induce the co-regulator expression.  The experimental set up for PGC1 induction is shown 
in Figure R20. From the initial cell stock, cells were split (passage 1-p1) and doxycycline was added. 
When experiments were seeded, doxycycline regime was maintained (passage 2 -p2). All 
experiments shown are performed using cells at p2, unless otherwise specified. 
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Figure R 20. Experimental set up for PGC1-reconstitution  
 
We were able to express PGC1 in three different PCa cell lines (androgen receptor 
dependent-LnCaP and androgen receptor independent-PC3 and DU145), reaching protein levels 
equivalent to that observed in PGC1-expressing MeWo melanoma cell line (Fig.R21 A-B). We could 
further confirm the expression and functionality of PGC1 in the PCa cell lines by means of mRNA 
levels of the co-regulator and its known target genes (ACO2, GOT1, IDH3A) (Fig.R21 C-D). As 
doxycycline is a tetracycline antibiotic that could affect cell homeostasis, we confirmed that the 
doxycycline dose that we were using did not affect to neither PGC1A nor IDH3A gene expression 
(Fig.R21 E). 
As we have previously seen in the introduction part of this thesis, PGC1 is a transcriptional 
co-regulator involved in mitochondrial biogenesis and oxidative phosphorylation76. Therefore, in order 
to validate the biological consequences of PGC1 expression, we studied the mitochondrial content, 
volume and markers of the electron transport chain (ETC) (Fig R22) in Pgc1a-expressing PC3 cells. 
Live cells were stained with Mitotracker Red (MTR), a red-fluorescent dye that stains mitochondria 
and its accumulation is dependent upon membrane potential. We could observe that Pgc1a 
expression in PC3 cells induced an accumulation of MTR staining, reflecting an increase in 
mitochondrial content and membrane potential, which was accompanied by increased mitochondrial 
volume (Fig R22A-B). Moreover, markers of different ETC complexes (ATP5A, UQCRC2, SDHB, 
COXII and NDUFB8) were monitored by protein expression. Pgc1a induction led to an increase in all 
markers evaluated, which again supports a higher mitochondrial content. Therefore, we can confirm 
that our experimental setting is compatible with functional Pgc1 expression.  
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Figure R 21. PGC1α re- expression in PCa cell lines. A, Analysis of PGC1α protein expression in PC3, DU145 
and LnCaP cell lines transduced with TRIPZ-HA-Pgc1a vector after treatment with 0.5 µg mL-1 of doxycycline 
(one representative experiment out of three independent experiments). B, Densitometry of PGC1α protein 
expression in MeWo (endogenous) and PC3 TRIPZ-HA-Pgc1a (ectopic) cell lines, relative to -Actin (n=3). C, 
Expression of PGC1α by q-RT PCR in PC3, DU145 and LnCaP cell lines after induction with doxycycline (n=3). 
D, Analysis of ACO2, GOT1 and IDH3A (PGC1α target genes) expression by q-RT PCR in PC3, DU145 and 
LnCaP cell lines after induction with doxycycline (n=3). E, PGC1A and IDH3A expression in parental PC3 cell 
line (non-transfected) after treatment with 0.5 µg mL-1 of doxycycline. Gene expression normalization was 
performed with ACTB (PC3 PGC1A and DU145 PGC1A) and GAPDH (LnCaP PGC1A and PC3) housekeeping 
genes (n=3). In C and D, data are normalized to the No Dox condition, represented with a black dotted line. Dox: 
doxycycline. Statistical analysis: One sample t-test with 1 as hypothetical value (B, C, D and E). p, p-value. 
*p<0.05, **p<0.001. Error bars indicate s.e.m.  
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Figure R 22. Mitochondrial biology in PC3 Pgc1α -expressing cells. A, Images showing mitochondrial 
staining with mitotracker red (MTR) at 63X (one representative experiment shown). B, Mitochondrial volume in 
PC3 Pgc1α cell line after doxycycline treatment. C, Protein expression of electron transport chain (ETC) markers 
after Pgc1α re-expression in PC3 cell line (C). n=3 in all cases. No Dox: Pgc1α non-expressing conditions; Dox: 
Pgc1α induced conditions. p, p-value. **p<0.001. Error bars indicate s.e.m.  
 
III.2 Validation of PGC1 tumour supressive activity in PCa human cell lines 
 
III.2.1 Effect of Pgc1 expression in cell proliferation 
 
We next evaluated the impact of PGC1 expression in PCa cell proliferation. Expression of 
Pgc1 resulted in decreased bi-dimensional growth in three different PCa cell lines (Fig R23A). We 
excluded the possibility that doxycycline treatment could influence cell proliferation by treating non-
transduced PC3 cell line with the antibiotic (Fig R23B). Moreover, we could observe a Pgc1-
dependent decrease in anchorage-independent growth in both cell lines analysed by means of 
number of colonies formed (Fig R23C).  
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Figure R 23. Effect of Pgc1α re-expression in proliferation. A, Effect on proliferation after Pgc1α re-
expression in PC3, DU145 and LnCaP cell lines (n=3-7). B, Effect on proliferation of doxycycline treatment (0.5 
𝝁g mL-1) in non-transfected PC3 cell line (n=3). C, Study of Pgc1α re-expression in anchorage independent 
growth in PC3 and DU145 cell lines (n=3).  Statistical analysis: Student paired t-test (A, B) and one-sample t-
test with 1 as hypothetical value (C). In C, data normalized to No Dox condition represented as a black dotted 
line. Error bars indicate s.e.m. No Dox: Pgc1α non-expressing conditions; Dox: Pgc1α induced conditions.  p, p-
value. *p<0.05,**p<0.001. 
 
In order to proliferate, cells must complete the division cycle, which among other steps, 
implies DNA replication169. Therefore, we further confirmed the effect of PGC1 in proliferation 
through bromodeoxyuridine (BrDU) staining. BrDU is a synthetic nucleoside (analogue of thymidine) 
that is incorporated into newly synthesized DNA of replicating cells. Thus, it is an appropriated readout 
of cell division. We observed educed DNA replication by means of BrDU-positivity when expressing 
Pgc1 in PC3 and DU145 cell lines (Fig R24A). We next analysed the cell cycle pattern by propidium 
iodide (PI) staining. PI is a nuclear and chromosome counterstain that binds to DNA through 
intercalation between bases. The cell cycle is a process by which cells divide. It consists in four 
different phases: G1, S, G2 and mitosis (M). During G1, cells increase in size, and prepare to DNA 
replication (S). Transition into G2 is accompanied with additional checkpoints that ensure the 
readiness to entre cell division, and finally, cell divides (M). In this context, Pgc1 expression induced 
cell arrest (increase in G1 phase) and decreased DNA replication (decrease in S phase) in PC3 cell. 
However, we could not detect the same effect in DU145 cell line, in which no significant changes 
were observed (Fig R24B). Taking all this together, we conclude that Pgc1 decreases 2D and 
anchorage independent growth, and induces cell cycle arrest in G1. 
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Figure R 24. Effect of Pgc1α in DNA replication and cell cycle. A, Study of Pgc1α re-expression on 
bromodeoxyuridine (BrDu) incorporation assay and B, Effect of Pgc1α on cell cycle progression in PC3 and 
DU145 cell lines (n=3). Statistical analysis: Student paired t-test (B) and one-sample t-test with 1 as hypothetical 
value (A). Error bars indicate s.e.m. In A, data normalized to No Dox condition represented as a black dotted 
line. No Dox: Pgc1α non-expressing conditions; Dox: Pgc1α induced conditions.  p, p-value. *p<0.05,**p<0.001. 
 
III.2.2 Effect of Pgc1 re-expression in tumour formation and growth 
 
We next attempted to study the effect of Pgc1 expression in vivo, using xenograft assays. 
Pgc1-expressing PC3 cells were injected in the flank of immunocompromised mice (nude mice), 
that were fed chow or doxycycline containing diet. Tumour size was monitored every 2-3 days, during 
6 weeks (Fig R25A). At the end point of the experiment, the tumours were harvested, weighted and 
protein and RNA was extracted. We confirmed PGC1 expression in tumours from mice fed with 
doxycycline diet by western blot (Fig R25B) and by real qRT PCR together with some of its target 
genes (ACO2, HADHA, IDH3A, GOT1) (Fig R25C).  
The analysis of tumour formation revealed that Pgc1 re-expressing cells were significantly 
less able to form tumours in vivo (Fig R25D). Interestingly, and in line with the proliferation assays 
(Results III.2.1), immunohistochemical analysis of Ki67 (proliferation marker) showed decreased 
proliferation in Pgc1-expressing tumours compared with controls. In summary, Pgc1 expression 
reduces cell proliferation in vitro (prostate cancer cell lines), and also in in vivo (xenograft models). 
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Figure R 25. Xenograft experiments with Pgc1 expressing cells. A, Schematic representation of xenograft 
experiment (two flank injections). B, Pgc1α protein expression in xenograft samples (No Dox n=14 tumours and 
Dox n=6 tumours).C, Analysis of Pgc1α expression and its target genes in xenograft samples. D, Evaluation of 
tumour formation capacity in xenograft experiments from mice fed with or without doxycycline diet. E, Cell 
proliferation in the xenograft samples by Ki67 immunoreactivity. No Dox: Pgc1α non-expressing conditions; Dox: 
Pgc1α induced conditions. Statistical analysis: one-tailed Mann-Whitney U test. Error bars indicate median with 
interquartile range. p, p-value. *p<0.05,**p<0.01, ***p<0.001. 
 
III.2.3 Effect of Pgc1 expression in metastasis 
 
We have reported that Pgc1a loss in GEMMs results in cell dissemination to the bone. 
Therefore, we aimed at studying the capacity of Pgc1 to oppose a pre-existing metastatic 
phenotype. In order to do so, we carried out xenotransplant assays in nude mice using luciferase-
expressing Pgc1-inducible PC3 cells. First, we injected intracardiacally the cells (previously induced 
with doxycycline) in order to study their metastatic capacity (Fig R26A). The intracardiac injection of 
these cells revealed that Pgc1 expression blunted metastatic growth in the lung (Fig R26B), and 
led to a remarkable decrease in bone colonization (Fig R26C) by means of reduced ex vivo photon 
flux and increased metastasis-free survival.  
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Figure R 26. PGC1 decreases metastatic growth in lung and bone colonization. A, Schematic 
representation of metastasis assay through intra-cardiac (IC) injection. B and C, Evaluation of the metastatic 
capacity of Pgc1α-expressing PC3 cells using IC xenotransplant assays (n=8 mice for No Dox and n=6 for Dox). 
Luciferase-dependent signal intensity (upper panels) and metastasis-free survival curves (lower panels) of Pca 
cells in lungs (B) and limbs (C) were monitores for up to 28 days. Representative luciferase images are 
presented, referring to the quantification plots. No Dox: Pgc1α non-expressing conditions; Dox: Pgc1α induced 
conditions. Error bars represent minimum and maximum values. Statistic tests: two-tailed Mann-Whitney U test 
(upper panels) and log-rank test (lower panels). p, p-value. *p < 0.05, **p < 0.01, ***p < 0.001. 
 
Next, we analysed the metastasisre-initiation capacity by means of local injection of Pgc1-
expressing PCa cells at the metastatic site. As PCa exhibits an osteotropic nature170,171, we performed 
intra-tibial injection of cells (Fig R27A). The appearance of tumour masses in the bone was 
monitored. The results showed that PGC1 exerts an anti-metastatic activity reflected as a decrease 
in bone tumour mass (ex vivo photon flux) and hind limb lesion incidence (Fig R27B) in PGC1-
expressing cells. Taking all these results together, we conclude that PGC1 is a metastasis 
suppressor, and prevents tumour growth in a distant organ.   
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Figure R 27. PGC1 expression decreases the metastatic activity in the bone. A, Schematic representation 
of bone metastasis assay through intra-tibial (IT) injection. B, Evaluation of the metastatic capacity of Pgc1α-
expressing PC3 cells using IT xenotransplant assays. Photon flux quantification at 20 days (upper panel) and 
incidence of metastatic lesions at the end point (lower panel). Representative luciferase images are presented 
referred to the quantification plots. For photon flux analysis, the average signal from two limbs per mouse is 
presented. For incidence analysis, mice with at least one limb yielding luciferase signal >50,000 units were 
considered metastasis –positive. Images (i) and (ii) depict tibia photon flux images from specimens that are 
proximal to the median signal in No Dox and Dox respectively. No Dox: Pgc1α non-expressing conditions; Dox: 
Pgc1α induced conditions. Error bars represent minimum and maximum values. Statistic tests: two-tailed Mann-
Whitney U test (B left) and Fisher´s exact test (B right). p, p-value. *p < 0.05, **p < 0.01, ***p < 0.001. 
 
Metastasis progression can be viewed as a succession of multi-step cell-biological processes 
that through an invasion cascade, leads to the formation of a secondary tumour in a distant organ. In 
epithelial cancers, such as prostate cancer, epithelial cells start proliferating in an uncontrolled 
manner. These cells invade locally through surrounding extracellular matrix (ECM) and stromal 
layers, leading to invasive cancer (primary tumour). Cells can then acquire mesenchymal properties 
through a process called epithelial to mesenchymal transition (EMT) that is associated to the 
dissolution of adherent and tight junctions, loss of cell polarity, heightened invasiveness and 
intravasation(Fig R28 Steps 1-2). Cells that adapt and are able to survive in circulation will eventually 
extravasate into a secondary tissue (Fig R28 Step 3). These cells that can stay dormant, form 
micrometastases or lead to full flown metastasis, a process that can take from months to years (Fig 
R28 Step 4)7,12. 
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Figure R 28. Scheme of tumour dissemination and metastasis. From the primary tumour, cell intravasate to 
the lymphatic or blood vessels. They then adapt to environmental changes (cells that do not survive suffer a 
process called anoikis) and extravasate in order to invade a secondary organ (Metastasis).  
 
PGC1 impacts on various steps along the metastatic process: it inhibits proliferation and 
cell division (step1) and the metastatic activity of prostate cancer cells (steps 3 and 4). On the basis 
of our previous data, we next aimed to decipher whether PGC1 could regulate the metastatic 
initiation process (step 2).  
 
III.2.4 PGC1 function in metastasis initiation 
 
III.2.4.1 Effect of PGC1 in 2D invasion, migration and adhesion 
 
Cell migration and invasion are two key processes necessary to initiate the metastasis. 
Therefore, we first analysed the effect of PGC1 expression in transwell migration and invasion (Fig 
R29 A-B). As explained in the methods section, transwell migration was performed using 8 m pore-
membrane and DMEM complemented with 10% FBS as chemoattractant. Pgc1-expression led to a 
decrease in migration at 24 hours in PC3 and DU145 PCa cells. Moreover, invasion in transwell 
experiments, in which the membrane was coated with Matrigel, revealed a decrease of the invasive 
properties of Pgc1-expressing PC3 cells. 
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Figure R 29. Pgc1a inhibits transwell migration and has a clear effect in cell invasion. Effect on transwell 
migration and invasion after Pgc1α re-expression in PC3 (A and B) and DU145 (A) cell lines. No Dox: Pgc1α 
non-expressing conditions; Dox: Pgc1α induced conditions. Error bars represent s.e.m. Statistical analysis: one 
sample t-test with 1 as hypothetical value. Migration (n=8) and Invasion (n=4). The dotted line represent No Dox 
condition. p, p-value. ***p < 0.001. 
 
During metastasis, cancerous cells not only have to migrate and invade across the ECM for 
intravasation, but also have to stabilize through cell adhesion. Cell adhesion molecules participate in 
the cell-matrix linkage and their activation/deactivation is key in order to allow cell motility. According 
to this, we next studied the capacity of these cells to adhere to a collagen I coated surface (Fig R30A). 
Pgc1 expression led to a significant increase in cell adhesion. Cell motility and contraction requires 
cell-matrix interaction and formation of focal contacts, as well as detachment from the surface to allow 
onward cell movement. Therefore, the more adhesive the cells to the matrix, the less able they would 
be to start cell motility and contraction. This is in line with the increase observed in cell area when 
Pgc1 is induced, which also impedes cell movement (Fig R30B-C)172.  
 
III.2.4.2 PGC1 effect in collagen I matrix invasion  
 
In order to confirm the data obtained in 2D systems, we studied cell invasion in bovine 
collagen I matrix, which represent better the ECM. First, we studied the invasive growth capacity of 
these cells. Spheroids were pre-formed during 3 days in methylcellulose drops, and then included in 
a bovine collagen I matrix. Pictures were taken at day 0 and after 48 hours, and the increase in 
spheroid area was measured.  
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Figure R 30. PGC1a increases cell adhesion and area. A, Study of cell adhesion on collagen I during 30 
minutes of PC3 cell lines after Pgc1α re-expression. Data normalized to No Dox condition represent with black 
dotted line.B, Cell area measurement based on C, Phalloidin staining slides (one representative experiment out 
of 4 shown). A scheme of cell movement is shown, more adhesion is represented with blue dots. No Dox: Pgc1α 
non-expressing conditions; Dox: Pgc1α induced conditions. Error bars represent s.e.m. Statistical analysis: one 
sample t-test with 100 as hypothetical value (a) and one tailed Student t-test (b). p, p-value. ***p < 0.001. 
 
 
As it is shown in pictures from figure R31A, Pgc1 expression decreased the invasive 
growth in PC3 cells. Furthermore, we set up a 3D invasion assay to calculate the invaded distance 
of PC3 cells included in bovine collagen I, towards a chemoattractant (in this case DMEM 
complemented with 10% FBS). Cells that were able to reach 50 m and 100 m from the origin (plate 
base) were counted performing stacks with the confocal microscope (Fig R31B). This assay 
corroborated the reduced invasive capacity of Pgc1-expressing PC3 cells (Fig R31C). 
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Figure R 31. Pgc1a decreases invasive growth and 3D invasion in bovine collagen I matrixes. A, Study of 
invasive growth (by means of increase in tumour area) in PC3 Pgc1α re-expressing cell line. One representative 
experiment shown (images at 4x) out of three. B, Scheme of experimental set up for reverse 3D invasion. C, 
Effect on reverse 3D invasion of Pgc1a re-expression in PC3. No Dox: Pgc1α non-expressing conditions; Dox: 
Pgc1α induced conditions. Error bars represent s.e.m. n=3 in all experiments. Statistic tests: one sample t-test 
with 1 as hypothetical value. p, p-value. **p < 0.01. 
 
III.2.4.3 Analysis of invasive signs in PGC1α xenografts 
 
According to the results obtained in vitro and in mice, where invasive signs and capacities 
were observed, we aimed at analysing the signs of invasion in xenograft tumours. The analysis 
revealed that the ones lacking PGC1 expression showed increased perineural, muscular and 
vascular invasive signs (Fig R32A-B). This data reflects the relevance of PGC1 absence in order 
to initiate invasive features in vivo, which as mentioned before, are fundamental for tumour 
dissemination and metastasis cascade. 
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Figure R 32. Pgc1a inhibits vascular invasion and invasion signs in in vivo systems. A, Haematoxylin-
eosin representative micrographs (20X) of prostate tissue with vascular invasion signs (right panel, box indicates 
magnified area for the detail of the referred observation) and without them (left panel). B, Histological 
characterization (400X) and quantification of invasive lesions in xenograft specimens (No Dox=14; Dox=8; 
numbers in the graph represent tumours positive/negative for the specific invasion). No Dox: Pgc1α non-
expressing conditions; Dox: Pgc1α induced conditions. 
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SUMMARY AND CONCLUSIONS 
 
o PGC1 is not detected in prostate cancer (PCa) cell lines, in agreement with patient data. 
 
o PGC1 expression in PCa cell lines leads to a decrease in proliferation and anchorage 
independent growth in vitro and a reduced capacity to form tumours in xenograft models. 
 
o PGC1 causes a decrease in the metastatic activity and in the capacity of the cells to re-
initiate a tumour in the metastatic organ (bone). 
 
o PGC1 absence leads to presence of invasive signs both in mice and xenograft tumours. 
 
o PGC1 avoids metastasis initiation decreasing cell transwell migration and invasion, 3D 
invasion and invasive growth. 
 
o Cell area and adhesion are increased upon PGC1 expression, leading to crucial changes 
in migratory capacities of these cells. 
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IV Mechanism of action of PGC1α in PCa 
 
We have confirmed in vivo that the lack of PGC1 leads to metastatic signs (Fig R32) and 
that its reconstitution in PCa human cell lines confers tumour and metastasis suppressor capacity, and 
inhibits cell migration and invasion. Next, we asked how and which mechanisms are induced by PGC1 
in order to inhibit tumour progression and dissemination. As previously mentioned, PGC1 is a 
metabolic transcriptional co-factor that plays a critical role in coordinating several metabolic pathways, 
such as glucose, lipid and energy homeostasis, as well as regulating mitochondrial biogenesis173-175. 
According to this, we next aimed to study the transcriptional and metabolic programs regulated by 
PGC1 in our three prostate cancer (PCa) models: cell lines, xenograft tumours and mice. 
IV.1 PGC1-elicited metabolic modulation in PCa 
 
PGC1 is a member of the peroxisome proliferator-activated receptor (PPAR)  Coactivator-1 
(PGC1) family. As previously mentioned, these are multifunctional transcriptional co-regulators that act 
as “molecular switches” in many metabolic pathways.  Their versatile functions are achieved by 
interacting with the corresponding transcriptional factors. Among its functions, PGC1 increases 
mitochondrial biogenesis and metabolism, oxidative phosphorylation, fatty acid oxidation (FAO) and is 
implicated in ROS detoxification82,176. Aiming at studying the metabolic function of PGC1 in prostate 
cancer and its implication in the tumour suppressive activity of PGC1, we applied different metabolic 
and biochemical assays (Figure R33). 
 
Figure R 33. Study of the metabolic functions of PGC1 in PCa. The metabolic phenotype induced by PGC1 
will be studied through metabolomics and biochemical assays. 
Mitochondrial metabolism
OxPHOS
Fatty acid oxidation
METABOLIC PHENOTYPE
Sea Horse /ATP production
FAO assay
Metabolomics
ROS detoxification ROS production evaluation
HYPOTHESIS 
PGC1 transcriptional and/or metabolic programs are involved in its tumour and metastasis 
suppressor activity 
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Through the use of unlabelled and stable isotope labelling (metabolic fluxes) metabolomics, 
quantitative knowledge of metabolic rates over a metabolic network gives insights into the regulation of 
metabolism177. In this thesis work, two different metabolomics strategies were carried out in order to 
study the metabolic routes activated in Pgc1-expressing cells (Fig R34). In the first one, 13C-labelled 
glucose (13C-U6-Glucose) tracing and unlabelled metabolomics experiments were performed, while in 
the second one, 13C-labelled glutamine (13C-U6-Glutamine) was traced. Time settings for the metabolic 
fluxes were established according to the differential uptake of nutrients by the cells. Moreover, frozen 
xenograft and GEMMs tissue samples were analysed using the first strategy platform. 
 
 
 
 
 
Figure R 34. Metabolomics strategies in PCa cell lines, xenograft and GEMMs samples. A, Glucose 13C 
labelling metabolomics and untargeted metabolomics from intracellular extracts (PC3 PGC1A and DU145 
PGC1A). In this same strategy, frozen xenograft and prostate lobes from Pten KO and DKO were analyzed by 
LC/MS. B, Glutamine 13C labelling time course at 30 minutes, 1, 2, 4 and 6 hours. In this case, intra and 
extracellular extraction was carried out. 
 
IV.1.1 Glycolysis and mitochondrial metabolism analysis 
 
Most of the glucose consumed by the cells is normally catabolized through glycolysis to 
pyruvate, which is transported to the mitochondria. In the mitochondria of aerobic cells, pyruvate is 
converted into acetyl-CoA and fuels the tricarboxylic acid (TCA) cycle. Through consequent reactions 
that occur in the TCA cycle, reductive intermediates are released, which will then fuel as well the 
electron transport chain (ETC), where oxidative phosphorylation (OXPHOS) takes place. This coupling 
between glucose catabolism and oxidative phosphorylation has a high-energy yield in the form of ATP. 
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In addition, glutamine can be hydrolysed to glutamate by glutaminases (GLS and GLS2). This 
glutamate is converted into -ketoglutarate (-KG) by glutamate dehydrogenase (GDH) or 
transaminases. -KG can then be metabolized in the TCA cycle98 (Fig R35). 
 
Figure R 35. Scheme of the TCA cycle 
and entrance of glucose and glutamine 
into it. The entrance of glucose is labelled 
in green and the glutamine one in purple. 
OAA: oxaloacetate, α KG, α-
Ketoglutarate, FADH2: Flavin adenine 
dinucleotide, NADH: Nicotinamide 
adenine dinucleotide, TCA: TriCarboxylic 
Acid cycle. 
 
The unlabelled metabolomics 
analysis in two PCa cell lines revealed 
an increase pool of TCA 
intermediates (Fig R36), which could 
reflect changes in this metabolic 
pathway. Because of this, we 
analysed TCA cycle activity checking 
13C-labelled intermediates of it in 
Pgc1α-expressing PCa cell lines, 
PC3 and DU145. In both cases, an increase in the m+2 carbon of the TCA cycle intermediates (citrate, 
succinate, fumarate and malate) in Pgc1-expressing cells was observed in comparison with non-
expressing ones. This labelling reflects the synthesis of acetyl-CoA (which is a two-carbon molecule) 
from glucose and its entrance into the TCA cycle (Fig R37).  
 
Figure R 36. TCA intermediates total pools from unlabelled metabolomics. Effect of Pgc1α expression on 
abundance of TCA cycle intermediates in PC3 and DU145 cells measured by LCMS (n=4, independent 
experiments). Statistical test: two-tailed Student´s t-test, p:p-value, *p<0.05; **p < 0.01. OAA: oxaloacetate. a.u.= 
arbitrary units. 
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Figure R 37. TCA cycle intermediates ‘study in PC3 and DU145 cell lines. Analysis of 13C-Glucose tracing in 
TCA cycle intermediates in Pgc1𝛂-expressing PC3 and DU145 cell lines (n=4, independent experiments in both 
cell lines). TCA=TriCarboxylicAcid. Data is shown in % of metabolite labelled from the total pool. Dox: Pgc1α 
induced conditions. 
 
We wanted to further confirm these results with the 13C-labelled glutamine time course 
metabolic fluxes performed in PC3 cell line. We could not only confirm the increase in the 13C-labelling 
of TCA intermediates in Pgc1-expressing cells, but also observed faster cycling of carbons through 
the TCA cycle. The appearance of m+3 and m+2 labelling shows the increase in the speed rate. The 
more the cells complete cycles, the more labelled carbons are released. Moreover, we could also 
observe that in culture, PC3 cell line uptakes more glutamine than glucose, as the percentage of 
intracellular labelled glucose is much lower than the glutamine one (Fig R38).  
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Figure R 38. 13C-Glutamine time course reveals an increased TCA cycle speed in Pgc1𝛂-expressing cells. 
Effect of Pgc1𝛂 expression in PC3 cell line in the intermediates of the TCA cycle. The entrance of Glutamine is 
labelled in purple. The speed of the reactions is represented by cycles in the center of the figure. 
TCA=TriCarboxylicAcid. Data is shown in % of metabolite labelled from the total pool. Dox: Pgc1α induced 
conditions. 
 
Once observed that PGC1 was further activating the TCA cycle in PCa cell lines, we wanted 
to confirm whether the increase oxidation of glucose and glutamine through the TCA cycle was actually 
coupled with an increased activity of the electron transport chain (ETC), and therefore mitochondrial 
respiration. In order to ascertain so, we performed Seahorse experiments to calculate the oxygen 
consumption rate (OCR) in Pgc1-expressing PCa cells under the addition of different metabolic drugs 
that allowed us to calculate the basal and maximal respiration, and the rate of ATP production from 
oxygen (Fig R39). The initial values from the Seahorse experiments give us the basal respiration. 
Oligomycin is an inhibitor of the complex V of the ETC, which synthesises ATP from ADP. Therefore, 
its use will give us information about the rate of OCR that is used to produce ATP. The FCCP is a 
potent mitochondrial oxidative phosphorylation uncoupler that disrupts ATP synthesis by transporting 
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protons across mitochondrial inner membranes, depolarizing the mitochondrial membrane potential. 
After its addition, the maximal respiration is calculated. The rotenone inhibits the transfer of electrons 
from iron sulfur centers in complex I to ubiquinone and antimycin inhibits the electron transport between 
cytochromes b and c. With these two inhibitors, the mitochondrial function is blocked, and the remaining 
use of oxygen is non-mitochondrial. These OCR values are extracted from the other values to obtain 
mitochondrial-specific information (Fig R39). 
 
 
Figure R 39. Sea horse experiment scheme. The basal (1) and maximal respiration (3), and the ATP production 
from OCR (2) can be calculated from the graph values. Number 4 in the graph shows the non-mitochondrial oxygen 
consumption rate, which is deleted from all the values to obtain mitochondrial-specific data. 
 
According to the Seahorse analysis, Pgc1 expression led to a significant increase in basal 
and maximal respiration. Furthermore, the production of ATP from OCR was also increase in those 
cells (Fig R40A). In order to verify that the doxycycline treatment itself was not affecting the assay, the 
experiment was performed in parallel with parental PC3 (non-transfected cells) (Fig R40B). Moreover, 
the increase in basal respiration was confirmed in DU145 PCa cell line (Fig R40C). Regarding these 
results, Pgc1 expression is not only fuelling the TCA cycle, but also increasing mitochondrial 
respiration. 
 
Pyruvate fuels the TCA cycle through acetyl-CoA, but also it can be converted into lactate. In 
fact, in 1956 Otto Warburg first reported the conversion of glucose into lactate (which is secreted to the 
media) by cancer cells. This catabolic reaction has an extremely low energy yield and, consequently, 
cells require a high glucose consumption rate to satisfy their energy and anabolic demands. Because 
of this, the glucose fermentation is the most ubiquitous metabolic phenotype seen across cancer cells85. 
According to this and in line with our previous results, we wanted to analyse the extracellular 
acidification rate (ECAR) and lactate production, as cells with a glycolytic phenotype exhibit higher rates 
of proton and lactate production.  
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Figure R 40. Mitochondrial respiration is increased in Pgc1𝛂-expressing cells. A, Seahorse scheme of 
Pgc1𝛂-expressing PC3 cell line. From that graph, the basal (1) and maximal respiration (3), and the ATP production 
from OCR were obtained (2) Number 4 in the graph shows the non-mitochondrial oxygen consumption rate (B) 
(n=4). C, Effect of Pgc1𝛂 expression in production of ATP from oxygen in the mitochondria in DU145 cell line (n=3). 
D, Effect of doxycycline addition (0.5 𝝁g mL-1) in PC3 cell line without TRIPZ-HA-Pgc1a vector (non-transfected) 
(n=3). Statistical analysis: one-tailed Student´s t-test. p, p-value. *p<0.05, **p<0.001. Error bars indicate s.e.m. 
pmoles= picomoles; min=minute; 𝝁g=microgram. OCR= Oxygen Consumption Rate. 
 
The concentration of the extracellular lactate was measured, and we could confirm in PC3 cell 
line that Pgc1 expression led to a decrease in lactate production. We observed as well a tendency to 
decrease in DU145 cell line, but it was not significant (Fig R41A). Once again, we confirmed that the 
use of doxycycline was not affecting the experiment outcomes (Fig R41B). Furthermore, Pgc1-
expressing cells presented a decrease in the ECAR, which is in line with an increase in the OCR, as it 
can be seen in figure R41C.  
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Figure R 41. Acidification and lactate production increased in PCa cell lines. A, OCR/ECAR ratio from Sea 
Horse analysis (n=4). B, Determination of lactate production in Pgc1𝛂-expressing PC3 and DU145 cell lines (n=3). 
C, Effect in lactate production of doxycycline addition (0.5 𝝁g mL-1) in PC3 cell line without TRIPZ-HA-Pgc1α vector 
(non-transfected) (n=3). Statistical analysis: one-sample t-test with a hypothetical value of 1 (B, C). p, p-value. 
*p<0.05, **p<0.001. The dotted line represents No Dox conditions. Error bars indicate s.e.m. a.u= arbitrary units.  
 
Altogether, our results show that PGC1 increases oxidative phosphorylation through the 
activation of the TCA cycle (Fig R37-38-40). Moreover, this is in line with a decrease glycolytic rate by 
means of a decrease in the ECAR and in the lactate production (Fig R41). These results reflect that 
PGC1 induces a reverse-Warburg effect metabolic phenotype in PCa, which to some extent could be 
related with the tumour suppressor activity of PGC1. 
We next aim to confirm the implication of PGC1 in ATP production in our different study 
systems. We measure the ATP signal in PC3 and DU145 PCa cell lines (Fig R42A). In both cases, we 
could see an increase in the signal after Pgc1- expression, which reflects a higher ATP production. 
Moreover, taking advantage of the metabolomics performed in xenograft and GEMMs samples (Fig 
R34), we could confirm changes in the ATP abundance associated with the expression of PGC1 (Fig 
R42B-C). Strikingly, Pgc1 positive derived xenografts showed an increase of ATP abundance, while 
its abundance in DKO mice (Pten pc-/- Pgc1a pc-/-) showed a clear tendency to decrease. Regarding 
these results, and using our three PCa systems (cell lines, xenograft and GEMM tissue extracts), we 
can conclude that PGC1 increases ATP abundance, which is in agreement with the previous results 
that reflect an activation of mitochondrial metabolism and reduced glycolytic activity. 
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Figure R 42. Pgc1𝛂 expression leads to an increase in ATP production. A, Effect of PGC1𝛂 expression in 
ATP production in PC3 and DU145 cell lines (n=20 for No Dox and n=10 for Dox conditions, independent 
experiments). B and C, ATP abundance data from LC/HRMS analysis in xenograft (No Dox n=8 tumors; Dox=4 
tumors) and Pten KO (n=3) and DKO (n=5) mice. Dox: Pgc1α induced conditions. Error bars represent s.e.m (A) 
and median with interquartile range (B and C). Dox: Pgc1α induced conditions. pc= prostate specific. Pten KO= 
Pten pc-/- Pgc1a pc+/+ and DKO= Pten pc-/- Pgc1a pc-/-. Statistical analysis: one-tailed Student t-test (A) and one-tail 
Mann-Whitney U-test. p, p-value. *p < 0.05. a.u= arbitrary units.  
 
IV.1.2 ROS balance 
 
PGC1α controls many aspects of oxidative metabolism, including mitochondrial biogenesis and 
respiration. It is known that it has the ability to induce a reactive oxygen species (ROS) scavenging 
programme178. At the same time that it regulates the expression of antioxidant genes, PGC1α also 
enhances mitochondrial metabolism, which can lead to the production of ROS179. It has been previously 
observed that oxidative stress plays a role in metastatic potential in breast cancer and 
melanoma114,128,129. Therefore, we tested whether ROS production was altered in our experimental 
settings, and if it was contributing to the PGC1α phenotype. We analysed mitochondrial ROS using 
MitoSOX dye, which measures the superoxide production in the mitochondrial matrix, and DCF, which 
enables the measurement of hydrogen peroxide (H2O2) in cells. Pgc1α expression PC3 cell line led to 
an increase in mitochondrial ROS (MitoSOX), which could be due to the increase in oxidative 
phosphorylation. However, this increase was not consistent in DU145 PCa cell line. In addition, no 
significant changes were observed in cytosolic ROS (DCF) (Fig R43A). In order to ascertain if the 
increase in mitochondrial ROS was responsible of the decrease in proliferacion, we treated PC3 Pgc1α-
expressing cells with antioxidants, NAC and MnTBAP. The results showed that neither NAC nor 
MnTBAP were able to rescue the antiproliferative effect elicited by Pgc1α in PC3 cells (Fig R43B). 
Therefore, ROS is not mediating the proliferation arrest induced by PGC1α in in vitro. 
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Figure R 43. PGC1 balances ROS production in PC3 cell line. A, Evaluation of cellular (DCF) and 
mitochondrial specific (Mitosox) ROS production in Pgc1-expressing PC3 (n=4 independent experiments). B, 
Effect of the indicated antioxidant treatments on cell number (relative to day 0) of Pgc1-expressing PC3 (n=3 
independent experiments). Error bars represent s.e.m. Statistics test: two tailed Student t-test. * p< 0.05. p=p-
value. a.u. =arbitrary units. NAC=N-acetyl cysteine; MnTBAP= Manganese (III) tetrakis (4-benzoic acid)porphyrin 
chloride. 
 
IV.1.3 Lipid metabolism 
 
We performed the study of lipid metabolism and fatty acid oxidation (FAO) in our PCa 
systems, due to the implication of PGC1 in it 82,180. We analysed FAO in Pgc1-expressing PC3 and 
DU145 cells. We observed a significant increase in in PC3 cells, and a tendency to increase in DU145 
cells, whereas doxycycline treatment of non-transduced cells did not impact on this parameter (Fig 
R44A). During the process of β-oxidation within the mitochondria, fatty acids undergo oxidative removal 
of successive two-carbon units in the form of acetyl-CoA and release lipid intermediates (acyl-
carnitines)105 According to this, we analysed the abundance of these intermediates in the metabolomics 
data. PC3 and DU145 presented a higher abundance of different acyl-carnitines in response to Pgc1 
expression (Fig R44B-C). Furthermore, we could also provide evidence about acyl-carnitine 
abundance in xenografts and GEMMs. In Pgc1-positive derived xenografts lynoleyl carnitine 
abundance was significantly higher, and decenoyl and alpha-linolenyl carnitines had a tendency to 
increase. Although no statistical significant results were obtained in GEMM samples metabolomics, the 
carnitine abundance of DKO mice (Pten pc-/- Pgc1a pc-/-) reflected a tendency to decrease (Fig R44 D-
E). 
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Figure R 44. Effect of Pgc1𝛂 expression in lipid metabolism. A, Evaluation of the dehydrogenation of tritiated 
palmitate (readout of fatty acid -oxidation) in Pgc1𝛂-expressing PC3 (n=6) and DU145 (n=3) cells, and effect of 
doxycycline addition (0.5 𝝁g mL-1) in PC3 cell line without TRIPZ-HA-Pgc1a vector (non-transfected) (n=3). B-C, 
Untargeted LC/HRMS analysis of differential abundance in metabolites involved in fatty acid catabolism in Pgc1𝛂 
expressing PC3 (B) and DU145 (C) cells. Abundance of carnitines in xenograft tumours (No Dox n=8; Dox n=4) 
(D) and Pten KO (n=3) and DKO mice (n=5) (E). No Dox: Pgc1a-non inducing conditions, Dox: Pgc1α induced 
conditions. pc= prostate specific. Pten KO= Pten pc-/- Pgc1a pc+/+ and DKO= Pten pc-/- Pgc1a pc-/-.  No Dox: Pgc1a-
non inducing conditions, Dox: Pgc1a inducing conditions. Statistical analysis: one sample t-test with hypothetical 
value of 1 (A) two-tailed Student t-test (B and C) and one-tail Mann-Whitney U-test (D-E).Error bars indicate 
s.e.m.(A,B and C) or interquartile range (D and E) p, p-value. *p < 0.05, **p < 0.01. a.u= arbitrary units. 
 
As previously mentioned, cells must build biomass activating anabolic pathways to continue 
proliferating98. According to this, we went deeper into the lipid metabolism study and took advantage of 
the 13C-labelled glucose metabolomics. Glucose is converted into pyruvate, which contributes to the 
synthesis of acetyl-CoA. This metabolite is a precursor of fatty acid, lipid and cholesterol synthesis 98. 
We monitored the incorporation of carbons from 13C-labelled glucose into fatty acids (Fig R45). 
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Interestingly, we found a significant decrease in 13C incorporation intro palmitate when Pgc1 was 
expressed. Altogether, this data shows the role of PGC1α in FAO and a decrease in the novo lipid 
synthesis pathway. 
 
 
 
Figure R 45. PGC1α expression reduced de novo lipid synthesis in PCa. Effect of Pgc1𝛂 expression on 
palmitate paired mass isotopomer abundance after 13C-glucose labelling in PC3 cells (n=3, independent 
experiments).Statistical analysis: two-tailed Student t-test. p, p-value. *p < 0.05, **p < 0.01. a.u= arbitrary units. No 
Dox: Pgc1a-non inducing conditions, Dox: Pgc1a inducing conditions. 
 
As reported before, Pgc1 expression is accompanied by a global metabolic rewiring, which 
has been demonstrated by an increased oxidation of glucose in the mitochondria (TCA cycle activation), 
elevated oxygen consumption and ATP production, and FAO. Moreover, we could observe that this 
over-activation of mitochondrial oxidative processes was in concordance with decreased anabolic 
routes (decreased lactate production and de novo lipid synthesis). Nevertheless, although this 
metabolic switch is mediated by PGC1, we have not determined yet if it is associated with its tumour 
suppressive activity. 
 
IV.1.4 Effect of PGC1 in asparagine synthesis 
 
Taking a deeper look at the results obtained in the 13C-labelled glutamine time course, we found 
that Pgc1-expressing PC3 cells produced a higher amount of asparagine from glutamine than non-
expressing ones, showing an increase in m+4 labelled carbons and a higher production rate. This 
asparagine was produced through glutamine conversion to glutamate, which is converted as well to α-
ketoglutarate (KG) by glutamate dehydrogenase (GDH) or transaminases. Then, KG is metabolized 
in the TCA cycle to succinate, fumarate, malate and oxaloacetate (OAA). This last one is converted 
into aspartate through OAA transaminases. The aspartate is then used to synthetize asparagine 
through the asparagine synthetase (ASNS) (Fig R46). In addition, we looked at ASNS gene and protein 
expression by RT-qPCR and western blot analysis respectively. Surprisingly, the increase in 
asparagine synthesis observed in the metabolomics experiment, was accompanied by an increase 
ASNS gene and protein expression after Pgc1 expression in PC3 PCa cell line. As far as we are 
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concern, this is the first evidence that shows that Pgc1 can trigger asparagine synthesis in PCa (Fig 
R47 A-B).  
 
  
Figure R 46. Pgc1𝛂 expression increases asparagine synthesis in PC3 cells. Time course of 13C-labelled 
glutamine metabolomics in Pgc1𝛂 expressing PC3 cells. Data is shown in % of metabolite labelled from the total 
pool. Asparagine m+4 levels are shown in arbitrary units (a.u).  
 
Figure R 47. PGC1 induces ASNS gene and protein expression in PC3 cell line. A and B, Analysis by q-RT-
PCR (n=3) and by wester blotting respectively of ASNS expression (one experiment shown out of 2) in Pgc1𝛂 
expressing PC3 cells. Dox: Pgc1α induced conditions. Gene expression normalization was performed with 
GAPDH. Statistical analysis: one sample t-test with hypothetical value of 1 (A). p, p-value. *p < 0.05. a.u= arbitrary 
units.  
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IV.1.5 Targeting the metabolic rewiring elicited by PGC1  
 
To ascertain if the tumour suppressive activity of PGC1 is associated with the metabolic 
rewiring led by it, we targeted metabolic pathways induced by PGC1: FAO and mitochondrial 
metabolism/oxidative phosphorylation. On the one hand, we used etomoxir (ETO), a known FAO 
inhibitor181. On the other hand, we inhibited the mitochondrial pyruvate carrier (MPC), and therefore the 
pyruvate entrance in the mitochondria, using UK5099182 (Fig R48).  
 
 
Figure R 48. Targeting the metabolic rewiring elicited by 
PGC1α. Scheme of pathways inhibited with UK5099 
(Pyruvate entrance into the mitochondria) and etomoxir 
(ETO), which inhibits the fatty acid oxidation (FAO). 
 
The results showed that ETO treatment in PC3 
Pgc1-expressing cells, led to a minimal but statistically 
significant increase in proliferation at day 4 when 
compared with not-treated Pgc1-expressing cells (Fig 
R49A). UK (UK5099) treatment did not have a 
significant effect in Pgc1-expressing cells at day 4, and 
led to a significant decrease in proliferation at day 6 (Fig 
R49B). Thus, FAO could have a role in the PGC1-
dependent decrease in proliferation in PC3. Next, trying 
to distinguish between proliferation and metastasis 
initiation, we investigated the effect of both inhibitors on cell migration (Fig R49C). FAO inhibition did 
not rescue the anti-migratory capacity of Pgc1. Surprisingly, the inhibition of MPC with UK5099 led to 
a significant rescue of cell migration. Of note, the results obtained in the proliferation assay differ from 
those observed when migration was analysed. This may reflect the specificity of action of PGC1-
induced metabolic rewiring. In fact, different metabolic programs are necessary for tumour proliferation 
and dissemination 183,184.  
In this case, the entrance of pyruvate into the mitochondria could be important for the reduction 
in migration, but not cell proliferation of PC3 Pgc1-expressing cells. However, the specificity of the 
inhibitors must be taken into account. Although the effectiveness of ETO was analysed in all FAO 
assays performed in this thesis, the UK5099 inhibitory activity, and therefore the blocking of pyruvate 
entrance into the mitochondria, was not confirmed in parallel to the experiments performed. 
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Figure R 49. Inhibitors of PGC1 metabolic function. A and B, Effect of ETO (25 𝝁M) and UK5099 (25 𝝁M) 
treatment in PC3 PGC1 cell line on proliferation at days 4 and 6 respectively. C, Migration analysis in PC3 PGC1 
cell line after ETO and UK treatment. Statistical analysis: one-tailed Student t-test. Asterisks indicate statistical 
difference between No Dox and Dox conditions and dollar symbols between Dox conditions. Dox: Pgc1α induced 
conditions. p, p-value. *p < 0.05, **p < 0.01, ***p < 0.001, *$ < 0.05. OAA: oxaloacetate; TCA: Tricarboxylic Acid 
Cycle. OAA: oxaloacetate, α KG, α-Ketoglutarate 
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METABOLIC PART: SUMMARY AND CONCLUSIONS 
 
o PGC1 expression is accompanied by a global metabolic rewiring in PCa (Figure R50). 
 
o Integrative metabolomics and biochemical assays reflected an increase of oxidative 
processes such as FAO and TCA cycle activation, which were confirmed by an elevated 
OCR and ATP levels. 
 
o The over-activation of mitochondrial oxidative processes led to a decrease in anabolic 
routes, such as de novo lipid synthesis. Moreover, a reverse Warburg effect (aerobic 
glycolysis) was observed. 
 
 
o The entrance of pyruvate into the mitochondria could play a role in the migration capacities 
of PCa cells. 
 
o PGC1 expression led to increased asparagine synthesis from glutamine, which could play 
a role in its tumour suppressive activity, or act as a release for the carbon overflow. 
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Figure R 50. Schematic representation of the main findings of the metabolic study. Cit: citrate, OAA: 
oxaloacetate; FA: Fatty Acid; ETC: Electron Transport Chain; TCA: Tricarboxylic Acid Cycle; Asn: Asparagine. 
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METABOLIC PART: EXPERIMENTAL IMPROVEMENTS  
AND FUTURE PERSPECTIVES 
 
o The inhibition of the FAO and the MPC did not have a clear effect in proliferation and 
migration in PC3 PCa cell line, other metabolic routes could be targeted in Pgc1-
expressing cells. 
 
o The role of asparagine synthesis in Pgc1-expressing cells must be identified in order to 
ascertain if it plays a role in its tumour suppressive or it’s a side effect of Pgc1 metabolic 
function. 
 
o Further experiments should be carried out to understand whether PGC1- induced 
metabolic rewiring is linked to its tumour and metastasis suppressive activity. 
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IV.2 Transcriptional modulation by PGC1 in PCa 
 
PGC1 regulates gene expression through the interaction with diverse transcription factors 
(TFs)173. In order to obtain an overview of the genes and the transcriptional programs altered upon 
Pgc1 expression, we performed a gene expression profiling from Pgc1-expressing versus non-
expressing PC3 cells. We identified 174 probes with significantly altered signal.  
 
Figure R 51. PGC1α gene expression 
array. KEGG (Kyoto Encyclopaedia of 
Genes and Genomes) analysis of the 
transcriptional program regulated by 
PGC1α. The dotted line indicates p=0.05. 
p, p-value. 
 
As predicted, the Kyoto 
Encyclopaedia of Genes and 
Genomes (KEGG) analysis showed 
that most of the genes altered in the 
array were related to metabolic 
pathways, such as mitochondrial 
catabolic programs and energy-
producing processes174,185 (Fig. R51).  
 
 
 
 
The expression of several genes implicated in PGC1 transcriptional program was validated 
by RT-qPCR in different PCa cell lines with inducible expression of Pgc1 (PC3, DU145 and LnCaP) 
(Fig R52A-C). We validated genes involved in fatty acid metabolism (ACADM, ACSL4 and ACAT1), 
mediating the entrance of pyruvate into the mitochondria and production of ATP (MPC1, MPC2, IDH3A, 
FH, SDHA, SUCLA2, CLYBL, GOT1, ISCU and ETFDH), implicated in ROS scavenging (GSTM4, NNT 
and SOD2) and implicated in autophagy (TP53INP2) and in maintaining the electrochemical gradients 
of Na+ and K+ ions. As performed in previous experiments, we confirmed that doxycycline treatment did 
not interfere with the experimental outcome (Fig R52D). Moreover, we confirmed the modulation of the 
PGC1-target genes in xenografts samples and GEMMs (Ptenpc-/-, Pgc1apc-/-). In xenograft samples, 
we validated the up-regulation of LAMB2 (Laminin subunit beta 2), an extracellular matrix glycoprotein, 
and ACACB (Acetyl-Coenzyme A Carboxylase Beta), enzyme which catalyses the carboxylation of 
acetyl-CoA to malonyl-CoA (Fig R53). 
 
 
- Log2 (adj p-value)
0 10 20 30 40
Metabolic pathways
Citrate cycle (TCA cycle)
Parkinson's disease
Oxidative phosphorylation
Alzheimer's disease
Huntington's disease
Pyruvate metabolism
Cardiac muscle contraction
Propanoate metabolism
Glyoxylate and dicarboxylate metabolism
Valine, leucine and isoleucine degradation
Glycolysis / Gluconeogenesis
Drug metabolism - cytochrome P450
Metabolism of xenobiotics by cytochrome…
Fatty acid metabolism
Glutathione metabolism
Results IV 
  164 
R
E
S
U
L
T
S
 I
V
 
 
 
Figure R 52. Validation of PGC1 microarray in PCa cell lines. (A, B and C) Validation of the microarray by q-
RT PCR in PC3 (ACADM, IDH3A, SDHA, ISCU and ATP1B1 n=4; ACSL4,ACAT1,MPC1, 
MPC2,SUCLA2,CLYBL,GOT1,ETFDH,GSTM4,NNT, SOD2, ATP1B1, TP53INP2 n=3), DU145 (IDH3 and FH n=4; 
GOT1,ATP1B1,CLYBL, MPC1, ATP5C1 and TP53INP2 n=3) and LnCaP (ATP1B1 n=4; GOT1 and IDH3 n=3) 
Pgc1a cell lines; independent experiments shown. D, Effect of doxycycline treatment (0.5 µg mL-1) in the 
expression of genes altered in the microarray in PC3 non-transfected cells. Data normalized to No Dox condition, 
represented by a black dotted line. Dox: Pgc1α induced conditions (A, B and C). Error bars represent s.e.m. 
Statistical analysis: one-sample t test with hypothetical value of 1. p, p-value. *p < 0.05, **p < 0.01, ***p < 0.001.  
DU145 LnCaPB C
F
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 N
o
 D
o
x
F
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 N
o
 D
o
x
G
O
T1
AT
P
1B
1
ID
H
3
FH
C
LY
B
L
M
P
C
1
AT
P
5C
1
TP
53
IN
P
2
0
5
10
15
G
O
T1
AT
P
1B
1
ID
H
3
0
1
2
3
4
5
*
P
=
0
.0
7
P
=
0
.0
8
*
**
* *
*
P
=
0
.0
6
P
=
0
.0
8
P
=
0
.0
6
FA met TCA; TCA-related ETC ROS scavenger OthersPyr met
F
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 N
o
 D
o
x
PC3 DoxA
**
*
*
*
*
*
**
*
*
**
*
*
*
A
C
A
D
M
A
C
S
L4
A
C
AT
1
M
P
C
2
M
P
C
1
ID
H
3A
S
D
H
A
S
U
C
LA
2
C
LY
B
L
G
O
T1
IS
C
U
E
TF
D
H
G
S
TM
4
N
N
T
S
O
D
2
AT
P
1B
1
TP
53
IN
P
2
0
5
10
15
20
P
=
0
.0
9
5
*
P
=
0
.0
5
F
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 N
o
 D
o
x
P
G
C
1A
ID
H
3A
IS
C
U
SD
H
A
0.0
0.5
1.0
1.5
2.0
Dox
n.s
n.s n.s
n.s
D
Results IV 
 
 165 
R
E
S
U
L
T
S
 I
V
 
 
 
Figure R 53. Microarray validation in xenograft tumours and mice. (A and B) Validation of the array in 
xenograft especimens (No Dox=11 tumours, Dox=6 tumours) and in mice (n=7 in both genotypes) respectively 
(Pten KO= Pten pc-/-; Pgc1a pc+/+ and DKO=Pten pc-/-; Pgc1a pc-/-). No Dox: Pgc1α non-expressing conditions; Dox: 
Pgc1α induced conditions. Error bars represent minimum and maximum values. Statistical analysis: one-tailed 
Mann Whitney U test (D and E). p, p-value. *p < 0.05, **p < 0.01, ***p < 0.001. 
 
IV.2.1 Proteomic validation of transcriptional outcome 
 
In order to validate and further confirm the results obtained in the gene expression profiling, 
we performed labelled-free proteomic analysis. The proteins significantly altered in Pgc1 expressing 
versus non-expressing cells are shown in Annex Table 2. As predicted, there was an enrichment of 
proteins involved in mitochondrial biogenesis, TCA cycle and the ETC (e.g.: ODO2, FUMH, ATPB, 
MDHC). Moreover, there was an increase of proteins involve in ROS balance and detoxification 
(GSTK1, DLDH, PRDX2, SAHH2 and AJKA12) in Pgc1 expressing cells. Therefore, this data confirms 
the canonical functions of PGC1 and validates the results previously obtained in the metabolomics 
and transcriptomic analysis. 
 
IV.2.2 Promoter enrichment analysis 
 
PGC1 is a transcriptional co-factor, we next aimed to identify the transcription factor that 
mediated the activity of PGC1, and hence we performed a promoter enrichment analysis. The results 
showed a predominant abundance in genes regulated by the Estrogen-related receptor  (ERR). We 
corroborated these results with Gene Set Enrichment Analysis (GSEA; normalized enrichment 
score=2.02; nominal P value=0.0109) (Fig R54A). ERR is a nuclear receptor that plays an essential 
role in both tumour biology and energy metabolism140. The effects of ERR and PGC1 in mitochondrial 
biogenesis and metabolic pathways involved in maintaining cellular energy homeostasis have been 
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widely studied186,187 (Fig R54B). In fact, we have shown and confirmed that PGC1 is capable of 
regulating functions attributed to ERR, such as mitochondrial oxidative metabolism (Results IV.1).  
 
Figure R 54.Promoter enrichment analysis revealed ERR as the main TF regulating PGC1 transcriptional 
program.  A, Promoter enrichment analysis of the PGC1α transcriptional program. The red dotted line indicates 
p=0.05. B, Schematic representation of ERRα promoter site. The binding of its co-factor (in this case PGC1α) 
leads to the activation of a transcriptional program implicated in mitochondrial biogenesis and oxidative 
metabolism.  
 
In order to ascertain to which extent the growth inhibitory and anti-metastatic activity of 
PGC1 required its ability to interact with ERR, we developed three different approaches: the use of 
a PGC1α mutant that does not allow it binding with TFs, the use of XCT790 (inverse agonist of ERRα) 
and the silencing of ERR in Pgc1-expressing PCa cell lines. 
 
IV.2.2.1 PGC1 mutant in its LXXL region 
 
First, we approached the inhibition of PGC1-mediated transcriptional program taking 
advantage of a mutant variant of it. This mutant, named PGC1L2L3M, is unable to interact with ERR 
and other transcription factors188. PGC1 presents three LXXLL motifs. From these, only L2 and L3 
appear to interact with nuclear receptors (NR). In fact, it has been shown that these two regions are 
essential for ERR transcriptional activity (Fig R55A). We first cloned the PGC1L2L3M mutant in the 
lentiviral inducible vector TRIPZ and generated a stable PC3 cell line. We confirmed the correct 
expression of the mutant (comparable to wild type (WT)) and the impairment of its transcriptional 
regulatory activity. Thus, gene expression analysis showed that PGC1L2L3M was defective on its 
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transcriptional activity as the expression of several PGC1-ERR target genes was unaffected 
compared to Pgc1-expressing wild-type conditions (PGC1WT) (Fig R55 B-C).Next, we studied the 
effect of PGC1L2L3M in 2D growth (Fig R55D). Interestingly, we observed a significant increase in 
proliferation at days 4 and 6 in the mutant.  
 
 
Figure R 55. PGC1 mutant reverts its effect in gene expression and proliferation. A, Scheme of PGC1α 
mutations. The modifications in lysine residues prevent PGC1α to any transcriptional factor. B, Protein expression 
of PGC1α in PC3 Pgc1αwt and PC3 Pgc1αL2L3M cells. One representative experiment out of 3 is shown. C, Gene 
expression analysis of ERRα target genes in PC3 Pgc1αwt and PC3 Pgc1α L2L3M cell lines (IDH3A n=8; ATP1B1 
n=4; ACAT1, ISCU, GOT1 and ACADM n=3). D, Proliferation effect in PC3 Pgc1αwt and PC3 Pgc1αL2L3M cell lines. 
Dox=Pgc1αwt or PC3 Pgc1αL2L3M expressing conditions. Error bars represent s.e.m. Statistical analysis: One 
sample t-test when comparing fold changes, one-tailed Student t-test when comparing Dox conditions. Asterisks 
indicate statistical difference between No Dox and Dox conditions and dollar symbols between WT and mutant 
(L2L3M) conditions. The dotted line represents No Dox conditions. WD= wild type. p, p-value. *p < 0.05, **p < 0.01, 
***p < 0.001, *$ < 0.05, **$ < 0.01, ***$ < 0.001. n.s= non-significant. 
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Moreover, PGC1L2L3M was unable to suppress bone metastasis in nude mice (Fig, R56). All 
these results may highlight the relevance of the transcriptional activity mediated by PGC1 in its tumour 
and metastasis suppressor activity. However, as this mutant is not specific for ERR transcriptional 
factor, we decided to perform a second approach based on using an inverse agonist of it. 
 
 
 
Figure R 56. PGC1L2L3M expression failed to suppress bone metastasis. A, Evaluation of the 
metastatic capacity of PC3 Pgc1αwt (WT-expressing) and PC3 Pgc1αL2L3M (L2L3M-expressing) cells respectively 
using intra-tibial (IT) xenotransplant assays (upper panels). Photon flux quantification WT n=6 mice; L2L3M n=7 
mice, two hind limbs per mouse. Incidence of metastatic lesions presented as histograms (lower panels). 
Representative luciferase images are presented referring to the quantification plots. For photon flux analysis, 
average signal from two limbs per mouse is presented. For incidence analysis, mice with at least one limb yielding 
luciferase signal >50,000 units were considered metastasis-positive. Images (i) and (ii) depict tibia photon flux 
images from specimens that are proximal to the median signal in No Dox and Dox respectively. No Dox=Pgc1αwt 
or Pgc1αL2L3M non induced conditions Dox= Pgc1αwt or Pgc1αL2L3M expressing conditions. Error bars represent 
minimum and maximum values. Statistical test: one-tailed Mann-Whitney U-test (upper panels) and Fisher´s exact 
test (lower panel). *p < 0.05, **p < 0.01, ***p < 0.001. n.s=non-significant. 
 
IV.2.2.2   Inhibition of ERR activity using XCT790 
 
The XCT790 is a thiazole-based inverse agonist compound that inhibits ERR activity and 
that has been previously used to study the role of this transcriptional factor in metabolic signalling 
pathways189. XCT790 binds to ERR, stabilizing it, and thus reducing its activity (Fig R57A). We treated 
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PGC1-expressing and non-expressing PC3 cells with 8 M XCT790 and analysed the expression of 
PGC1 target genes. The results showed that in the presence of XCT790, PGC1 was no longer able 
to upregulate the expression of its target genes (Fig R57B). To analyse if XCT790 could revert the 
proliferative and invasive effect led by PGC1 expression, we performed proliferation (2D growth) and 
transwell migration and invasion assays. XCT790 treatment during 48 hours, led to a recovery in 2D 
growth in comparison with the decrease in proliferation present in Pgc1-expressing PC3 cells at day 
six of experiment (Fig R57C). Moreover, a tendency to rescue the decrease in migration was observed 
(Fig R57D). Interestingly, this effect was pronounced in transwell invasion, in which the treatment with 
XCT790 restore the invasive properties of the cells (Fig R57E). According to these results, the 
transcriptional program activated by PGC1 and ERR leads the tumour suppressor activity. However, 
to validate and confirm these results, we carried out a third and last strategy. 
 
 
Figure R 57. ERR inhibition with XCT790 reverts PGC1 effect in proliferation and transwell migration 
and invasion. A, Scheme of the mode of action of XCT790, the inverse agonist of ERRα,in order to inhibit the 
transcriptional program B, Expression by q-RT PCR of target genes of ERRα (ATP1B1 and IDH3A n=4; ACAT1 
n=3). C, Effect on proliferation of XCT790 (8𝝁M) in PC3 PGC1A cell line at days 4 and 6 (n=3). D and E, Effect of 
ERRα inhibition in transwell migration and invasion respectively (n=3). No Dox: Pgc1α non-expressing conditions; 
Dox: Pgc1α induced conditions. Error bars represent s.e.m. Statistical analysis: One sample t-test when comparing 
fold changes, one-tailed Student t-test when comparing Dox conditions. Asterisks indicate statistical difference 
between No Dox and Dox conditions and dollar symbols between vehicle and XCT790 treatment. The dotted line 
represents No Dox conditions. p, p-value. *p < 0.05, **p < 0.01, ***p < 0.001, *$ < 0.05, **$ < 0.01, ***$ < 0.001. 
n.s=non-significant.  
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IV.2.2.3 Silencing of ERR 
 
To further discriminate between PGC1 functions that depend on ERR or other nuclear 
receptors, we undertook a targeted silencing approach. In order to do so, we transduced Pgc1-
inducible PC3 cells with an ERR-targeting or a scramble short hairpin RNA (shRNA) and confirmed 
the silencing by protein expression analysis (Fig R58). In coherence with the L2L3M mutant and the 
treatment with XCT790 results, ERR silencing blunted the effect of Pgc1 in cell growth (Fig R59A). 
In vivo silencing of ERR in the presence of the ectopically expressed PGC1 resulted in a significant 
increase in bone metastasis incidence from 40% (in Pgc1-expressing cells transduced with scramble 
shRNA) to full penetrance (Fig R59B). In conclusion, ERR is required for the effect led by Pgc1 in 
PCa. Next, we aimed at confirming that ERR was also responsible for the metabolic rewiring observed 
in PGC1-expressing cells. 
 
 
 
Figure R 58. ERR silencing in Pgc1 expressing cells. A, Schematic view of the transcriptional program 
inhibition. B, Protein expression analysis of ERR𝛂 and PGC1𝛂 expression in Pgc1𝛂-expressing PC3 cells 
transducted with Scramble (Scr) shRNA or ERR𝛂 shRNA (sh79 and sh80). One representative experiment out of 
3 shown. 
 
IV.2.2.4 PGC1- ERR transcriptional program inhibition: metabolic profile. 
 
We have previously seen that PGC1 expression in PCa cells leads to a metabolic rewiring 
characterized by an increase in oxidative phosphorylation and ATP production. In addition, the gene 
expression profile performed in Pgc1α-expressing cells revealed the contribution of ERR to the 
activation of a transcriptional program that, according to the results, is implicated in the tumour and 
metastasis inhibition in PCa. Next, we wondered whether the inhibition of the transcriptional program 
activated by PGC1-ERR can impact on the mitochondrial metabolism observed. For the metabolic 
analysis, we followed the same strategies used before (PGC1 mutant, XCT790 treatment and ERR 
silencing).  
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Figure R 59. ERR silencing re-stablish proliferation and metastasis activity in PCa cells. A, Percentage of 
growth by crystal violet in Pgc1𝛂-expressing PC3 cells transducted with Scramble (Scr) shRNA or ERR𝛂 shRNA 
(sh79 and sh80). Evaluation of metastatic capacity of Pgc1𝛂-expressing PC3 cells transducted with Scramble (Scr) 
shRNA or ERR𝛂 shRNA (sh79 and sh80) using intra-tibial (IT) implantation for 14 days (n=8 mice; two injections 
per mouse). Incidence of metastatic lesions presented as histograms (right panel). For photon flux analysis (left 
panel), average signal from two limbs per mouse is presented. For incidence analysis (right panel), mice with at 
least one limb yielding luciferase signal >50,000 units were considered metastasis-positive. No Dox=Pgc1𝛂wt or 
Pgc1𝛂L2L3M non induced conditions Dox= Pgc1𝛂wt or Pgc1𝛂L2L3M expressing conditions. Error bars represent 
minimum and maximum values. Statistical test: one-tailed Mann-Whitney U-test (upper panels) and Fisher´s exact 
test (lower panel). *p < 0.05, **p < 0.01, ***p < 0.001. n.s=non-significant. r symbols between scramble shRNA 
and ERR𝛂 shRNAs.The dotted line represents No Dox conditions. p, p-value. *p < 0.05, **p < 0.01, ***p < 0.001, 
*$ < 0.05, **$ < 0.01, ***$ < 0.001.  
 
First, we analysed the basal respiration in PC3-Pgc1L2L3M mutant and in PC3-Pgc1 cells 
treated with XCT790. In both cases, the effect of Pgc1 on the oxygen consumption rate was 
significantly impaired compared with Pgc1WT and non-treated cells (Fig R60A-B). To further confirm 
these results, we analysed the basal and maximal respiration, and the production of ATP from OCR in 
Pgc1-inducible PCa cells transduced with ERR sh79 or with a scramble short hairpin RNA. ERR 
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silencing under Pgc1 expression abolished the increase in basal and maximal respiration, and the 
production of ATP from OCR (Fig R60C).  
 
Figure R 60. Blocking Pgc1𝛂/ERR𝛂 effects on respiration through inactivation of its transcriptional 
program. A, Basal respiration in PC3 Pgc1𝛂wt (WT-expressing) and PC3 Pgc1𝛂L2L3M (L2L3M-expressing) cells 
(n=4).  B, Effect of XCT790 on basal respiration (n=3). C, Basal, maximal and ATP production from OCR in Pgc1𝛂-
expressing PC3 cells transduced with Scramble (Scr) shRNA or ERR𝛂 shRNA (sh79) (n=3). Dox: Pgc1α induced 
conditions. Error bars represent s.e.m. Statistical analysis: One sample t-test when comparing fold changes, one-
tailed Student t-test when comparing Dox conditions. Asterisks indicate statistical difference between No Dox and 
Dox conditions and dollar symbols between Dox conditions when treated with XCT790, or using PC3 Pgc1𝛂L2L3M 
and ERR𝛂 shRNA (sh79).The dotted line represents No Dox conditions. p, p-value. *p < 0.05, **p < 0.01, ***p < 
0.001, *$ < 0.05, **$ < 0.01, ***$ < 0.001.  
 
Finally, we analysed the ATP abundance in PC3 PGC1 L2L3M mutant and in PC3 Pgc1 
cells treated with XCT790. In line with what was seen before, the impairment of the PGC1-ERR 
transcriptional program significantly decreased ATP production (Fig 61A-B). According to all these 
results, PGC1-ERR transcriptional program is not only responsible for the tumour and metastasis 
suppression in PCa, but also for the metabolic rewiring observed. Now that we know this, the next step 
would be to decipher whether the metabolic phenotype activated is the responsible for the anti-
metastatic capacity of Pgc1-expressing cells.  
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Figure R 61. Effect of inhibition of PGC1𝛂 transcriptional program in ATP production. A, ATP production in 
PC3 Pgc1𝛂wt (WT-expressing) and PC3 Pgc1𝛂L2L3M (L2L3M-expressing) cells. B, Effect of XCT780 in ATP 
production in PC3 Pgc1a expressing cell lines. Error bars represent s.e.m. Statistical analysis: one-tailed Student 
t-test. Asterisks indicate statistical difference between No Dox and Dox conditions and dollar symbols between 
Dox conditions when treated with XCT790, or using PC3 Pgc1𝛂L2L3M and ERR𝛂 shRNA (sh79). Dox: Pgc1α 
induced conditions. p, p-value. *p < 0.05, **p < 0.01, ***p < 0.001, *$ < 0.05, **$ < 0.01, ***$ < 0.001. a.u= arbitrary 
units.  
 
IV.3 Mechanistic study of PGC1 role in metastasis initiation 
 
IV.3.1 Effect of PGC1 on EMT process 
 
We have previously demonstrated that PGC1 expression could be implicated in metastasis 
initiation inhibition by blocking cell migration and invasion. A prerequisite step for metastasis is the 
degradation of basement membranes that allow cell invasion. Cancer cells leave the primary tumour 
mass by losing cell-cell and cell-matrix contacts that results in alterations in cell shape and the 
acquisition of mesenchymal features through the activation of EMT. Nowadays is widely accepted the 
role of EMT in favouring cell invasion and migration in many cancer types, including prostate cancer190. 
In addition, matrix metalloproteinases, which degrade the matrix, are key enzymes that allow 
invasion191. Therefore, we decided to evaluate the expression levels of epithelial and mesenchymal 
genes as well as metalloproteinase 1 expression by q-RT PCR in PC3 cells, xenograft tumours and 
mice, to study whether PGC1 could revert an EMT process. Gene expression analysis in Pgc1-
expressing PC3 cells revealed an increase of a well-established epithelial gene (Keratin 8-KRT8) and 
a decrease of mesenchymal ones (TWIST and SNAIL1), which could reflect a reverse EMT program. 
However, other genes implied with the EMT process were not altered and CDH1, which is an epithelial 
marker, showed a decrease in expression (Fig. R62A). Furthermore, no changes neither in 
mesenchymal nor epithelial markers were observed in xenograft tumours and mice (Figure. R62B-C). 
Therefore, our results do not support the implication of PGC1 in the activation of a reverse EMT 
program that would impede metastasis initiation. 
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Figure R 62. Pgc1a expression has no clear effect in epithelial and mesenchymal genes expression. A, 
mRNA expression of mesenchymal (TWIST, SNAI2, SNAIL1, ZEB2, ZEB1, Vimentin, SNAI3), epithelial markers 
(CDH1 and KRT8) and matrix metallo-proteinase 1 (MMP1) in PC3 cell line after Pgc1a re-expression (n=6) (A), 
in xenograft samples (no dox n=8-11; dox=6) (B) and in Pten KO (n=15) versus DKO mice (n=11) (C).Pten KO= 
Pten pc-/-;Pgc1a pc+/+ and DKO=Pten pc-/-;Pgc1a pc-/-. Statistical analysis: One sample t-test (A) and one-tailed Mann 
Whitney U test (B and C). p, p-value. *p < 0.05.  
 
IV.3.2 Cytoskeletal dynamics in invasion 
 
Another key step for metastasis initiation is the acquisition of an invasive behaviour that 
involves the activation of signalling pathways that control the cytoskeletal dynamics. In fact, the 
contractile force generated by the actomyosin contractility has been shown to play a crucial role in 
migration of tumour cells 18. Moreover, carcinoma associated fibroblast (CAFs) use the contractile force 
to remodel the ECM for migration of cancer cells61. This actomyosin contractility is generated through 
the Rho family of small GTPases and Rho-Rho-kinase (ROCK) signalling 192,193. Because of this, and 
aiming to find the mechanism by which PGC1 arrests cell migration, we studied the protein expression 
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of different well known markers involved in cell contractility and actin polymerization (Fig. R63). Rho 
GTPases switch between guanosine triphosphate (GTP)-bound active state and guanosine 
diphosphate (GDP)-bound inactive state to translate extracellular signals into different responses. This 
activity is controlled by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins 
(GAPs). Rho-GTPases, when activated, control the phosphorylation of Rho-associated protein kinases 
(ROCK1/2), affecting the downstream effectors of it. On the one hand, ROCK can phosphorylate LIMK, 
a kinase that phosphorylates as well cofilin, inactivating it. Cofilin is an actin depolymerization factor 
(ADF/cofilin) that stimulates severance and depolymerization of actin filaments20. On the other hand, 
ROCK can increase the phosphorylation of the myosin light chain 2 (MLC2), which promotes 
actomyosin contractile force generation (Fig. R63).  
 
Figure R 63. Cytoskeleton dynamics in Pgc1α-expressing cells. A, Scheme of cytoskeleton associated routes 
and dynamics (adapted from Wang SK and Chang RT. Clin Ophthalmol 2014). B, Protein expression analysis by 
western blot of protein associated to contractility and adhesion (one experiment shown out of 3).  
 
Protein expression of markers involved in contractility (cofilin, LIMK) and adhesion (paxillin) 
revealed phosphorylation changes in cytoskeleton dynamics. The focal adhesion associated protein 
paxillin showed decreased phosphorylation in Pgc1α-expressing cells, as well as the phosphorylation 
of contractility associated proteins, LIMK and its phosphorylated target cofilin. The phosphorylation of 
cofilin would suggest a decrease of actin polymerization and, in turn, a decrease in cell contractility. Of 
note, MLC2 phosphorylation was analyzed but we were not able to detect neither the total nor the 
phosphorylated form of the protein (data not shown). According to these results, PGC1α expression 
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could lead to a decrease in cell contractility through LIMK activation and cofilin phosphorylation. 
Nevertheless, further experiments should be performed in order to decipher the activation of the route. 
 
 
TRANSCRIPTOMICS AND METASTASIS INITIATION PART: SUMMARY AND CONCLUSIONS 
 
o Gene expression and proteomic analysis in Pgc1α-expressing cells revealed that most of 
the genes regulated by PGC1 were implicated in metabolic pathways, such as TCA cycle, 
oxidative phosphorylation and pyruvate metabolism. 
 
o The promoter enrichment analysis showed that PGC1 transcriptional program was mainly 
controlled by the transcription factor ERR.  
 
o Genetic and pharmacologic approaches that block PGC1 transcriptional program/activity 
revealed the implication of the ERRα transcription factor in the tumour and metastasis 
suppression, and in the metabolic rewiring induced by PGC1. 
 
o Epithelial to Mesenchimal transition (EMT) process is not associated with PGC1 expression 
in cell lines and xenograft tumours, and are not responsible for the metastasis phenotype in 
the mouse model. 
 
o Although further studies should be carried out, LIMK and cofilin phosphorylation could be 
playing a role in the cytoskeleton dynamics of Pgc1-expressing cells.  
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V Personalized medicine and prognostic potential of PGC1α 
 
We finally aimed at studying the potential role of PGC1α for personalized medicine in PCa, 
with a specific focus on patient stratification and targeting vulnerabilities elicited by PGC1α inhibition. 
 
 
V.1 Metabolic vulnerabilities in prostate cancer cells 
 
The design of personalized health care is based on preventive or therapeutic strategies based 
on molecular understanding of the disease194. Interestingly, the study of metabolism has emerged as 
an important tool to develop personalized medicine. The metabolome is a measure of the output of 
biological pathways and it is considered to be a good representation of the functional state of cancer 
cells194. According to this, we took advantage of the metabolic vulnerabilities of Pgc1α non- 
expressing PCa cells. This cellular system allowed us to design and define potential treatments with 
differential effect between PCa cells according to PGC1α level. 
 
Going back to the metabolic profile (section IV.1.3), we demonstrated the capacity of Pgc1α 
expressing cells to inhibit ROS production. Taking this into account, we established a cellular 
condition that would alter ROS production. We based our experimental conditions on previous data 
showing that glucose deprivation leads to an increase in ROS production195. We cultured Pgc1α 
expressing and non-expressing PC3 cells under glucose deprivation during 48 hours. Non expressing 
Pgc1α cells showed an increased mitochondrial and cytosolic ROS production (Fig R64A). In line 
with a decrease in cell survival, comparing with Pgc1α-expressing cells (Fig R64B).  
 
To ascertain the causes of the decrease in survival, and according to previous data claiming 
that glucose withdrawal leads to apoptosis196,197, we checked apoptosis markers in our system. All 
cells (adhered ones and supernatant ones) were collected from the wells (see pictures from fig. R65) 
and protein analysis was performed. In agreement with decrease in survival, under glucose 
deprivation, Pgc1α non-expressing PC3 cells were positive for cleaved-PARP expression recognized 
marker of apoptosis198. Regarding these results, we concluded that low glucose induces an increase 
in ROS production in PCa cells that only Pgc1α-expressing cells can overcome.  
 
HYPOTHESIS 
PGC1α metabolic and transcriptomic functions harbour prognostic and therapeutic potential to be 
applied in personalized medicine 
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Figure R 64. ROS production in PC3 cells under glucose deprivation. A, Evaluation of cellular (DCF) and 
mitochondrial specific (Mitosox) ROS production in Pgc1α-expressing PC3 cells under glucose deprivation 
during 48 hours (n=9). B, Percentage of cell survival under glucose deprivation calculated by crystal violet (n=6). 
Statistic test: one-tailed (A) and two-tailed (B) student t-test. Error bars represent s.e.m. *** p<0.001. 
 
 
Figure R 65. Cell death under glucose deprivation in PC3 cells. In the left panel, representative pictures of 
Pgc1α-expressing and non-expressing PC3 cells under normal conditions (25mM) and glucose deprivation both 
during 48 hours (n=6). In the right panel, protein analysis by western blot of cleaved PARP (cl-PARP) as an 
apoptotic marker (one representative experiment out of 3 shown). No Dox= Pgc1α non-expressing conditions. 
Dox= Pgc1α-expressing conditions. 
 
We next hypothesized that those cells that do not express PGC1α, under low glucose 
conditions, die by apoptosis because of an impairment/a lack of production of antioxidants. In order 
to confirm that the reduced survival of non-expressing Pgc1α cells was associated with an increase 
in ROS, and the inability to buffer it, we treated the cells with two different antioxidants, N-Acetyl-
Cysteine (NAC) and Manganese (III) tetrakis (4-benzoic acid) porphyrin (MnTBAP).  
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The treatment with both antioxidants restored the survival of the non-expressing Pgc1α cells 
under low glucose conditions (Fig R66). These results highlight the relevance of PGC1α capacity to 
reduce ROS levels, and to survive under stress conditions such as glucose deprivation. This feature 
could have a great potential to target Pgc1α non-expressing cells, which, as demonstrated in this 
thesis work, present higher metastatic activity. Therefore, we next aimed at deciphering how Pgc1α 
expressing cells are able to buffer ROS production in PCa.  
 
 
Figure R 66. Antioxidants recover cell survival of PCa cells under glucose deprivation Representative 
images (n=3) are shown. Cells were incubated during 48 hours in low glucose conditions and treated with 
MnTBAP (200 µM) and NAC (1 mM). 
 
V.1.1 Mechanism of survival of Pgc1α expressing cells under glucose deprivation 
 
Glutamine can control ROS through the synthesis of glutathione (GSH), a tri-peptide (Glu- 
Cys-Gly), which serves to neutralize peroxide free radicals199. As glutamine is the rate limiting step 
for glutathione synthesis, we asked whether Pgc1α expressing cells were buffering ROS using this 
nutrient. In order to study it, we depleted the cells from glutamine and treated them with Bis-2-(5-
phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES), a potent inhibitor of Glutaminase 1, the 
enzyme responsible for the conversion of glutamine intro glutamate, precursor of GSH (Fig R67). 
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Neither glutamine deprivation nor 
BPTES treatment led to a reduction in cell 
survival of Pgc1α-expressing cells. This means 
that this pathway (synthesis of glutamate from 
glutamine and the expected synthesis of GSH) is 
not the responsible for the ROS buffering. Of 
note, glutamine withdrawal exacerbated the 
reduction of cell survival of Pgc1α non-
expressing cells under glucose deprivation 
(Fig.R68A-B). 
 
 
 
Figure R 68. Glutamine deprivation and BPTES treatment does not affect to cell survival in Pgc1α-
expressing cells. A, Percentage of survival under glucose and glutamine deprivation, and BPTES (8µM) 
treatment (n=3). B, Representative images of the experiments performed in order to calculate the survival (n=3). 
Statistical test: two-tailed Student t-test. Error bars represent s.e.m. p, p-value. *p < 0.05, ** p < 0.01. 
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Figure R 67. Schematic representation of 
glutamine deprivation and BPTES treatment. 
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To further investigate the PGC1α role in ROS balance, we went back to our transcriptomics, 
proteomics, and metabolomics results to seek for possible cues involved in reductive power 
production. Interestingly, upon expression of PGC1α we found upregulation of several genes 
(GSTK1, GSTM1, GSTM4, SOD2, NNT, HIGD1A and MGST3) and proteins (GSTK1, DLDH, SAHH2 
and PRDX2) involved in ROS balance and antioxidant activity, such as the nicotinamide nucleotide 
transhydrogenase (NNT), a mitochondrial enzyme that transfers reducing equivalents from NADH to 
NADPH. In fact, NNT is regarded as a major source of NADPH in the mitochondrion and reduced 
glutathione. Among others, there was an upregulation of the peroxiredoxin 2 (PRDX2), an antioxidant 
enzyme that has been seen to play a role in cancer200 (Fig R69A). In line with these results, data 
extracted from the unlabelled metabolomics performed revealed an increase in the NADP/NADPH 
ratio in Pgc1α-expressing cells (Fig R69B). Finally, as one of the protein involved in the methionine 
pathway was upregulated in the proteomics (SAHH2), and cystathionine showed a slight increase in 
the metabolomics, one possible pathway for the synthesis of glutathione could be through methionine 
(Fig R69C). However, further experiments should be done in order to elucidate so. According to the 
data obtained, Pgc1α expression leads to the upregulation of a set of antioxidant enzymes and 
metabolites that converge to balance ROS production in the cells. 
 
Figure R 69. The transcriptomics, proteomics, and metabolomics data revealed enzymatic activities 
involved in antioxidant pathways. A, Genes and proteins altered under Pgc1α expression in PC3 PCa cell 
line. B, NADPH/NADP ration in PC3 PGC1α cell line metabolites abundance is shown in arbitrary units (a.u.). C, 
Schematic view of glutathione (GSH) synthesis from methionine. Statistical test: two-tailed Student t-test. Error 
bars represent s.e.m. No Dox= Pgc1α non-expressing conditions. Dox= Pgc1α expressing conditions. . p, p-
value. **p < 0.01. 
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V.2 Prognostic potential of PGC1α-ERRα transcriptional signature 
 
We have previously demonstrated that the transcriptional regulation downstream of ERRα is 
key for the tumour suppressive activity of this transcriptional co-regulator. In fact, 
inhibition/suppression of the transcriptional program leads to PCa progression (Fig R70). Therefore, 
we reasoned that the association of PGC1α with aggressiveness and disease-free survival (DFS) 
observed (section I), should be recapitulated when monitoring ERRα target genes.  
 
 
 
Figure R 70. Summary of PGC1α-ERRα transcriptional program function. 
 
Accordingly, we sought to create a prognostic gene list based on the set of genes that were 
positively regulated by PGC1α in the cellular system (153 genes). From that list, we selected the 
subset of genes that were targets of ERRα (75 genes) and, finally, we curated the gene list focusing 
on those that exhibited a strong correlation with PGC1A in patient data sets (10 genes) (Fig R71). 
The selected genes were significantly correlated with the co-regulator (R˃0.2; p˂0.05) in at least three 
out of five studies. In addition, most of the genes selected showed decreased expression associated 
with disease progression (Fig R72). 
 
 
Figure R 71. Selection criteria for the curated gene set based on PGC1α-ERRα transcriptional program. 
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Figure R 72. Expression of genes from the curated gene set in different disease states. Representation of average 
gene signal of the 10 genes present in the PGC1α-ERRα curated gene set. Taylor B.S et al (N, 29; PCa, 131; Met, 
19); Grasso C.S. et al. (N, 12; PCa, 76; Met, 49); Lapointe J. et al. (N, 9; PCa, 17; Met, 4). In Taylor data set gene 
expression levels are presented in Log2. In Grasso and Lapointe data sets gene expression levels are presented in 
median centred Log2. Error bars represent minimum and maximum values. Statistical test: ANOVA. (N, normal; PCa, 
Prostate Cancer; Met, Metastasis). p=p-value. 
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In order to test whether the curated gene list presented prognostic potential, we first 
associated the expression of the 10 genes selected (ACACB, ACSL4, ATP1B1, GSTM4, ISCU, 
LAMB2, NNT, PPIC, SOD2 and SUCLA) with the progression of the disease in Taylor1 and Grasso151 
datasets. The results obtained revealed reduced PGC1α-ERRα curated gene set expression as the 
disease progressed (Fig R73A). Next, we analysed the association of PGC1α-ERRα curated gene 
set with disease recurrence. To this end, we compared patients harbouring primary tumours with 
gene set average signal values in the first quartile (Q1, signature positive) versus the rest (Q2-Q4, 
signature negative). Patients with signature-positive tumours showed a reduced disease-free survival 
in two independent data sets (Fig R73B). A hazard ratio of 2.44 (Taylor) and 1.78 (TCGA) was defined 
for signature-positive patients, whereas signature-negative individuals presented reduced risk of 
recurrence, with a hazard ratio of 0.23 (Taylor) and 0.56 (TCGA). Furthermore, we observed that the 
average signal of the curated gene set was positively correlated with time to PCa recurrence in Taylor 
data set, but not in TCGA (Fig R73C).  
 
 
Figure R 73. Expression of curated gene set in different disease states and association with disease free 
survival and recurrence. A, Representation of average gene signal of the 10 genes present in the PGC1α-
ERRα curated gene set. Taylor B.S et al (N, 29; PCa, 131; Met, 19); Grasso C.S. et al. (N, 12; PCa, 76; Met, 
49). Error bars represent minimum and maximum values. Statistical test: ANOVA (A), Kaplan-Meier estimator 
(B) and Pearson´s coefficient (C). (N, normal; PCa, Prostate Cancer; Met, Metastasis). p=p-value. 
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Finally, we checked the expression of genes included in the PGC1α-ERRα curated gene set 
in benign prostatic hyperplasia (BPH) and PCa specimens from a cohort of the Basurto University 
Hospital. We confirmed the decrease gene expression of the gene list in PCa patients versus BPH 
(Fig R74). Taken together, we have confirmed that ERRα-regulated metabolic transcriptional 
program is associated with the activity of PGC1α in PCa. This interplay is conserved in patient 
specimens, and defines a gene signature that harbours prognostic potential. 
 
 
SUMMARY AND CONCLUSIONS 
 
o Induction of metabolic stress by glucose deprivation leads to an increase in ROS production 
in Pgc1 non- expressing cells, causing cell death through apoptosis. This fact could be 
used to specifically target PCa cells and develop personalized medicine for patients lacking 
PGC1 expression with oxidative components. 
 
o PGC1 leads to the activation of an antioxidant program that balanced ROS production 
under glucose deprivation. According to the results, neither glucose nor glutamine are key 
nutrients to activate the program. Methionine metabolism could be playing a role in the 
synthesis of reductive power in Pgc1- expressing cells. 
 
o A PGC1-ERR transcriptional signature harbours prognostic potential in PCa. Its reduction 
is associated with disease progression, time to recur and disease free survival in PCa patient 
data sets. The transcriptional signature was validated in a cohort of patients from Basurto 
Hospital.  
 
 
 
G
e
n
e
 e
x
p
re
s
s
io
n
 (
a
.u
.)
ACACB ACSL4 ATP1B1 GSTM4 ISCU LAMB2 SUCLA
PCaBHP
0
1
2
3
PGC1A
***
**
**
***
**
** **
**
Figure R 74. Gene expression analysis of the curated gene list in PCa patients. RT-q PCR m RNA 
expression analysis of PGC1α-ERRα curate gene set in benign prostatic hyperplasia (BPH) and PCa specimens 
from Basurto University Hospital cohort (BPH n=14 patient specimens and Cancer n=15 patient specimens). 
Statistical test: one-tailed Mann Whitney U test. a.u, arbitrary units. Error bars represent s.e.m. p, p-value. *p < 
0.05, **p < 0.01, ***p < 0.001 
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EXPERIMENTAL IMPROVEMENTS AND FUTURE PERSPECTIVES 
 
o The use of glucose in order to induce ROS production is not accurate since other side effects 
could be playing a role in the process. The piperlongumine has been seen to increase the 
level of reactive oxygen species (ROS) and apoptotic cell death. The use of this compound 
could be necessary for future experiments. In addition, further experiments should be 
performed in order to ascertain whether methionine metabolism is involved in ROS buffering 
in Pgc1-expressing cells. 
 
o According to the criteria to stablish the PGC1α-ERRα, other strategies taking into account 
other clinical or genetic parameters could be performed. Also, the selection of the genes 
involve in the prognostic potential could be increased using other selection parameters. 
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VI Bioinformatics screenings: the hope from the OMICs to identify 
biologically relevant candidates in cancer  
 
VI.1 How to make big data understandable 
 
Thanks to the development and improvement of powerful research technologies, the 
volume of biological data generated in the last decades has exponentially increased. Cancer research 
has been profoundly impacted by the increasing availability of cancer genomes and transcriptomes, 
and by mass spectrometric quantification of proteins and metabolites (proteomics and metabolomics). 
Importantly, the use of these OMICs data in the last decade has enabled the discovery and selection 
of biomarkers in oncology. This has led to the understanding of the molecular and cellular 
mechanisms driving tumour initiation, maintenance and progression201. In turn, the development of 
this field is expediting the progress towards precision medicine (tailoring prevention, diagnosis, and 
treatment based on the molecular characteristics). In this thesis work, we have initially performed a 
comprehensive analysis based on publicly available PCa patient datasets. Gene Expression 
Omnibus (GEO) (https://www.ncbi.nlm.nih.gov/geo/) and The Cancer Genome Atlas (TCGA) 
(https://cancergenome.nih.gov/) were used to extract gene expression raw data and clinical 
annotations from PCa patients. Nevertheless, mining the sheer volume and the integration of data 
generated from the OMICs remains a big challenge for scientists202. Also, it has to be kept in mind 
the high complexity of biological processes, which is coupled with both the noisy nature of 
experimental data and the limitations of statistical analysis. 
The bottleneck that basic research faces from data generation to data management and 
interpretation, has encouraged the development of new informatics tools. In fact, bioinformatics has 
emerged as an essential tool for basic research. Using advanced computing, mathematics, 
technological platforms and an infrastructure to store, bioinformatics gives us access to analyse, 
integrate, and visualize large amounts of biological data and related information in an easier way. 
Nowadays, several platforms are available to store and analyse biological data from cancer patients, 
such as cbioportal (http://www.cbioportal.org/) and oncomine (https://www.oncomine.org), which are 
highly used to study cancer genomics and transcriptomics. However, it is key to understand how this 
information could be exploited in the translation towards cancer research for biomarker discovery, 
personalized medicine and patient stratification (Fig D1). In this thesis work we have taken advantage 
of publicly available data in order to perform a pre-empiric analysis (data mining analysis). This has 
allowed us to identify and select potential candidates altered in PCa, which expression presented an 
association with disease progression and aggressiveness, based on our pre-established selection 
criteria. Of note, the data mining analysis and the selection criteria used in this thesis work is an initial 
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but not a definitive approach, which relevance should be taken into account as a preliminary step to 
the generation of empiric data for candidate validation. 
 
Figure D 1. Bioinformatics model to make big data understandable. Data from OMICs is analysed using 
different platforms to integrate and correlate it for target discovery and for developing prognostic tools and 
improve personalized medicine. 
 
VI.2 Selecting the right candidate 
 
In order to identify key metabolic genes in our system, we focused our attention in the 
expression of master transcriptional co-regulators of metabolism75. Importantly, not only metabolic, 
but also gene expression dysregulation is a well-known hallmark of cancer3,203. Although the impact 
of individual metabolic genes in cancer biology has been elegantly documented98, little is known on 
how transcriptional dysregulation of metabolic programs impacts on cancer initiation and 
progression204. Indeed, several pro-oncogenic features are strongly controlled by dysregulated 
versions of transcriptional programs204. Taking all this into account, metabolic transcriptional co-
regulators emerge as ideal candidates, as they function both as metabolic sensors and transcriptional 
effectors, orchestrating an equilibrium between inhibitory actions of corepressors and the stimulatory 
effect of coactivators.  
Taking advantage of a data mining platform developed by a bioinformatician in the lab, we 
were able to extract gene expression raw data and clinical annotations from PCa public datasets. 
Using this platform, we performed association studies with gene expression data and different clinical 
parameters, such as disease progression, aggressiveness and survival. From our gene expression 
analysis, PGC1α emerged as the major metabolic transcriptional co-regulator altered in PCa. 
Similarly, Bowman R.L et al developed a user friendly web application for data visualization and 
analysis to explore adult and paediatric brain tumours expression datasets, allowing gene expression 
association with patient survival205.The relevance of these new techniques was also reflected in the 
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application of a systematic analysis of cancer gene-expression patterns using a high-throughput 
transcriptional profiling with 31 breast cancer datasets. This approach allowed the identification of 
two robust signatures that differentiate TP53 mutation status, and presented prognostic and 
predictive value for breast cancer patients206. Moreover, to study the biological and clinical 
implications of metabolic transformation in cancer cells, a recent study analysed the expression of 
metabolic genes across 20 different cancer types. In this work, authors demonstrated that cancers 
undergo a tissue specific metabolic rewiring that converged to a common metabolic landscape. In 
this scenario, downregulation of mitochondrial genes was associated with worst clinical outcome and 
correlated with an increased epithelial to mesenchymal (EMT) gene signature207. Interestingly, not 
only molecular data is being now publicly available for bioinformatics analysis. A free digital library-
laboratory named the Project Data Sphere platform (www.projectdatasphere.org) allows sharing, 
integrating and analysing historical, patient-level data from academic and industry phase III cancer 
clinical trials.  
These emerging online platforms allow not only the processing of gene expression, copy 
number alterations, mutations and their association with clinical parameters, but also serve as a 
source of clinically relevant cancer candidate genes. All these could improve the translation of basic 
research into clinic. 
Although our approach allowed the identification and analysis of a relevant candidate, it is 
limited to transcriptional co-regulators that exhibit transcriptional alterations, and does not account for 
other types of transcriptional modifiers nor genes that could be altered by non-transcriptional means. 
On the one hand, cancer-associated genetic alterations can affect proteins participating in nearly all 
levels of transcriptional control. That includes, trans-factors (transcriptional factors, signalling 
proteins, chromatin regulators and chromosome structuring proteins) and cis-elements (enhancers, 
promoters and insulators)208. In line with this notion, epigenetic changes have also been shown to 
play a critical role in tumorigenesis. In fact, genes encoding epigenomic regulators showed highly 
recurrent somatic alterations across a wide range of cancer types209. As in the case of transcriptional 
co-regulators, mutations affecting the epigenome would efficiently rewire cellular homeostasis, as 
they are able to affect multiple target genes simultaneously209. On the other hand, the sole use of 
transcriptomics for candidate discovery may not be sufficient for identifying potential signatures 
involved in cancer initiation and progression. In order to solve this problem, several strategies are 
being developed to integrate different OMICs together. However, the combination of different sets of 
data presents some challenges210. It is important to establish a criteria for the associations and 
integrations performed between the different layers of biology. The most applied one is the dogma of 
molecular biology: genes to transcripts to protein202. Nevertheless, this criteria does not take into 
account metabolites, which are functional readouts subsequent to the central dogma framework. Of 
note, these metabolites can loop back into different steps. For example, the accumulation of the 
metabolite fumarate has been shown to mediate demethylation of a regulatory region of the anti-
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metastatic miRNA cluster (miR-200ba429), leading to the expression of EMT-related transcription 
factors and enhancing migratory properties211.  
Despite the difficulties that the co-analysis of data sets present, some studies using more 
than one type of OMICs data set have been recently published. For instance, the integration of 
transcriptomic and metabolomics data revealed a high coincidence in biochemical pathways 
associated with tumour cell chemosensitivity to platinum-based drugs. In this case, data integration 
improved the detection of consensus pathways by 76%, revealing an association that was not visible 
when using the transcriptome analysis alone212. In line with the results obtained in this thesis work, a 
recent metabolic and transcriptomic integrative study comparing PCa and benign prostatic 
hyperplasia (BPH) patients revealed differences in cysteine, methionine and nicotinamide adenine 
dinucleotide metabolisms, as well as hexosamine biosynthesis213. These results underline the 
relevance of OMICs integrations in order to elucidate molecular perturbations that could harbour 
prognostic and therapeutic potential. 
Finally, other in silico methodology based on synthetic lethality has been recently published. 
Synthetic lethality is defined as a type of genetic interaction where the co-occurrence of two genetic 
events results in cell death, while the occurrence of either event is compatible with cell viability214. 
Metabolic reprogramming occurring in cancer cells is ideal to exploit the concept of synthetic lethality 
and to identify key pathways involved in cancer progression. In this study, genetic minimal cut sets 
(gMCSs) computation was used to define the minimal sets of reactions whose removal would render 
the function of a given metabolic task. In this case focused on biomass production, as it is a common 
feature of cancer cells. According to this notion, the results obtained in the analysis are promising as 
they could help to build algorithms to investigate and target metabolic vulnerabilities in cancer215. 
Regarding our work, the genes and pathways differentially altered in the absence of PGC1α could be 
studied using these algorithms to identify metabolic susceptibilities in PCa.  
In conclusion, the window of opportunities that bioinformatics and integrative OMICs 
methodologies offer us are unlimited, starting from the interrogation of public biological data to 
understand cancer. The number of publications based on online platforms, OMICs integrative 
approaches and families of algorithms is continuously increasing day-by-day. Thus, their use in the 
identification of cancer vulnerabilities, and its applicability in personalized medicine is closer.  
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VII PGC1α and cancer: friend or foe 
 
VII.1 PGC1α contribution to PCa in vivo 
 
The use of preclinical mouse models in cancer has enabled researchers to learn about 
tumour biology in complicated and dynamic physiological systems. Their use is nowadays the most 
rate-limiting step in the translation of basic tumour biology discoveries into diagnostic and clinical 
applications. A great effort is being performed to obtain reliable cancer mouse models, which could 
truly mimic the natural course of human tumour initiation, growth and metastatic dissemination. This 
would allow to substantially advance translational cancer research216.  
With the aim of studying the in vivo causal contribution of the candidate PGC1α, we used a 
well-established PCa mouse model based on the deletion of the tumour suppressor PTEN in the 
prostate epithelium. PTEN expression is reduced in 69% of human PCa, and 86% of castration 
resistant prostate cancer (CRPC) metastatic patients58,217. The targeted deletion of Pten in genetic 
engineered mouse models (GEMMs) has been widely used in different studies to study PCa initiation 
and progression61,218. Furthermore, the implication of PTEN and its main downstream pathway, PI3K, 
has been studied in PCa pathogenesis and progression62,43. It is important to highlight that this model 
does not present signs of clinical metastasis62. As bone metastasis causes a significant clinical 
burden for PCa patients, it is nowadays the focus of PCa research. In fact, the survival rate of PCa 
patients with metastatic disease has remained to be 30% 
(https://seer.cancer.gov/statfacts/html/prost.html), due to the lack of curative therapeutics for 
advanced and metastatic disease. Nonetheless, models that mimic the widespread clinical 
phenomenon of bone metastasis in advanced PCa patients are scarce.  
In this thesis work, we have demonstrated that the conditional deletion of Pgc1a and Pten 
in the prostate epithelium leads to clinical metastatic signs in lymph nodes and liver, and the presence 
of disseminated prostatic epithelial cells in the bone. Remarkably, two studies based on Pten deletion 
revealed metastatic signs both in the lymph nodes219 and in the pulmonary alveolar space218. 
Furthermore, other models of metastasis based on autonomic nerve development163 and the 
concomitant deletion of Pten and the tumour suppressors´ p53 and SMAD4, have been 
characterised164,166. Yet, none of these models presented bone metastasis. In this regard, only the 
transgenic adenocarcinoma of the mouse prostate model (TRAMP), which is based on targeting the 
SV40 early region comprising the large T and small t antigens, progresses to pulmonary, lymph node 
and bone metastasis. Importantly, this mouse model is based on non-representative features of the 
disease220. Therefore, though the Pten deletion-based model may be more suitable for therapeutic 
studies to attenuate disease progression in the primary tumour, other models such as TRAMP could 
be used to analyse mechanisms of metastasis in vivo. This fact suggests that suitable animal tumour 
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models should be developed to adequately mimic the evolution, the growth kinetics, the molecular 
and functional heterogeneity, and the phenotypic properties of human tumours. Due to the increasing 
knowledge developed in the last decade about tumour progression and dissemination, there is a great 
need to develop models to dissect the multistep pathways of tumorigenesis, which cannot be 
ascertained using cancer cell lines in culture nor human specimens.  
The mouse model used in this thesis work is a second/third generation mouse model, as it 
allows the conditional and spatially controlled deletion of a tumour suppressor and metabolic co-
regulator. Of note, orthotopic xenotransplants (considered first generation models) are highly used to 
study the mechanisms leading to cancer progression and metastasis216. Therefore, the use of these 
techniques could improve the understanding of PGC1α function in metastasis initiation in our work. 
Moreover, other models are being generated based on patient-derived xenografts and spontaneous 
tumours (fourth generation models) and on high-throughput technologies such as CRISPR/Cas9, that 
allow a faster functional testing of candidate genes. These new techniques will allow the study and 
expression modulation of target genes in a time and space controlled manner. Regardless the 
limitations of our model, timing is also a key factor. Due to technical and ethical facts, mice could not 
be maintained for longer time, which could have given us some clues about metastasis initiation and 
progression. Furthermore, and according to the invasive signs observed, it would be very interesting 
to analyse younger (3 months of age) DKO mice, to see whether Pgc1α loss affects not only 
progression, but also the initiation of cancer in vivo, as we have been able to see in vitro using PCa 
cell lines.  
To our knowledge, this is the first insight of enhanced progression of PCa based on the 
deletion of a principal regulator of metabolism (PGC1α) upon Pten loss. Moreover, although the 
implication of PGC1α in systemic metabolism has been extensively investigated 174,221,222, its activity 
in cancer is beginning to be understood. Interestingly, the loss of PGC1α in vivo protects against 
carcinogenesis, impairing tumour growth through mitochondrial and fatty acid metabolism 
regulation112. In contrast, the results from our in vivo model support the notion that PGC1α acts as a 
tumour suppressor in PCa. In line with our results, PGC1α depletion led to a higher number of 
intestinal tumours in mice, exerting a pro-apoptotic activity and tumour suppressor role113. Of note, 
different tissue types show profound differences in tumorigenesis, organization of oncogenic 
signalling pathways, and in their response to oncogenic driver mutations57. This could be one of the 
main obstacles when studying tumour development and evolution. The relevance of finding the 
precise experimental systems will be essential to ascertain the non-answered questions in cancer 
research. Of note, a big effort has been made during the last decades aiming to generate 3D 
organotypic cultures. These are derived from primary tissues, pluripotent stem cells, established cell 
lines, and whole or segmented organs, which consist of multiple tissue types223. Strikingly, organoid 
lines derived from PCa patients recapitulate the molecular diversity of PCa subtypes and maintain 
tumour identity, making them amenable to genetic and pharmacologic studies. In summary, this new 
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line of techniques has enabled a high reproducibility of in vivo systems in cancer to test drug response 
and the design of personalized therapy224,225. 
 
VII.2 Role of PGC1α metabolic activity in tumorigenesis 
 
Due to the increasing relevance of cancer metabolism, in the last decade several studies 
have been developed aimed at deciphering the role of the metabolic co-regulator PGC1α in 
tumorigenesis. However, a coherent picture of PGC1α in tumour pathogenesis has yet to emerge. 
PGC1α expression and function displays a great heterogeneity within tumours and its levels are 
dynamically regulated during different stages of cancer progression. This reflects the dual function of 
PGC1α in cancer and the complexity of studying this co-regulator in tumorigenesis. Thus, tissue 
context, disease stage, tumour heterogeneity and microenvironment must be taken into account 
when reaching conclusions. According to our results, PGC1α exerts a tumour suppressive activity in 
PCa decreasing proliferative and invasive features as well as metastatic activity162. In line with our 
results, PGC1α expression is also reduced in colon and ovarian human tumours110,111. Nevertheless, 
several studies in breast, melanoma, lung, liver, kidney and pancreatic cancer support the role of 
PGC1α as a promoter of tumour growth and metastasis112,114,115,118,121,126,128.  
In PCa, different studies suggest that PGC1α interaction with the androgen receptor (AR) 
or the activation of PGC1α expression through the androgen receptor AMP-activated protein kinase 
(AMPK) signalling axis drive tumour growth. Notably, in our panel of PCa cell lines we have not been 
able to detect PGC1α expression by protein or mRNA. In addition, we cannot rule out that in non-
basal conditions, stimulation of other factors such AR226 or AMPK116 in PCa cells could lead to PGC1α 
upregulation allowing its detection. Moreover, high mitochondrial content or biogenesis has been 
associated with PCa progression and has been shown to be necessary for anchorage- independent 
survival and propagation of stem like breast cancer cells227,228. In line with these results, highly 
metastatic melanoma cells contain fewer mitochondria and express lower levels of PGC1α129,130. In 
this context, we have not analysed whether mitochondrial content could affect the phenotype 
observed in PCa. Nonetheless, PGC1α expression leads to increased mitochondrial volume and 
activity in PCa cell lines, so we could hypothesize that this features could play a role in the tumour 
suppressive activity exerted by this co-regulator. 
Interestingly, PGC1α promotes mitochondrial biogenesis and protects against oxidative 
stress to influence survival in primary melanomas, while it suppresses migration and invasion to inhibit 
metastasis114,115,130. In addition, increased PGC1α expression in circulating mammary epithelium 
cancer cells enhances mitochondrial biogenesis, which has been associated with distant metastasis 
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and poor patient outcome128. These results highlight the relevance of the tumour stage in the dual 
function of PGC1α.  
 The implication of mitochondrial metabolism is of great relevance in different tumour 
types229. In this scenario, the metabolic activity of PGC1α plays an important role in tumorigenesis. 
On the one hand, in ERBB2-positive breast cancer cells, the PGC1α/ERRα complex modulates 
glutamine metabolism, enhancing the entrance of this nutrient to the TCA cycle for increasing the rate 
towards de novo fatty acid biosynthesis118. However, ectopic expression of PGC1α in ErbB2/Neu-
induced breast cancer cells led to an increase in tumour size in vivo together with a higher glucose 
and VEGF levels, but did not have any effect in in vitro proliferation126. On the other hand, PGC1α 
expression in colorectal cancer cells leads to high glycolysis and elevated oxidative stress 
suppressing tumour growth113. Moreover, decreased PGC1α correlates with poor outcome in renal 
cell carcinoma, while its expression restores mitochondrial function, induces oxidative stress and 
curbs tumour growth119. Therefore, PGC1α-exerted control of cellular bioenergetics, mitochondrial 
biogenesis and nutrient supply plays a role in proliferation and invasion, and influences differentially 
depending on the tumour type. Strikingly, this metabolic behaviour also affects the tumour 
microenvironment, as some studies remark the capacity of this co-regulator to promote 
vascularization and EMT programs in breast cancer and multiple myeloma127,128.  
Taking all these evidences into account, we aimed at inhibiting the PGC1α-induced 
metabolic state in PCa. We inhibited FAO and the entrance of pyruvate into the mitochondria using 
UK5099, an inhibitor of the mitochondrial pyruvate carrier (MPC). This approach was sustained by 
previous work in which these two pathways were associated with tumour aggressiveness and growth, 
survival rates and stemness markers230-233. Strikingly, UK5099 seemed to have a slight effect in cell 
migration but not in 2D proliferation. Although further work has to be done, this data may reflect a 
dual function of PGC1α-induced metabolic landscape, which may not have a role in tumour growth 
but affects metastasis initiation. Surprisingly, in our effort to further characterise the metabolic 
phenotype, we found a novel role of PGC1α, increasing asparagine synthesis in PCa cells. Whether 
the accumulation of asparagine in these cells plays a role in their tumour suppressor capacity is still 
unknown. Of note, in acute lymphoblastic leukemia, asparaginases (enzymes that convert asparagine 
to aspartate) are used as cornerstone treatments, as asparagine is essential to the survival of those 
cells234,235. In our system, the overload of the TCA cycle to produce intermediates for the ETC could 
lead to a higher release of carbons producing asparagine from aspartate. Nevertheless, asparagine 
may somehow play a role in the tumour suppressive activity of this co-regulator in PCa. Therefore, 
despite of the relevance of PGC1α in tumour metabolism and the results obtained, we have not been 
totally able to correlate its tumour and metastasis activity with the metabolic rewiring induced in PCa.  
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VII.2.1 Beyond the “Warburg effect” 
 
Although cancer is considered to be a genetic disease, metabolic alterations have been 
shown to deeply affect tumour biology and development3. Deciphering the metabolic background of 
cancer cells has been a constant field of study. Indeed, several advances have been made since Otto 
Warburg first reported in 1956 a differential metabolic phenotype in tumours. Warburg´s hypothesis 
postulates that tumour cells impair their oxidative mitochondrial metabolism and relay mainly on 
glycolysis, even under oxygen-rich conditions85. The study of cancer metabolism has led to the 
characterization and identification of different metabolic pathways implicated in cancer cell survival 
and proliferation. As a result, the capacity of cancer cells to adapt and rewire their metabolism is a 
well-known hallmark of cancer3. Cancer cells sustain their proliferation and survival by the differential 
use of nutrients to produce ATP, increase macromolecules biosynthesis and maintain cellular redox 
balance. By-products of metabolism can influence gene transcription, intracellular signal transduction 
cascades and induce epigenetic changes. It has been recently described how the accumulation of 
fumarate, due to mutations in FH enzyme leads to demethylation of an antimetastatic miRNA cluster 
and the expression of genes involved in EMT. Furthermore, a systems biology approach unveiled the 
methionine cycle and one carbon metabolism gene networks as major determinants of DNA 
methylation status in human cancer, linking methylation to cancer survival236. Moreover, a recent 
study has shown that polyamine biosynthesis, a metabolic route deeply involved in oncogenicity, is 
regulated by mTORC1, strengthening the integration and translation of growth signals into an 
oncogenic metabolic program237. In thesis work we have integrated the study of a transcriptional 
program and its influence in metabolism. By inducing the same metabolic landscape (increasing 
oxidative phosphorylation and mitochondrial metabolism), PGC1α can act as a tumour suppressor or 
oncogenic factor in a tissue-specific manner. Its binding to ERRα induces the expression of a 
transcriptional program that to some extent elicits different responses in cancer cells. This data 
reflects the tight coordination and the relevance of the crosstalk between cellular metabolism and 
gene transcription that tumour cells show when acquiring the capacity to adapt to the ever-changing 
environment.  
According to these examples, metabolites are not mere substrates and function as key 
effectors in different oncogenic events, which are tumour stage and organ dependent. Aiming to 
integrate metabolic discoveries, great advances have been made in the mathematical modelling of 
cancer metabolism. These models are based on genome-wide gene expression analysis and in flux 
balance, kinetic, reaction diffusion and tumour microenvironment models 238. Taking into account our 
work, the application of a mathematical models based on metabolomics, and gene and protein 
expression integration, we could determine and converge which pathways or signalling cascades are 
mediating the metastasis suppression in PCa. Moreover, we could also take advantage of previously 
described synthetic lethality-based algorithms215. Their application will allow us to identify the 
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metabolic vulnerabilities present in our system, and which pathways and additional genes could be 
fundamental for PGC1α function in PCa 
 
VII.3 PGC1α transcriptional circuits and their implication in drug resistance 
and therapy 
 
PGC1α does not work alone. It interacts and is activated or repressed by several factors 
that regulate transcriptional circuits of great relevance in cancer progression and metastasis. We 
have deciphered that the tumour and metastasis suppressor activities, as well as the metabolic 
landscape induced by PGC1α, are dependent on the transcription factor ERRα. PGC1α/ERRα 
transcriptional axis has been extensively studied in health and disease. Indeed, its functional 
integration with known oncogenes and the modulation of its activity has been related with pro- and 
anti-proliferative properties187. Interestingly, several studies that claim the pro-oncogenic effect of 
ERRα in breast cancer and melanoma have highlighted the possible applicability of this transcriptional 
factor as a therapeutic target239,240.  
In our study, ERRα is responsible for the bioenergetics potential of PGC1α and is 
responsible for cell growth, invasion and metastasis inhibition. In contrast, in other studies ERRα 
specifically mediates pro-survival functions in PGC1α-elevated highly aggressive melanomas239. The 
transcriptional program activated by these two factors has been also studied in breast cancer. In this 
scenario, PGC1α/ERRα axis supports anchorage independent growth and cell growth by inducing 
oxidative phosphorylation or glutamine-derived lipogenesis programs 118,241. Furthermore, it has been 
shown that, under stress conditions, PGC1α binds to p53 and modulates its transactivation function, 
resulting in preferential regulation of cell cycle arrest and metabolic genes125.  
Interestingly, many signalling axes (including metabolic rewiring, cancer progression and 
metastasis) in which PGC1α is involved are unique targets for inhibitors and present different 
sensitivity to drugs and therapeutic responses115,121. Pancreatic cancer stem cells (CSCs) exhibit 
dependency on oxidative phosphorylation, unlike the differentiated progeny that relies on glycolysis. 
This metabolic plasticity is regulated by a MYC/PGC1α balance. Strikingly, the use of metformin 
(mitochondrial inhibitor) in CSCs leads to energy crisis and apoptosis. Nevertheless, in this context, 
resistant CSC clones start expressing c-MYC to compensate the phenotype, and combinatory 
strategies must be used121. Another example is the use of Vemurafenib for targeted inhibition of 
BRAFV600E, which leads to PGC1α induction and mitochondrial respiration, contributing to melanoma 
survival115. Furthermore, in breast cancer it has been described that AMPK activation leads to 
increased expression of PGC1α/ERRα axis, which negatively regulates one-carbon metabolism 
genes, resulting in perturbations in purine biosynthesis. This promotes a higher sensitivity of breast 
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tumours to anti-folate therapy based on methotrexate122. From our perspective, ERRα is fundamental 
for PGC1α function in PCa, as demonstrated by the use of specific inhibitors (XCT790) and shRNA 
of ERRα in Pgc1α expressing PCa cell lines. However, for cancers that rely on this axis to overcome 
metabolic stress or disease progression, targeting ERRα could be a good approach. Of note, 
treatment-resistant cells and cells adapting to the new environment should be also considered. 
Because of this, when targeting signalling cascades combinatorial therapies must be developed. 
VII.4 Metastatic initiation and cell dissemination: many roads, one aim 
 
Metastasis is depicted as a multistep process in which tumour cells spread from the primary 
tumour to colonize distant organs7. In the different stages of the metastatic cascade distinct metabolic 
challenges arise and therefore, the capacity of these cells to adapt is key to reach the metastatic site 
229,242 (Figure D2). While the primary tumour has been a predominant focus of research in cancer 
metabolism for the past few years, the metabolic adjustments during dissemination have been less 
extensively studied. Regarding the implication of PGC1α in metastasis, we aimed at understanding 
how a metabolic co-regulator, beside its metabolic function, could affect cell migration and invasion. 
Moreover, it is important to remark that, contrary to other cancers where PGC1α presents an opposing 
activity in tumour proliferation and metastasis130, in our system this co-regulator acts as a coherent 
controller of cell proliferation, invasion and migration.  
 
 
Figure D 2. Tumour dissemination. Cells must undergo metabolic, cellular and cytoskeleton adaptations in 
order to intravasate into the blood vessels, extravasate in the secondary organ and re-build a tumour in the 
metastatic site (in the figure, main metastatic sites for PCa are shown). The molecular and cellular 
characterization of every step is of great relevance for understanding the dissemination process. EMT: Epithelial 
to Mesenchymal Transition; MET: Mesenchimal to Epithelial Transition. 
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In this thesis work we have based our study of metastasis initiation based on anabolism 
(previously discussed), the epithelial to mesenchymal transition (EMT) and cytoskeletal dynamics. 
Epithelial to mesenchymal transition 
EMT is a process that endows cells with migratory and invasive capacities. It is associated 
to the acquisition of stem cell properties and the inhibition of apoptosis and senescence2,15. Therefore, 
the mesenchymal state is tightly related to tumour development and the initiation of metastasis15. 
Aiming to understand the role of PGC1α in metastasis initiation, we checked the expression levels of 
different epithelial and mesenchymal markers. Contrary to previously published data in PCa patients 
and cell lines243-245 and to the association observed between PGC1α expression and the EMT 
program in breast cancer128, we were not able to find evidence that supported changes in EMT 
program in our PCa experimental systems. Nonetheless, when studying EMT, the mesenchymal or 
epithelial origin of the cells/tumours has to be taken into account. Although prostate cells are originally 
epithelial, due to their metastatic origin they acquire mesenchymal features. Moreover, while during 
intravasation epithelial cells must acquire mesenchymal features (EMT), extravasation and formation 
of a secondary tumour in the metastatic site implies the acquisition of epithelial behaviour 
(mesenchymal to epithelial transition (MET)). Because of this, the use of PCa cell lines could limit the 
detection of an EMT program. Furthermore, as we have only analysed the epithelial and 
mesenchymal markers by gene expression, it would be very interesting to look at them through 
imaging techniques in prostatic tissue samples from our GEMM. 
In PCa, the EMT process can be induced by several growth factors that activate FGF and 
TGF-β signalling and estrogen receptor β. In addition, different mechanisms work in concert to 
regulate EMT-like states, such as signal transduction cascades (Wnt and androgen receptor 
signalling), TFs and epigenetic mechanisms243. Although we have not gone into detail in ascertaining 
the reverse EMT activation, it would be interesting to analyse these signalling pathways in our system. 
Furthermore, an increasing body of evidence supports the concept that there is a link between 
metabolic reprogramming and EMT processes246. Indeed, mutations in SDH and FH enzymes led to 
hyper-methylated epigenome allowing EMT process247. According to this notion, the metabolic 
rewiring induced by PGC1α could also be playing a role in mediating EMT or MET processes. Despite 
of the relevance of the aforementioned studies, several recent studies argue against the need of 
undergoing and EMT process in tumour dissemination, and claim that is rather a permissive 
process248. 
 
 
 
 Discussion  
 
201 
 
D
IS
C
U
S
S
IO
N
 
Cytoskeletal dynamics 
In order to migrate, invade and extravasate to the blood or lymph, cells have to activate 
signalling pathways that control cytoskeletal dynamics, as well as turnover of cell-matrix and cell-cell 
adhesions172. Actin is the most abundant protein in cells and is responsible for cellular movement 
within the microenvironment. Two main actin binding proteins control de polymerization and 
depolymerisation of the actin filaments in the cells, MLC2 and cofilin, which phosphorylation is mostly 
controlled by ROCK serine/threonine kinases249. In highly metastatic melanoma cells (A375M2) 
phosphorylation of MLC2 is higher, an indicative of higher actomyosin contractility levels and 
migration191. In contrast, cofilin phosphorylation by LIMK leads to its inactivation, leading to 
suppression of actin turnover20 . While we were able to observe a reduced phosphorylation of cofilin 
and LIMK in our PCa cell lines, we were not able to detect changes in MLC phosphorylation neither 
by protein expression nor by immunofluorescence (data not shown). According to this, it would be 
possible to hypothesize that LIMK kinase is mediating the phosphorylation of cofilin to allow 
lamellipodium extension, and therefore, inhibiting cell migration and motility (Fig D3). Nonetheless, 
there is a big controversy towards cofilin function in cancer. Although overexpression of cofilin has 
been detected in invasive subpopulations of tumour cells in mammary, renal and ovarian tumours, it 
has also been reported to be downregulated in hepatocellular carcinoma cells with high metastatic 
potential250. Thus, these data could reflect a cell motility adaptation, which is organ-dependent. 
Moreover, it has to be taken into account that using metastatic PCa cell lines, we are capturing a 
snapshot of a whole process, which may not be suitable for studying cytoskeleton dynamics. Aiming 
to address so, working in collagen or matrigel matrixes could avoid such artefacts, as they represent 
more reliably the extracellular matrix (ECM).  
In line with this notion, aiming to find stabilization, cells establish links to the ECM through 
adhesion molecules, which also play a role in cancer17. For instance, paxillin is an adaptor/scaffolding 
protein that participates in cell signalling pathways involved in focal adhesions. Its phosphorylation 
leads to the recruitment of structural and regulatory proteins to the cell adhesion site17. In our PCa 
cells, we have observed that PGC1α expression reduces paxillin phosphorylation in PCa (Fig D3). 
Interestingly, phosphorylation of paxillin has been associated with increased migration in human 
osteosarcoma251. Moreover, paxillin phosphorylation through MLK3 kinase has been shown to favour 
breast cancer cell migration and invasion252. Also, its expression has been shown to have a 
correlation with clinical stage and metastasis in salivary adenoid cystic carcinoma, regulates breast 
cancer cell morphology, invasion and metastasis, and is overexpressed in early stages of lung cancer 
development253-255. Importantly, none of these studies showed the phosphorylation rates of paxillin. 
In addition, while elevated phosphorylation and/or expression of paxillin has emerged as a possible 
prognostic marker in ovarian, breast and hepatocellular carcinoma256-258, its elevated expression also 
exhibits non or negative correlation with patient outcome and recurrence-free survival259,260. These 
controversy between tumour types and dissemination stages may reflect the plasticity that tumour 
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cells acquire during disease development. Therefore, the expression and/or phosphorylation of these 
signalling molecules cannot be generalized, and the applicability of them as prognostic or target 
molecules is of great difficulty. Furthermore, it must be considered that cytoskeleton dynamics are 
controlled by several stimuli that activate or repress cell migration and invasion during tumour 
development and that cell confluency can highly affect the results. Therefore, the conclusions from in 
vitro data must be carefully evaluated. 
 
 
Figure D 3. Cytoskeletal control by PGC1α in PCa. Phosphorylation of both LIMK and cofilin has been shown 
to decrease under Pgc1α expression in PCa cell lines, as well as paxillin. These proteins are involved in actin 
polymerization and formation of focal adhesions (FA). Phosphorylation of cofilin by LIMK stabilizes actin 
filaments leading to cell migration, and paxillin phosphorylation initiates the recruitment of adhesion proteins that 
enable cell movement. 
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progression, some studies have attempted to study the functional crosstalk between these two fields. 
It has been observed that mitochondrial HSP90 proteins dampen the activation of the energy sensor 
and tumour suppressor AMPK, and limit the induction of autophagy. Strikingly, this is encompassed 
by a constant activation of cytoskeletal dynamics through persistent phosphorylation of the focal 
adhesion kinase (FAK)261. In fact, localization of FAK in the actin filaments results in the 
phosphorylation of paxillin17. The decrease in phosphorylated paxillin upon PGC1α expression could 
be due to FAK-mediated phosphorylation. Furthermore, glycolysis has been associated with 
increased rates of cytoskeletal remodelling, cell motility and formation of focal adhesions262. 
Nonetheless, no changes were observed in focal adhesion related proteins, and actin-binding 
proteins were not analysed in this study. Still, despite of these revealing studies, the implications and 
connection between metabolic adaptations and cytoskeleton dynamics and rearrangements needs to 
be more extensively depicted. 
 
VII.4.1 Metastasis and metabolic plasticity as evolutionary processes 
 
Given the adaptive role of PGC1α in shaping cellular metabolism and the transcriptional 
landscape during tumour development, it is tempting to speculate that it has a crucial role in tumour 
heterogeneity. This could also explain the distinct expression patterns observed across different 
cancer types. Tumour heterogeneity represents different populations of tumour cells within a tumour 
that show distinct morphological and phenotypic profiles263. The presence of this heterogeneity 
greatly increases the capacity of tumour cells to metastasize. Indeed, it has been recently discovered 
that different metastatic lesions (lymphatic and distant metastases) from the same primary tumour 
stemmed from different subclones in the primary tumour in human colorectal cancer264. Metastasis is 
a highly inefficient process (˂0.01% of tumour cells that enter into the systemic circulation will develop 
macroscopic metastases)12. Hence, deciphering the acquisition of genetic and/or epigenetic events 
driving molecular evolution that enable cells to invade a secondary organ is of great relevance to 
develop anti-metastatic therapies. Although we have explored the role of PGC1α in metastasis, other 
groups have studied the relevance of this co-regulator mediating metabolic adaptations in cancer 
stem cells, primary tumours and colonization114,121,130. Strikingly, a recent study has highlighted the 
relevance of PGC1α promoting lung and bone metastasis from breast cancer primary tumours as it 
confers to these cells bioenergetic flexibility against metabolic drugs131. The identification of the 
different functions of this co-regulator in an organ and stage-specific manner, will allow to know i) the 
molecular requirements of tumour cells in the primary site versus those in the metastatic site and ii) 
the limitations of these cells during the invasive cascade. Nevertheless, a key point will be to know 
which set of genes will be “metastasis initiation genes” or “metastasis progression genes” that work 
together in the metastatic process. As metastases still account for approximately 90% of cancer-
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associated patient mortality, truly informative prognostic biomarkers or signatures (as the one 
presented in this thesis work) and novel therapeutic targets are of great need12.  
 
VII.5 Ascertaining the role of PGC1α balancing ROS in cancer 
 
PGC1α exerts different mechanisms to modulate reactive oxygen species (ROS) 
metabolism in cells. As it stimulates mitochondrial-based respiration, it can increase ROS production 
in the mitochondrial transport chain. At the same time, certain components of the ROS scavenging 
pathway are stimulated by PGC1α, enabling cells to maintain normal redox status in response to 
changes in the oxidative metabolic capacity174. The capacity of PGC1α to regulate the production and 
scavenging of ROS is of critical importance in cancer. Still, the functional underpinning of ROS in this 
disease has not been totally understood109.  
Elevated oxidative signalling has been implicated in the promotion, tumorigenesis, 
angiogenesis, invasion and metastasis of cancers through different mechanisms. For instance, loss 
of p53 in mouse PCa resulted in ROS accumulation, increase inflammation and cancer 
progression265. Increased ROS has also been associated to proliferation and survival of PCa cells266, 
and in turn with an aggressive phenotype267. Moreover, the presence of prostate cancer-initiating 
cells has been associated with ROS elevation268. Interestingly, melanoma cells are able to survive 
under increased ROS levels due to their capacity to activate PGC1α-dependent detoxification 
genes114. This notion is coherent with the fact that oxidative stress inhibits distant melanoma 
metastasis129. 
ROS accumulation can lead to apoptosis, senescence or autophagy80,109. Induction of ROS 
inhibits cell growth and EMT in PCa cell lines269. Interestingly, the inhibition of glutathione synthesis 
and thioredoxin pathways, which are considered as main antioxidant pathways, results in cancer cell 
death in vitro and in vivo 270. Furthermore, in melanoma, metastasis but not tumour growth is 
promoted by antioxidants129. Of note, ROS balance differentially impacts on tumorigenesis depending 
on the tumour type, but also depending on tumour stage. This again shows the high complexity and 
heterogeneity between tumours (Fig D4). In our study, we have not been able to establish a relation 
between PGC1α, antioxidant properties and proliferation. The slight increase in ROS after PGC1α 
expression may be a side effect of the increase in oxidative phosphorylation and oxygen consumption 
rate. Nonetheless, to confirm that this increase was not mediating the decrease in proliferation, we 
use two different antioxidants (NAC and MnTBAP), which did not cause any effect in 2D growth. 
Nevertheless, once observed the duality of ROS balance in tumorigenesis, we could hypothesize that 
the effect of PGC1α on migration and invasion is ROS-dependent. In fact, it has been observed that 
downregulation of PGC1α leads to increased ROS and mediates endothelial cell migration271.  All this 
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supports the notion that cancer cells must adapt to the environment and the metabolic and cellular 
stress they undergo in the different stages of tumour dissemination. Interestingly, PGC1α mediates 
an antioxidant state in PCa, which could harbour therapeutic potential. Understanding these 
adaptations, and the molecular and metabolic pathways underlying, will allow us to develop new 
targeted therapies. 
 
 
Figure D 4. ROS balance by PGC1α in different tumours. The modulation of ROS is crucial for different 
tumour dissemination steps, as well as inside the tumour bulk, with the presence of cells with low capability to 
reach oxygen (hypoxic). PGC1α can mediate the response to ROS avoiding or leading to senescence and cell 
death. (Adapted from Cairns R.A. et al Nat. Rev 2011). 
 
VIII Use of PGC1α expression as a prognostic biomarker and to uncover metabolic 
vulnerabilities in PCa 
 
According to the world health organization, cancer is one of the leading causes of morbidity 
and mortality worldwide, and the number of new cases is expected to rise about 70% over the next 
two decades. The advances in cancer research during the last years has gone in parallel with the 
necessity to find and apply new and more specific therapies. Although traditionally patient care has 
been based on pathological and symptomatic examination of the disease, the generation and 
development of new techniques has enabled molecular profiling of cancer patients. This, to some 
extent, is allowing the availability of a greater degree of personalized medicine. Information about a 
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cancer patient´s proteic, genetic and metabolic profile could be used to tailor medical care to that 
individual needs, such as stratifying disease status and selecting the proper medication. Several 
biochemical, epigenetic, genetic, imaging, metabolomics and proteomic markers have shown high 
prognostic value and therapeutic potential272,273 (Figure D5). Nonetheless, the complexity of the 
disease must be approached in a multiplex way, using more than one specific marker, and combining 
different technologies towards a wider picture of cancer. This issue also highlights the complexity of 
integrating disease networks and OMICs data. Aiming to find the therapeutic and prognosis potential 
of the results presented in this thesis work, we carried out two different approaches. As reported in 
the results section, PGC1α is able to counteract ROS levels under stress conditions. Therefore, we 
first took advantage of this feature, which suggested a vulnerability of PCa cells that do not express 
the co-regulator. Secondly, we integrated and defined a gene signature based on PGC1a function, 
using PCa patient clinical and gene expression data. 
 
 
 
Figure D 5. Framework of personalized medicine. The integrative study and analysis of OMICs, together with 
clinical and pathological data, and lead us to selectively stratify cancer patients based on a patient-specific 
prognostic, and to establish the appropriate treatment (Adapted from Alyass A. et al BMC Medical Genomics. 
2015) 
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VIII.1 Taking advantage of PCa metabolic vulnerabilities 
 
PGC1α controls the expression of genes involved in ROS balance80. We first attempted to 
target Pgc1α-non expressing PCa cells, which are more aggressive, invasive, metastatic and 
proliferative than the Pgc1a-positive counterparts, using a ROS generating stimulus (glucose 
deprivation conditions). Interestingly, PGC1α elicited resistance to ROS-induced apoptosis under 
glucose deprivation. According to these results, the use of ROS-inducing agents could lead to the 
selective death of highly aggressive PCa cells. Strikingly, oxidative stress inhibits melanoma 
metastasis, and antioxidants promote disease progression but not tumour proliferation129. In turn, the 
use of antioxidants in metastasis could be harmful, but it may not have any effect when treating 
primary tumours. Although it is premature to propose antioxidants or oxidants as future strategies for 
treating cancer109, several antioxidant and oxidant-based therapies have been applied. For instance, 
a cocktail treatment based on selenium, vitamin E and carotene supplements (antioxidants) used in 
the Linxian trial showed to significantly reduce mortality in gastric cancer patients274. Furthermore, it 
has been observed that the intake of vitamin E reduces the risk of liver cancer275. Contrary to this, 
several antineoplastic drugs used in cancer chemotherapy induced high levels of oxidative stress, 
such as platinum coordination complexes (cisplatin) and anthracyclines (doxorubicin)107. 
Trying to decipher the metabolic underpinnings of PGC1α-induced ROS balance, we aimed 
at blocking different nutrient sources. We failed in all our attempts to find the molecular pathway used 
by PGC1α to inhibit cell death in our cells. Of note, further effort should be carried out to ascertain 
whether methionine metabolism could play a role in the production of antioxidant power. According 
to the phenotype that Pgc1α- expressing cells showed under glucose deprivation, we contemplated 
the possibility that cells were undergoing senescence, as ROS can can activate this process276. 
Nonetheless, we could not determine a direct correlation with senescence in those cells. Further 
experiments should be carried out to ascertain the cell morphology and phenotype in PCa cells under 
glucose deprivation. 
Finally, we have not been able to clarify if the tumour suppressive activity exerted by PGC1α 
is also mediated by the metabolic rewiring induced by the co-regulator. Other studies have revealed 
the relevance of metabolism in tumour progression and metastasis98. In line with this notion, the 
development of clinically useful modulators of metabolism is of great interest. Chemotherapies 
targeting metabolism have been effective for decades in cancer treatments277. Indeed, the success 
of these therapies demonstrated the existence of a therapeutic window to target malignant 
metabolism. Several metabolic inhibitors affecting different metabolic pathways and mutations have 
been developed and are close to clinical evaluation277. Interestingly, the food and drug administration 
(FDA) has recently approved the first-in-class cancer metabolism drug Enasidenib, an inhibitor of 
mutated isocitrate dehydrogenase 2 (IDH2), for treating acute myeloid leukaemia (AML)278. Once 
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again, the metabolic landscape that cancer cells show depending on tumour type and stage is too 
wide to approach the treatment of this disease in a unilateral way. Although it was initially thought 
that cancer cells showed a restricted metabolism, nowadays it is accepted that cancer cells acquire 
metabolic plasticity to survive in hostile environments. As a future approach, we could perform a 
metabolic drug screening in our system, to determine which compounds affect to a higher extent 
Pgc1α-non expressing cells, which are highly more aggressive.  
VIII.2 PGC1α gene signature for patient stratification 
 
The use of genetic and transcriptomic studies have been widely proposed for personalized 
medicine approaches. Indeed, the use of big data analysis has allowed the identification and analysis 
of potential molecular targets and biomarkers35,201. Prostate tumours are highly variable in their 
response to therapies, and clinically available gene signatures and prognostic factors explain only a 
fraction of this heterogeneity. Novel genetic biomarkers in PCa will allow the understanding of 
oncogenic heterogeneity in a patient-personalized clinical setting and the improvement of risk 
prognosis and treatment choice. We took advantage of our cell line transcriptomics data and public 
datasets. We based our analysis in PGC1α-regulated gene expression in PCa cell lines. We limited 
the analysis to genes that were controlled by ERRα and had a correlation with PGC1α expression in 
PCa patient datasets. This is only one alternative of the possible strategies to define a prognostic 
signature.  
The comprehensive integrative analysis performed, revealed a curated gene signature of 
10 genes that showed accurate prognostic potential in PCa. The reduction of signature expression 
was associated with disease progression, and shorter disease free survival. This could allow the 
stratification of PCa patients (gene signature-positive/negative), which would be complementary to 
other clinical classification systems. Patients with a lower expression of the gene signature are more 
prone to progress to metastasis, and therefore, the clinical decisions will be different from patients 
not exhibiting this signature (Figure D6). This data could help clinicians to predict the disease 
outcome and apply personalized cancer treatments. Our approach, which is based on the initial 
discovery of PGC1α as a PCa metastasis and tumour suppressor, relies on the transcriptional control 
that this co-regulator exerts and the transcriptional program that it activates. Of note, the stratification 
and prognosis value of our signature implies the use of prostatic tissue, obtained after prostatectomy.  
In addition to our study, many others have developed prognostic signatures in PCa based 
on gene expression data35. A postoperative nomogram is a frequent tool used to predict PCa 
progression. It is basedon serum prostate-specific antigen, Gleason score, surgical margin status and 
pathological stage and estimates 5-7 year progression free probability after radical prostatectomy. 
Interestingly, a computational study performed with gene expression data obtained from PCa tissue 
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samples, revealed a gene signature (11 genes) that predicted disease recurrence more accurately 
and with a higher sensitivity than the nomogram279. 
 
 
 
Figure D 6. PGC1α signature-based stratification and prognostic potential. Prostate cancer patients will be 
stratified into signature positive and negative, and different prognosis and therapeutics will be applied. 
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More recently, several biomarkers and gene signatures have been associated with 
screening and detection of early cancer, and for risk stratification of aggressive cancer40. For instance, 
the Oncotype DX® Prostate Cancer assay scores the aberrant expression of 12 cancer-associated 
genes, associated with AR signalling, stromal response, cellular organization and proliferation 
pathways280. Of note, a PCa prognostic kit is available, Prolaris® , and is also based on the expression 
of cell cycle genes, which predicts disease aggressiveness and estimates the risk of biochemical 
recurrence (BCR)281. Furthermore, the Decipher Prostate Cancer Classifier profiles the expression 
signature of 22 aggressive cancer-associated RNA markers, and has also shown to have risk 
prognosis of metastasis following surgery282. Contrary to our gene signature that relies on a 
transcriptional program tightly regulated by PGC1α, the signatures described before are based on 
genes involved in cancer progression and proliferation, being in some cases non-specific. 
Remarkably, all these signatures rely on the establishment of a “score” value. In order to have a social 
and clinical impact, we will have to address the following lacking points of our gene signature: i) the 
establishment of a “score” value based on the differential expression of the gene signature (including 
PGC1α), ii) the finding of other biological sources to validate the gene signature, iii) the establishment 
of a stratification system based on the gene-signature score and iv) its correlation with patient 
prognosis. 
Studies based on other genomic hallmarks have been recently performed. A study 
comparing indolent PCa to normal prostate epithelium identified a microRNA (miRNA) signature that 
presented a potential clinical utility as biomarker, prognostic indicator and therapeutic target for early 
detection 283. In addition, integration of genomic hallmarks and genomic alterations of localized non-
indolent PCa showed a multimodal biomarker with disease relapse based on biochemical recurrence 
(BCR) prediction. In line with our study, a metabolic gene signature of increased one-carbon 
metabolism and decreased proline degradation was identified to be associated with disease free 
survival284. This study using patient-derive xenografts (PDX) highlighted the relevance of metabolic 
heterogeneity in PCa. Nonetheless, they couldn´t confirm the association of the gene signature with 
disease progression. Although all the studies have been performed based on nuclear DNA, a recent 
approach has remarked the relevance of mitochondrial DNA in PCa aggressiveness285. In addition, 
mitochondrial single-nucleotide variants (mtSNVs), which in some cases presented associations with 
nuclear genomic mutations, have been linked to PCa aggressiveness285. Due to the implications of 
PGC1α in mitochondrial biogenesis and metabolism, it would be very interesting to study the possible 
alterations in mitochondrial DNA in PCa. Remarkably, and although further investigation should be 
performed, we can conclude that our signature is not restricted to gene expression, as it also 
represents a metabolic state, which could harbour therapeutic potential. To our knowledge, the gene 
signature established in this thesis work is the only one associating the expression of a transcriptional 
program with disease progression, recurrence and disease free survival in PCa.  
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Although in this thesis work we have not approached the study of non-invasive genetic 
biomarkers, several tests have also been developed for the detection and prognosis of cancer genetic 
characteristics in body fluids. Of note, it would be very interesting to check whether the signature 
presented in this thesis work is also detectable in body fluids. These technical approaches are based 
on the fact that tumour cells can secrete genomic fragments or molecules to the circulatory system, 
in which also cancer circulating cells are present. For instance, the urine-based expression of a panel 
of genes (PCA3, serine peptidase inhibitor Kazal type 1, Golgi phosphoprotein 2 and TMPRSS2: 
ERG) is used for the early detection of PCa. Furthermore, the methylation levels of GSTP1 in plasma 
have been associated with advanced stages in PCa, and the detection of mRNA expression of 
homeobox C6 (HOXC6) and Distal-less homeobox 1 (DLX1) in urine has been identified to improve 
the identification of high-grade tumours, when combined with standard clinical risk factors40. An 
interesting approach is also the non-invasive RNA-based diagnosis of PCa. The exosome diagnostic 
tool extracts critical molecular information from exosomes (small vesicles) present in blood of urine 
(http://www.exosomedx.com/prostate-cancer) and establishes a correlation with PCa aggressiveness 
based on three important genetic biomarkers. Furthermore, our groups has recently described 
extracellular vesicles as emerging structures to characterize PCa in urine. They emerge as an 
attractive source for non-invasive diagnostic, prognostic and predictive biomarker discovery in 
PCa286. However, although this technique could be complementary to the DNA-based strategies, 
there is still a significant amount of work to be done in order to identify molecules present in exosomes 
and their role in tumorigenesis. 
 
VIII.3 How to regulate the master co-regulator 
 
PGC1α downregulation in PCa is not achieved by genomic alterations, as one-copy losses 
could only be observed in metastatic specimens (Fig R8). PGC1α expression can be regulated by 
several transcriptional cues and changes in its protein stability through post-translational 
modifications (Fig D7) 81,287,288.Given the multiple levels at which this co-regulator can be controlled, 
it is tempting to speculate that this regulatory nodes could be targeted for cancer therapy. The 
implication of some of them in cancer has been already established115,121,162. In pancreatic ductal 
adenocarcinoma (PDAC) MYC suppression elicited PGC1α transcriptional activation. This led to an 
increased mitochondrial respiration, maintenance of stemness and tumorigenic activity of pancreatic 
CSC, making them vulnerable to metformin treatment. Nonetheless, differentiated and resistant 
PDAC cells were more dependent on glycolysis, as a result of increased MYC/PGC1α ratio. Thus, 
this regulation determines not only the metabolic plasticity of PDAC cells, but also sensitivity to 
metformin. Another well-known example of PGC1α transcriptional regulation is the one exerted by 
MITF in BRAF mutated melanomas115. We have not studied post-translational modifications in 
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PGC1α nor alterations in the known-transcriptional regulators of the co-regulator in PCa. It would be 
interesting to study whether PGC1α promoter presents variations in methylation in PCa patients. This, 
together with the OMICs performed in this thesis work, could help define new targeted therapies for 
PCa patients that show reduced PGC1α expression.  
 
 
Figure D 7. Transcriptional and post-translational control of PGC1α. Arrows represent positive regulation 
and lines negative control of PGC1α. The right arrow represents the activation of PGC1α, which will lead to 
binding and activation of transcriptional programs mediated by different transcriptional factors 
 
Interestingly, exercise reduces the risk to develop several cancers, and it might improve 
clinical outcomes following the diagnosis of a primary disease289. At the same time, exercise 
increases mitochondrial PGC1α content and promotes mitochondrial biogenesis290. In this thesis work 
we have described PGC1α as a tumour suppressor in PCa162. Therefore, it is tempting to speculate 
that patient exposure to exercise may impact on the development and progression of the disease. 
Thus, it would be interesting to study the effect of exercise in PCa patients. 
 
VIII.4 Future work 
 
During this thesis work, we have deciphered the role of PGC1α as a tumour and metastasis 
suppressor in PCa, which is mediated through the activation of an ERRα-dependent transcriptional 
program that causes a catabolic rewiring and inhibition of invasiveness. We have further validated 
the role of PGC1α in ROS management under metabolic stress, which could harbour therapeutic 
potential. Lastly, we identified and built a gene signature based on PGC1α activity with high 
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prognostic value (Fig D8). Nonetheless, whether ROS balancing or the catabolic state induced are 
implicated in the cytoskeleton changes or the tumour and metastasis suppression activity of PGC1α 
remains unknown. Deciphering whether the metabolic rewiring induced is implicated in PGC1α 
activities could help to develop new therapies for PCa. Finally, though it has not been an aim in this 
thesis work, knowing which factors regulate PGC1α expression will be instrumental to create a 
combinatorial therapy in PCa. 
 
Figure D 8. Schematic representation of remaining questions from this thesis work. Dotted line circles 
represent cues of therapeutic potential 
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The results obtained throughout this thesis work confirm our initial hypothesis and 
demonstrate that altered transcriptional control of metabolism in PCa affects disease progression and 
aggressiveness. The results are summarized as follows: 
 PGC1α is a major metabolic transcriptional co-regulator altered in PCa, which downregulation 
is associated with disease progression, aggressiveness, and disease free survival. 
 Pgc1a and Pten conditional homozygous deletion in murine prostate epithelium leads to 
metastatic dissemination to lymph nodes and liver, and to disseminated prostatic epithelial cells 
in the bone. 
 PGC1α re-expression in PCa cell lines inhibits proliferation, invasion, migration and metastatic 
activity. 
 PGC1α induces a metabolic rewiring towards a catabolic state with enhanced antioxidant 
potential in PCa. 
 PGC1α alters cell adhesion and cytoskeletal rearrangements in PCa, in line with its anti-
invasive activity. 
 The transcriptional program that mediates the prostate tumour suppressive activity of PGC1α 
in PCa is dependent on the transcription factor ERRα. 
 PGC1α confers survival capacities under glucose deprivation-induced ROS. 
 A PGC1α/ ERRα transcriptional signature harbours prognostic potential in PCa. 
 
 
GENERAL CONCLUSION 
PGC1α emerges as the major metabolic transcriptional regulator suppressing PCa 
metastasis and its mechanistic characterization could harbour prognostic and therapeutic 
potential 
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Table 1. Significantly altered proteins after Pgc1 expression. 
NAME ANOVA (P) DOX/NO DOX DESCRIPTION
ANXA2 0,002 0,435 Annexin A2 
DDX5 0,000 0,459 Probable ATP-dependent RNA helicase 
HS105 0,000 0,468 Heat shock protein 105 
ODO2 0,024 2,075
Dihydrolipoyllysine-residue succinyltransferase component of 2-
oxoglutarate dehydrogenase complex, mitochondrial 
LPPRC 0,011 2,092 Leucine-rich PPR motif-containing protein, mitochondrial 
FUMH 0,000 2,170 Fumarate hydratase, mitochondrial 
STAT1 0,004 2,172 Signal transducer and activator of transcription 1-alpha/beta 
CH60 0,005 2,186 60 kDa heat shock protein, mitochondrial 
ODPB 0,005 2,223 Pyruvate dehydrogenase E1 component subunit beta, mitochondrial 
ALDOA 0,001 2,241 Fructose-bisphosphate aldolase A 
GSTK1 0,002 2,250 Glutathione S-transferase kappa 1 
DLDH 0,000 2,261 Dihydrolipoyl dehydrogenase, mitochondrial 
ACADM 0,004 2,262 Medium-chain specific acyl-CoA dehydrogenase, mitochondrial 
ATPB 0,006 2,268 ATP synthase subunit beta, mitochondrial 
ETFB 0,002 2,298 Electron transfer flavoprotein subunit beta 
SYWC 0,000 2,303 Tryptophan--tRNA ligase, cytoplasmic 
PGM1 0,006 2,311 Phosphoglucomutase-1 
G6PI 0,007 2,316 Glucose-6-phosphate isomerase
RADI 0,002 2,435 Radixin 
OPA1 0,001 2,482 Dynamin-like 120 kDa protein, mitochondrial 
CYC 0,001 2,529 Cytochrome c 
MDHM 0,001 2,539 Malate dehydrogenase, mitochondrial 
AKA12 0,004 2,590 A-kinase anchor protein 12 
AATM 0,000 2,625 Aspartate aminotransferase, mitochondrial 
CH10 0,006 2,646 10 kDa heat shock protein, mitochondrial 
ATPA 0,000 2,649 ATP synthase subunit alpha, mitochondrial 
ODP2 0,002 2,657
Dihydrolipoyllysine-residue acetyltransferase component of pyruvate 
dehydrogenase complex, mitochondrial 
ACON 0,001 2,669 Aconitate hydratase, mitochondrial 
PRDX2 0,001 2,680 Peroxiredoxin-2 
S10A6 0,046 2,684 Protein S100-A6 
ECHB 0,001 2,690 Trifunctional enzyme subunit beta, mitochondrial 
CISY 0,002 2,694 Citrate synthase, mitochondrial 
K2C8 0,000 2,733 Keratin, type II cytoskeletal 8 
ODO1 0,002 2,738 2-oxoglutarate dehydrogenase, mitochondrial 
ADT2 0,002 2,749 ADP/ATP translocase 2 
DECR 0,002 3,169 2,4-dienoyl-CoA reductase, mitochondrial 
MDHC 0,002 3,180 Malate dehydrogenase, cytoplasmic 
AIFM1 0,000 3,236 Apoptosis-inducing factor 1, mitochondrial 
ACADV 0,005 3,302 Very long-chain specific acyl-CoA dehydrogenase, mitochondrial 
KAD1 0,000 3,369 Adenylate kinase isoenzyme 1 
ECHA 0,000 3,521 Trifunctional enzyme subunit alpha, mitochondrial 
KCRB 0,000 3,564 Creatine kinase B-type 
AT1B1 0,000 3,569 Sodium/potassium-transporting ATPase subunit beta-1 
IDH3A 0,000 3,697 Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial 
SAHH2 0,000 3,911 Putative adenosylhomocysteinase 2 
ISG15 0,002 4,862 Ubiquitin-like protein ISG15
MX1 0,002 5,379 Interferon-induced GTP-binding protein Mx1 
AATC 0,000 5,671 Aspartate aminotransferase, cytoplasmic 
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Table 2. Transcriptional analysis of PGC1α-expressing versus non-expressing cells (microarray raw 
data). 
ProbeID SYMBOL Acc_No FC AdjP Gene_descr 
ILMN_1768469 TCN1 NM_001062.3 -1,99 0,01 
transcobalamin I (vitamin B12 binding 
protein, R binder family) (TCN1), mRNA. 
ILMN_1725139 CA9 NM_001216.1 -1,82 0,03 carbonic anhydrase IX (CA9), mRNA. 
ILMN_1692511 TMEM106C NM_024056.2 -1,81 0,00 
transmembrane protein 106C 
(TMEM106C), mRNA. 
ILMN_1672961 LOC652624 XM_942165.1 -1,68 0,04 
similar to 40S ribosomal protein SA 
(p40) (34/67 kDa laminin receptor) 
(LOC652624), mRNA. 
ILMN_1680313 STX4 NM_004604.3 -1,64 0,04 syntaxin 4 (STX4), mRNA. 
ILMN_1789614 TPT1 NM_003295.2 -1,64 0,01 
tumor protein, translationally-controlled 1 
(TPT1), mRNA. 
ILMN_1805376 KCNJ6 NM_002240.2 -1,63 0,01 
potassium inwardly-rectifying channel, 
subfamily J, member 6 (KCNJ6), mRNA. 
ILMN_1785711 NEDD8 NM_006156.2 -1,63 0,02 
neural precursor cell expressed, 
developmentally down-regulated 8 
(NEDD8), mRNA. 
ILMN_2174437 CIDEC NM_022094.2 -1,61 0,00 
cell death-inducing DFFA-like effector c 
(CIDEC), mRNA. 
ILMN_1680208 LOC284821 XR_016232.1 -1,58 0,01 
similar to ribosomal protein L13a 
(LOC284821), mRNA. 
ILMN_1685079 TELO2 NM_016111.2 -1,57 0,01 
TEL2, telomere maintenance 2, homolog 
(S. cerevisiae) (TELO2), mRNA. 
ILMN_3265895 HNRNPR 
NM_001102398.
1 
-1,50 0,01 
heterogeneous nuclear ribonucleoprotein 
R (HNRNPR), transcript variant 1, 
mRNA. 
ILMN_1881909  BU536065 -1,48 0,03 
AGENCOURT_10229596 
NIH_MGC_141   cDNA clone 
IMAGE:6563923 5, mRNA sequence 
ILMN_1807807 SKA2 NM_182620.3 -1,48 0,01 
spindle and kinetochore associated 
complex subunit 2 (SKA2), transcript 
variant 1, mRNA. 
ILMN_3245020 WASH1 NM_182905.3 -1,46 0,02 
WAS protein family homolog 1 
(WASH1), mRNA. 
ILMN_1760412 SHISA2 
NM_001007538.
1 
-1,45 0,03 
shisa homolog 2 (Xenopus laevis) 
(SHISA2), mRNA. 
ILMN_3299407 LOC728553 XR_041708.1 -1,41 0,03 misc_RNA (LOC728553), miscRNA. 
ILMN_1723912 IFI44L NM_006820.1 -1,40 0,01 
interferon-induced protein 44-like 
(IFI44L), mRNA. 
ILMN_1753755 B4GALT2 NM_003780.3 -1,39 0,03 
UDP-Gal:betaGlcNAc beta 1,4- 
galactosyltransferase, polypeptide 2 
(B4GALT2), transcript variant 2, mRNA. 
ILMN_1721833 IER5 NM_016545.4 -1,38 0,01 
immediate early response 5 (IER5), 
mRNA. 
ILMN_1717765 NUDT11 NM_018159.3 -1,37 0,01 
nudix (nucleoside diphosphate linked 
moiety X)-type motif 11 (NUDT11), 
mRNA. 
ILMN_1781155 LYN NM_002350.1 -1,34 0,02 
v-yes-1 Yamaguchi sarcoma viral related 
oncogene homolog (LYN), mRNA. 
ILMN_1658327 BAZ1A NM_013448.2 -1,29 0,03 
bromodomain adjacent to zinc finger 
domain, 1A (BAZ1A), transcript variant 
1, mRNA. 
ILMN_2059689 TMEM54 NM_033504.2 -1,29 0,05 
transmembrane protein 54 (TMEM54), 
mRNA. 
ILMN_1663512 COX5B NM_001862.2 1,27 0,05 
cytochrome c oxidase subunit Vb 
(COX5B), mRNA. 
ILMN_2097858 KIAA1737 NM_033426.2 1,27 0,05 KIAA1737 (KIAA1737), mRNA. 
ILMN_1800008 ACAT1 NM_000019.2 1,28 0,05 
acetyl-Coenzyme A acetyltransferase 1 
(ACAT1), nuclear gene encoding 
mitochondrial protein, mRNA. 
ILMN_3237641 MUDENG NM_018229.2 1,28 0,05 
MU-2/AP1M2 domain containing, death-
inducing (MUDENG), mRNA. 
ILMN_3201480 LOC643358 XR_038953.1 1,28 0,04 misc_RNA (LOC643358), miscRNA. 
ILMN_1786718 NDUFV1 NM_007103.2 1,28 0,04 
NADH dehydrogenase (ubiquinone) 
flavoprotein 1, 51kDa (NDUFV1), mRNA. 
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ILMN_1740170 CHCHD10 NM_213720.1 1,28 0,05 
coiled-coil-helix-coiled-coil-helix domain 
containing 10 (CHCHD10), mRNA. 
ILMN_3188124 
LOC1001305
11 
XR_038018.1 1,28 0,04 misc_RNA (LOC100130511), miscRNA. 
ILMN_1685781 C14orf142 NM_032490.4 1,29 0,04 
chromosome 14 open reading frame 142 
(C14orf142), mRNA. 
ILMN_3307827 DNAJC4 NM_005528.3 1,29 0,04 
DnaJ (Hsp40) homolog, subfamily C, 
member 4 (DNAJC4), mRNA. 
ILMN_1677237 CHCHD9 XM_928381.2 1,29 0,04 
coiled-coil-helix-coiled-coil-helix domain 
containing 9 (CHCHD9), mRNA. 
ILMN_3205656 LOC391075 XR_016557.2 1,30 0,04 misc_RNA (LOC391075), miscRNA. 
ILMN_1752968 LAMB2 NM_002292.3 1,30 0,04 
laminin, beta 2 (laminin S) (LAMB2), 
mRNA. 
ILMN_2409062 ISCU NM_213595.1 1,30 0,04 
iron-sulfur cluster scaffold homolog (E. 
coli) (ISCU), nuclear gene encoding 
mitochondrial protein, transcript variant 
2, mRNA. 
ILMN_2294762 AMY1A NM_004038.3 1,30 0,04 
amylase, alpha 1A (salivary) (AMY1A), 
transcript variant 1, mRNA. 
ILMN_3208715 LOC440063 XR_018394.2 1,30 0,03 misc_RNA (LOC440063), miscRNA. 
ILMN_2408415 RPL9 
NM_001024921.
2 
1,31 0,04 
ribosomal protein L9 (RPL9), transcript 
variant 2, mRNA. 
ILMN_1672024 ISCA1L 
NM_001080540.
1 
1,31 0,04 
iron-sulfur cluster assembly 1 homolog 
(S. cerevisiae)-like (ISCA1L), mRNA. 
ILMN_2223130 SMARCA5 NM_003601.2 1,31 0,05 
SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, 
subfamily a, member 5 (SMARCA5), 
mRNA. 
ILMN_3275771 LOC642567 XR_038054.1 1,31 0,04 misc_RNA (LOC642567), miscRNA. 
ILMN_2370535 GAS2L1 NM_006478.3 1,31 0,04 
growth arrest-specific 2 like 1 (GAS2L1), 
transcript variant 1, mRNA. 
ILMN_2094106 HSD17B12 NM_016142.1 1,31 0,03 
hydroxysteroid (17-beta) dehydrogenase 
12 (HSD17B12), mRNA. 
ILMN_1738229 NDRG3 NM_022477.2 1,32 0,04 
NDRG family member 3 (NDRG3), 
transcript variant 2, mRNA. 
ILMN_1774062 SLC25A5 NM_001152.1 1,32 0,04 
solute carrier family 25 (mitochondrial 
carrier; adenine nucleotide translocator), 
member 5 (SLC25A5), mRNA. 
ILMN_1801378 COQ3 NM_017421.3 1,32 0,03 
coenzyme Q3 homolog, 
methyltransferase (S. cerevisiae) 
(COQ3), mRNA. 
ILMN_1670379 ANTXR1 NM_032208.1 1,32 0,04 
anthrax toxin receptor 1 (ANTXR1), 
transcript variant 1, mRNA. 
ILMN_2396410 CS NM_004077.2 1,32 0,04 
citrate synthase (CS), nuclear gene 
encoding mitochondrial protein, mRNA. 
ILMN_1671191 UQCRC1 NM_003365.2 1,32 0,05 
ubiquinol-cytochrome c reductase core 
protein I (UQCRC1), mRNA. 
ILMN_3290577 LOC391833 XR_038761.1 1,32 0,04 misc_RNA (LOC391833), miscRNA. 
ILMN_1804328 WWP1 NM_007013.3 1,32 0,05 
WW domain containing E3 ubiquitin 
protein ligase 1 (WWP1), mRNA. 
ILMN_1706013 FTHL11 NR_002204.1 1,33 0,03 
ferritin, heavy polypeptide-like 11 
(FTHL11) on chromosome 8. 
ILMN_2167616 NACA NM_005594.2 1,33 0,03 
nascent-polypeptide-associated complex 
alpha polypeptide (NACA), mRNA. 
ILMN_2406501 SOD2 
NM_001024466.
1 
1,33 0,05 
superoxide dismutase 2, mitochondrial 
(SOD2), nuclear gene encoding 
mitochondrial protein, transcript variant 
3, mRNA. 
ILMN_2197846 HADHB NM_000183.2 1,34 0,05 
hydroxyacyl-Coenzyme A 
dehydrogenase/3-ketoacyl-Coenzyme A 
thiolase/enoyl-Coenzyme A hydratase 
(trifunctional protein), beta subunit 
(HADHB), nuclear gene encoding 
mitochondrial protein, mRNA. 
ILMN_2169839 CNBP NM_003418.1 1,34 0,04 
CCHC-type zinc finger, nucleic acid 
binding protein (CNBP), mRNA. 
ILMN_1712708 TRIM47 NM_033452.2 1,34 0,03 
tripartite motif-containing 47 (TRIM47), 
mRNA. 
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ILMN_1778104 ACADM NM_000016.2 1,34 0,05 
acyl-Coenzyme A dehydrogenase, C-4 
to C-12 straight chain (ACADM), nuclear 
gene encoding mitochondrial protein, 
mRNA. 
ILMN_3293367 LOC391370 XM_372926.5 1,35 0,05 
similar to hCG1818387 (LOC391370), 
mRNA. 
ILMN_3224907 LOC728672 XR_015580.2 1,35 0,03 misc_RNA (LOC728672), miscRNA. 
ILMN_3242288 LOC641768 XM_935907.3 1,35 0,03 
similar to ribosomal protein S26, 
transcript variant 2 (LOC641768), 
mRNA. 
ILMN_1752027 UBE3B NM_130466.2 1,35 0,02 
ubiquitin protein ligase E3B (UBE3B), 
transcript variant 1, mRNA. 
ILMN_2051232 SDHA NM_004168.1 1,35 0,02 
succinate dehydrogenase complex, 
subunit A, flavoprotein (Fp) (SDHA), 
nuclear gene encoding mitochondrial 
protein, mRNA. 
ILMN_1695316 SLC39A8 NM_022154.5 1,36 0,03 
solute carrier family 39 (zinc transporter), 
member 8 (SLC39A8), transcript variant 
1, mRNA. 
ILMN_1656913 MDH1 NM_005917.2 1,36 0,02 
malate dehydrogenase 1, NAD (soluble) 
(MDH1), mRNA. 
ILMN_1744534 LYRM5 
NM_001001660.
2 
1,36 0,04 LYR motif containing 5 (LYRM5), mRNA. 
ILMN_1774272 ESRRA NM_004451.3 1,36 0,02 
estrogen-related receptor alpha 
(ESRRA), mRNA. 
ILMN_1705464 MRPL41 NM_032477.1 1,36 0,01 
mitochondrial ribosomal protein L41 
(MRPL41), nuclear gene encoding 
mitochondrial protein, mRNA. 
ILMN_1721623 APOO NM_024122.2 1,36 0,04 apolipoprotein O (APOO), mRNA. 
ILMN_2211950 SRP14P1 NR_003273.1 1,37 0,03 
signal recognition particle 14kDa 
(homologous Alu RNA binding protein) 
pseudogene 1 (SRP14P1), non-coding 
RNA. 
ILMN_1808584 FAM36A NM_198076.4 1,37 0,03 
family with sequence similarity 36, 
member A (FAM36A), mRNA. 
ILMN_3237270 
LOC1001336
09 
XM_001720815.
1 
1,37 0,02 
similar to membrane-associated ring 
finger (C3HC4) 3 (LOC100133609), 
mRNA. 
ILMN_1735432 ISCU NM_014301.2 1,38 0,02 
iron-sulfur cluster scaffold homolog (E. 
coli) (ISCU), nuclear gene encoding 
mitochondrial protein, transcript variant 
1, mRNA. 
ILMN_1758474 PRKRA NM_003690.3 1,38 0,03 
protein kinase, interferon-inducible 
double stranded RNA dependent 
activator (PRKRA), mRNA. 
ILMN_1804656 C12orf62 NM_032901.2 1,38 0,03 
chromosome 12 open reading frame 62 
(C12orf62), mRNA. 
ILMN_1712430 ATP5G1 NM_005175.2 1,38 0,02 
ATP synthase, H+ transporting, 
mitochondrial F0 complex, subunit C1 
(subunit 9) (ATP5G1), nuclear gene 
encoding mitochondrial protein, 
transcript variant 1, mRNA. 
ILMN_1672191 ATP5F1 NM_001688.4 1,38 0,02 
ATP synthase, H+ transporting, 
mitochondrial F0 complex, subunit B1 
(ATP5F1), nuclear gene encoding 
mitochondrial protein, mRNA. 
ILMN_1812995 CTSL1 NM_001912.3 1,38 0,04 
cathepsin L1 (CTSL1), transcript variant 
1, mRNA. 
ILMN_2367215 PRCP NM_005040.2 1,38 0,02 
prolylcarboxypeptidase (angiotensinase 
C) (PRCP), transcript variant 1, mRNA. 
ILMN_1803647 FAM162A NM_014367.3 1,39 0,03 
family with sequence similarity 162, 
member A (FAM162A), mRNA. 
ILMN_1687858 CALM2 NM_001743.3 1,39 0,03 
calmodulin 2 (phosphorylase kinase, 
delta) (CALM2), mRNA. 
ILMN_1756898 COQ9 NM_020312.1 1,39 0,02 
coenzyme Q9 homolog (S. cerevisiae) 
(COQ9), mRNA. 
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ILMN_1683598 ACSL4 NM_004458.1 1,39 0,04 
acyl-CoA synthetase long-chain family 
member 4 (ACSL4), transcript variant 1, 
mRNA. 
ILMN_1658437 SFXN4 NM_213649.1 1,39 0,01 sideroflexin 4 (SFXN4), mRNA. 
ILMN_1660787 SUCLA2 NM_003850.1 1,39 0,04 
succinate-CoA ligase, ADP-forming, beta 
subunit (SUCLA2), mRNA. 
ILMN_1769158 ISOC2 NM_024710.1 1,39 0,01 
isochorismatase domain containing 2 
(ISOC2), mRNA. 
ILMN_1652357 PDHX NM_003477.1 1,40 0,04 
pyruvate dehydrogenase complex, 
component X (PDHX), nuclear gene 
encoding mitochondrial protein, mRNA. 
ILMN_2368530 IL32 
NM_001012633.
1 
1,40 0,02 
interleukin 32 (IL32), transcript variant 4, 
mRNA. 
ILMN_1655796 02-mar 
XM_001127871.
1 
1,40 0,01 
membrane-associated ring finger 
(C3HC4) 3 (MARCH3), mRNA. 
ILMN_2342066 METRNL 
NM_001004431.
1 
1,41 0,01 
meteorin, glial cell differentiation 
regulator-like (METRNL), mRNA. 
ILMN_2313821 AIFM1 NM_145813.1 1,41 0,02 
apoptosis-inducing factor, 
mitochondrion-associated, 1 (AIFM1), 
nuclear gene encoding mitochondrial 
protein, transcript variant 3, mRNA. 
ILMN_1741214 NXPH4 XM_938935.2 1,41 0,01 neurexophilin 4 (NXPH4), mRNA. 
ILMN_1651800 GSTM4 NM_147148.1 1,41 0,02 
glutathione S-transferase M4 (GSTM4), 
transcript variant 2, mRNA. 
ILMN_1745152 UQCC NM_018244.3 1,41 0,02 
ubiquinol-cytochrome c reductase 
complex chaperone (UQCC), nuclear 
gene encoding mitochondrial protein, 
transcript variant 1, mRNA. 
ILMN_3301065 LOC728590 
XM_001725160.
1 
1,41 0,02 
hypothetical LOC728590 (LOC728590), 
mRNA. 
ILMN_1813704 KIAA1199 NM_018689.1 1,41 0,03 KIAA1199 (KIAA1199), mRNA. 
ILMN_1815346 TMEM136 NM_174926.1 1,42 0,03 
transmembrane protein 136 (TMEM136), 
mRNA. 
ILMN_1728132 LDHB NM_002300.4 1,42 0,01 
lactate dehydrogenase B (LDHB), 
mRNA. 
ILMN_3227315 LOC729009 XR_042330.1 1,42 0,01 misc_RNA (LOC729009), miscRNA. 
ILMN_2091846 FTHL2 NR_002200.1 1,42 0,01 
ferritin, heavy polypeptide-like 2 (FTHL2) 
on chromosome 1. 
ILMN_1733869 OGDH NM_002541.2 1,42 0,02 
oxoglutarate (alpha-ketoglutarate) 
dehydrogenase (lipoamide) (OGDH), 
nuclear gene encoding mitochondrial 
protein, transcript variant 1, mRNA. 
ILMN_1725241 GSTK1 NM_015917.1 1,42 0,01 
glutathione S-transferase kappa 1 
(GSTK1), mRNA. 
ILMN_1706583 DLAT NM_001931.2 1,42 0,02 
dihydrolipoamide S-acetyltransferase 
(DLAT), mRNA. 
ILMN_1748831 PPP1R13B NM_015316.2 1,42 0,04 
protein phosphatase 1, regulatory 
(inhibitor) subunit 13B (PPP1R13B), 
mRNA. 
ILMN_1683146 FTH1 NM_002032.2 1,43 0,03 
ferritin, heavy polypeptide 1 (FTH1), 
mRNA. 
ILMN_1668408 AIFM1 NM_145813.1 1,43 0,01 
apoptosis-inducing factor, 
mitochondrion-associated, 1 (AIFM1), 
nuclear gene encoding mitochondrial 
protein, transcript variant 3, mRNA. 
ILMN_2363361 SFXN4 NM_213650.1 1,43 0,01 
sideroflexin 4 (SFXN4), transcript variant 
3, mRNA. 
ILMN_3294222 
LOC1001326
73 
XR_039018.1 1,44 0,02 misc_RNA (LOC100132673), miscRNA. 
ILMN_1696911 FTHL8 NR_002203.1 1,44 0,01 
ferritin, heavy polypeptide-like 8 (FTHL8) 
on chromosome X. 
ILMN_1741422 FUT8 NM_178156.1 1,44 0,02 
fucosyltransferase 8 (alpha (1,6) 
fucosyltransferase) (FUT8), transcript 
variant 3, mRNA. 
ILMN_1758034 ETFDH NM_004453.1 1,44 0,01 
electron-transferring-flavoprotein 
dehydrogenase (ETFDH), nuclear gene 
encoding mitochondrial protein, mRNA. 
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ILMN_3305475 LOC729708 
XM_001725700.
1 
1,44 0,02 
similar to rcTPI1, transcript variant 1 
(LOC729708), mRNA. 
ILMN_1845037  BC031266 1,44 0,01 cDNA clone IMAGE:5277162 
ILMN_3241462 LOC730754 
NM_001093779.
2 
1,44 0,01 
similar to ribosomal protein S18 
(LOC730754), mRNA. 
ILMN_1699644  
XM_001127871.
1 
1,44 0,01 
membrane-associated ring finger 
(C3HC4) 3 (MARCH3), mRNA. 
ILMN_1755954 CPEB3 NM_014912.3 1,44 0,04 
cytoplasmic polyadenylation element 
binding protein 3 (CPEB3), mRNA. 
ILMN_1760727 ANG 
NM_001097577.
1 
1,45 0,02 
angiogenin, ribonuclease, RNase A 
family, 5 (ANG), transcript variant 2, 
mRNA. 
ILMN_1695946 TRNP1 
NM_001013642.
2 
1,45 0,04 
TMF1-regulated nuclear protein 1 
(TRNP1), mRNA. 
ILMN_1796349 SMPDL3A NM_006714.2 1,45 0,01 
sphingomyelin phosphodiesterase, acid-
like 3A (SMPDL3A), mRNA. 
ILMN_2079285 ATP5L NM_006476.4 1,45 0,01 
ATP synthase, H+ transporting, 
mitochondrial F0 complex, subunit G 
(ATP5L), nuclear gene encoding 
mitochondrial protein, mRNA. 
ILMN_1794912 ATP5H 
NM_001003785.
1 
1,45 0,01 
ATP synthase, H+ transporting, 
mitochondrial F0 complex, subunit d 
(ATP5H), nuclear gene encoding 
mitochondrial protein, transcript variant 
2, mRNA. 
ILMN_1806634 NNT NM_012343.3 1,46 0,01 
nicotinamide nucleotide 
transhydrogenase (NNT), nuclear gene 
encoding mitochondrial protein, 
transcript variant 1, mRNA. 
ILMN_1772369 PDHA1 NM_000284.1 1,46 0,01 
pyruvate dehydrogenase (lipoamide) 
alpha 1 (PDHA1), mRNA. 
ILMN_2053679 ACADM NM_000016.2 1,46 0,04 
acyl-Coenzyme A dehydrogenase, C-4 
to C-12 straight chain (ACADM), nuclear 
gene encoding mitochondrial protein, 
mRNA. 
ILMN_1763852 ACACB NM_001093.3 1,46 0,03 
acetyl-Coenzyme A carboxylase beta 
(ACACB), mRNA. 
ILMN_1750278 FTHL12 NR_002205.1 1,46 0,01 
ferritin, heavy polypeptide-like 12 
(FTHL12) on chromosome 9. 
ILMN_1664577 DLD NM_000108.3 1,46 0,03 
dihydrolipoamide dehydrogenase (DLD), 
mRNA. 
ILMN_1669032 PPIC NM_000943.4 1,47 0,01 
peptidylprolyl isomerase C (cyclophilin 
C) (PPIC), mRNA. 
ILMN_1745826 KATNAL2 
XM_001129888.
1 
1,47 0,03 
katanin p60 subunit A-like 2 (KATNAL2), 
mRNA. 
ILMN_1671478 CKB NM_001823.3 1,47 0,01 creatine kinase, brain (CKB), mRNA. 
ILMN_1654861 ACO2 NM_001098.2 1,49 0,01 
aconitase 2, mitochondrial (ACO2), 
nuclear gene encoding mitochondrial 
protein, mRNA. 
ILMN_2223903 PPIC NM_000943.4 1,49 0,02 
peptidylprolyl isomerase C (cyclophilin 
C) (PPIC), mRNA. 
ILMN_2230016 HIGD1A NM_014056.1 1,49 0,02 
HIG1 domain family, member 1A 
(HIGD1A), mRNA. 
ILMN_1724059 GAS2L1 NM_152236.1 1,49 0,02 
growth arrest-specific 2 like 1 (GAS2L1), 
transcript variant 2, mRNA. 
ILMN_1782579 IMMT 
NM_001100169.
1 
1,49 0,03 
inner membrane protein, mitochondrial 
(mitofilin) (IMMT), nuclear gene 
encoding mitochondrial protein, 
transcript variant 2, mRNA. 
ILMN_1751956 MGST3 NM_004528.2 1,49 0,01 
microsomal glutathione S-transferase 3 
(MGST3), mRNA. 
ILMN_1811754 NDUFB10 NM_004548.1 1,50 0,01 
NADH dehydrogenase (ubiquinone) 1 
beta subcomplex, 10, 22kDa 
(NDUFB10), mRNA. 
ILMN_2229940 C2orf7 NM_032319.1 1,50 0,02 
chromosome 2 open reading frame 7 
(C2orf7), mRNA. 
ILMN_1740258 KRTAP20-2 NM_181616.1 1,50 0,03 
keratin associated protein 20-2 
(KRTAP20-2), mRNA. 
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ILMN_1706841 PGAM4 
NM_001029891.
2 
1,51 0,01 
phosphoglycerate mutase family 
member 4 (PGAM4), mRNA. 
ILMN_3230241 LOC728975 XR_042006.1 1,51 0,01 misc_RNA (LOC728975), miscRNA. 
ILMN_1719392 FH NM_000143.2 1,51 0,03 
fumarate hydratase (FH), nuclear gene 
encoding mitochondrial protein, mRNA. 
ILMN_1727813 BRP44 NM_015415.2 1,51 0,01 
brain protein 44 (BRP44), transcript 
variant 2, mRNA. 
ILMN_3264466 FAM54B NM_019557.5 1,52 0,01 
family with sequence similarity 54, 
member B (FAM54B), transcript variant 
1, mRNA. 
ILMN_1718853 UQCRC2 NM_003366.2 1,53 0,01 
ubiquinol-cytochrome c reductase core 
protein II (UQCRC2), mRNA. 
ILMN_1725271 GPR3 NM_005281.2 1,53 0,01 
G protein-coupled receptor 3 (GPR3), 
mRNA. 
ILMN_1701269 ATP5C1 NM_005174.2 1,53 0,02 
ATP synthase, H+ transporting, 
mitochondrial F1 complex, gamma 
polypeptide 1 (ATP5C1), nuclear gene 
encoding mitochondrial protein, 
transcript variant 2, mRNA. 
ILMN_3297898 LOC729769 
XM_001131246.
2 
1,53 0,01 
similar to Ubiquinol-cytochrome c 
reductase hinge protein (LOC729769), 
mRNA. 
ILMN_1803423 ARHGEF6 NM_004840.2 1,54 0,01 
Rac/Cdc42 guanine nucleotide 
exchange factor (GEF) 6 (ARHGEF6), 
mRNA. 
ILMN_2073235 FTHL12 NR_002205.1 1,54 0,01 
ferritin, heavy polypeptide-like 12 
(FTHL12) on chromosome 9. 
ILMN_1730416 CYCS NM_018947.4 1,55 0,01 
cytochrome c, somatic (CYCS), nuclear 
gene encoding mitochondrial protein, 
mRNA. 
ILMN_1665775 MOSC2 NM_017898.3 1,55 0,01 
MOCO sulphurase C-terminal domain 
containing 2 (MOSC2), mRNA. 
ILMN_2408572 RNASE4 NM_194430.1 1,55 0,01 
ribonuclease, RNase A family, 4 
(RNASE4), transcript variant 1, mRNA. 
ILMN_1701457 FAHD1 
NM_001018104.
1 
1,56 0,01 
fumarylacetoacetate hydrolase domain 
containing 1 (FAHD1), nuclear gene 
encoding mitochondrial protein, 
transcript variant 1, mRNA. 
ILMN_1759453 UQCRB NM_006294.2 1,57 0,03 
ubiquinol-cytochrome c reductase 
binding protein (UQCRB), mRNA. 
ILMN_3243859 NDUFB9 NM_005005.2 1,57 0,01 
NADH dehydrogenase (ubiquinone) 1 
beta subcomplex, 9, 22kDa (NDUFB9), 
mRNA. 
ILMN_1714461 RNF14 NM_183399.1 1,59 0,01 
ring finger protein 14 (RNF14), transcript 
variant 3, mRNA. 
ILMN_1751362 FASTKD1 NM_024622.2 1,59 0,01 
FAST kinase domains 1 (FASTKD1), 
mRNA. 
ILMN_1736752 COMTD1 NM_144589.2 1,59 0,01 
catechol-O-methyltransferase domain 
containing 1 (COMTD1), mRNA. 
ILMN_3306730 RBM47 NM_019027.3 1,60 0,04 
RNA binding motif protein 47 (RBM47), 
transcript variant 2, mRNA. 
ILMN_1760174 MCCC1 NM_020166.3 1,63 0,01 
methylcrotonoyl-Coenzyme A 
carboxylase 1 (alpha) (MCCC1), nuclear 
gene encoding mitochondrial protein, 
mRNA. 
ILMN_2407346 LDHD NM_194436.1 1,67 0,03 
lactate dehydrogenase D (LDHD), 
nuclear gene encoding mitochondrial 
protein, transcript variant 2, mRNA. 
ILMN_1776602 RNASE4 NM_194431.1 1,67 0,01 
ribonuclease, RNase A family, 4 
(RNASE4), transcript variant 3, mRNA. 
ILMN_1663538 CLYBL NM_206808.1 1,68 0,01 citrate lyase beta like (CLYBL), mRNA. 
ILMN_1718136 UQCRHL 
NM_001089591.
1 
1,68 0,01 
ubiquinol-cytochrome c reductase hinge 
protein-like (UQCRHL), mRNA. 
ILMN_1781386 WIPI1 NM_017983.4 1,69 0,03 
WD repeat domain, phosphoinositide 
interacting 1 (WIPI1), mRNA. 
ILMN_1720838 DECR1 NM_001359.1 1,70 0,01 
2,4-dienoyl CoA reductase 1, 
mitochondrial (DECR1), nuclear gene 
encoding mitochondrial protein, mRNA. 
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ILMN_1698533 IDH3A NM_005530.2 1,72 0,01 
isocitrate dehydrogenase 3 (NAD+) 
alpha (IDH3A), nuclear gene encoding 
mitochondrial protein, mRNA. 
ILMN_2184049 COX7B NM_001866.2 1,73 0,01 
cytochrome c oxidase subunit VIIb 
(COX7B), nuclear gene encoding 
mitochondrial protein, mRNA. 
ILMN_1736901 ZDHHC23 NM_173570.2 1,74 0,01 
zinc finger, DHHC-type containing 23 
(ZDHHC23), mRNA. 
ILMN_1780861 LOC653506 XM_927769.1 1,75 0,01 
similar to meteorin, glial cell 
differentiation regulator-like 
(LOC653506), mRNA. 
ILMN_1688775 METRNL XM_941466.2 1,76 0,00 
meteorin, glial cell differentiation 
regulator-like (METRNL), mRNA. 
ILMN_1751258 NDUFA4 NM_002489.2 1,76 0,00 
NADH dehydrogenase (ubiquinone) 1 
alpha subcomplex, 4, 9kDa (NDUFA4), 
nuclear gene encoding mitochondrial 
protein, mRNA. 
ILMN_1722309 ENDOG NM_004435.2 1,77 0,00 
endonuclease G (ENDOG), nuclear 
gene encoding mitochondrial protein, 
mRNA. 
ILMN_2391861 GSTM1 NM_000561.2 1,77 0,01 
glutathione S-transferase M1 (GSTM1), 
transcript variant 1, mRNA. 
ILMN_2252160 UBC NM_021009.3 1,83 0,00 ubiquitin C (UBC), mRNA. 
ILMN_1801703 CPLX1 NM_006651.3 1,92 0,00 complexin 1 (CPLX1), mRNA. 
ILMN_1686906 TP53INP2 NM_021202.1 1,95 0,01 
tumor protein p53 inducible nuclear 
protein 2 (TP53INP2), mRNA. 
ILMN_1666967 BRP44L NM_016098.1 2,00 0,01 brain protein 44-like (BRP44L), mRNA. 
ILMN_1656145 GOT1 NM_002079.1 2,03 0,00 
glutamic-oxaloacetic transaminase 1, 
soluble (aspartate aminotransferase 1) 
(GOT1), mRNA. 
ILMN_1697543 SPINK5L3 
NM_001040129.
2 
2,17 0,04 
serine protease inhibitor Kazal-type 5-
like 3 (SPINK5L3), mRNA. 
ILMN_2226324 BRP44L NM_016098.1 2,26 0,00 brain protein 44-like (BRP44L), mRNA. 
ILMN_1730291 ATP1B1 NM_001677.3 2,42 0,00 
ATPase, Na+/K+ transporting, beta 1 
polypeptide (ATP1B1), transcript variant 
1, mRNA. 
ILMN_2407824 ATP1B1 
NM_001001787.
1 
2,88 0,00 
ATPase, Na+/K+ transporting, beta 1 
polypeptide (ATP1B1), transcript variant 
2, mRNA. 
ILMN_1658071 ATP1B1 NM_001677.3 3,07 0,00 
ATPase, Na+/K+ transporting, beta 1 
polypeptide (ATP1B1), transcript variant 
1, mRNA. 
ILMN_1658333 ECM1 NM_004425.2 3,14 0,00 
extracellular matrix protein 1 (ECM1), 
transcript variant 1, mRNA. 
ILMN_2329735 ECM1 NM_022664.1 5,77 0,00 
extracellular matrix protein 1 (ECM1), 
transcript variant 2, mRNA. 
ILMN_1768469 TCN1 NM_001062.3 -1,99 0,01 
transcobalamin I (vitamin B12 binding 
protein, R binder family) (TCN1), mRNA. 
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